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 The layer of cells lining the outer surface of the mammalian ovary, the 
ovarian surface epithelium (OSE), is a constant feature throughout the dynamic 
tissue remodeling that occurs throughout the reproductive cycle (follicle growth, 
ovulation, corpora lutea formation and pregnancy). Abnormal development of these 
cells is responsible for 90% of all epithelial ovarian cancers in women and 
epidemiological studies have shown that susceptibility to ovarian cancer is 
negatively correlated with increasing pregnancy. Little is known about how OSE 
cells are affected at each stage of the cycle, so the main aim of this study was to 
determine how the reproductive cycle affected proliferation and degeneration of OSE 
cells. This study utilised three animal models each with a different type of 
reproductive cycle: a mono-ovular seasonal breeder (Sheep), a mono-ovular 
polyoestrous breeder (Cow) and a poly-ovular non human primate (marmoset) to 
allow comparisons to be made. Comparison of OSE proliferative activity was made 
in sheep and marmoset at each stage of the cycle including pregnancy and 
anoestrous. The bovine model was used to investigate apoptotic cell death.   
Proliferative activity of somatic cells within the sheep ovary was monitored 
throughout the reproductive cycle by detection of cell cycle markers PCNA and Ki67 
using immunohistochemistry. The pattern of OSE proliferation was correlated with 
the pattern of follicle development at each stage (sheep and marmoset). During 
pregnancy cell proliferation was significantly lower in OSE and in granulosa cells, 
reflecting a suppression of mature follicle development during these stages whereas 
in cycling animals proliferation was increased. Differences in OSE proliferation were 
observed in relation to the local underlying tissue environment in both sheep and 
marmoset. Epithelial cell rupture and regeneration enhanced the hormonal mitogenic 
action on epithelial cells, which showed highest proliferation over corpora lutea in 
each animal model. 
To test the hypothesis that these changes are mediated by hormones or 
growth factors ovine OSE cells were cultured and proliferative activity monitored 
after treatment with several factors: fetal calf serum (FCS), follicular fluid from 
follicles of varying sizes, corpora lutea extracts, recombinant human IGF-1, 
 iii 
oestradiol and progesterone. IGF alone was demonstrated to have an affect on 
increasing proliferation of cultured OSE cells. Levels of FSHr and LHr were 
monitored by quantitative real- time PCR and it was demonstrated that the 
concentration of gonadotrophin receptors in OSE, increased prior to and after 
ovulation, at which time the in vivo OSE proliferation also peaked. 
 The in situ apoptosis index was determined in bovine tissue using TUNEL 
throughout the regular cycle, and at mid and late-pregnancy stages. The results 
showed that pregnancy induced apoptotic activity in OSE cells and up regulated the 
tumour suppressor gene p53. Cultured bovine OSE cells also exhibited an increased 
level of apoptosis following progesterone treatment. Since p53/p53 gene expression 
in OSE over the corpora lutea producing progesterone also increased, this 
progesterone-mediated apoptosis may be mediated through an up-regulation of p53 
synthesis.  
 The effect of pregnancy and low production of gonadotrophins in the 
regulation of OSE cell morphology and activity was further investigated in the 
marmoset monkey (a non-human primate) treated with GnRH antagonist and infused 
with BrdU to monitor proliferative activity. OSE proliferation was correlated to 
ovarian events (follicular growth, ovulation and luteinization) and this was 
suppressed during pregnancy. Inhibition of gonadotrophin secretion by treatment 
with a GnRH antagonist also markedly inhibited OSE proliferation.  
 Taken together these studies support the hypothesis that pregnancy and 
periods of anovulation reduce proliferation of OSE cells and alter the pattern of 
apoptotic cell death and that this effect is independent of species and reproductive 
pattern. Suppression of gonadotrophins and other growth factors during pregnancy 
could enhance p53-mediated apoptosis of damaged and mitogenic cells arising from 
repeated ovulations. This effect may partly explain why increasing number of 
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Photomicrographs showing the morphology of the OSE layer 
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the outliers. Values are percentages of labelled GCs per follicle, 
and different letters above the bars indicate statistical differences 
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percentiles and asterisks represent the outliers. Values are 
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different letters above the bars indicate statistical differences 
between groups (P0.05). The total number of analyzed follicles is 
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Antral follicles size distribution at different reproductive status. 
Distribution of antral follicles with different diameters  1 mm, 2-
3mm, 3-4mm and 4-5mm at cycling (n = 6), anoestrous (n = 5), 
early-mid pregnancy (E-M Preg.) (30-75 days) (n = 8), and mid-
late pregnancy (M-L Preg.) (80–135 days) (n = 9). Values are total 
percentages of each size of antral follicle per group. Different 
letters indicate statistical differences between groups among antral 
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Cytokeratin expression in ovine OSE. Immunohistochemistry for 
(A) intact OSE cells (in vivo) and (B) isolated OSE cells (in vitro), 
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Box plots are of the proliferative responses of cultured sheep OSE 
cells to FCS, corpora lutea extracts (CL-E, n = 7), follicular fluid 
from medium follicles (6–8 mm) (FF-MF, n = 20) and large 
follicles (10–12 mm) (FF-LF, n = 15). Follicular fluid was 
separately pooled from medium or large follicles, and a fraction 
from each pool was charcoal-stripped (CS). Each box plot 
represents the means of four independent assays for each 
treatment, and lines represent the whiskers. Values are expressed 
relative to the value in untreated cells (control) that was taken as 
1. Different letters above bars indicate a statistical difference 












Box plots are of the proliferative responses of cultured sheep OSE 
cells to FCS, recombinant human IGF-1 (100 ng/ml), progesterone 
(P) (3,300 and 3,000 ng/ml) and 17-estradiol (E) (3,300 and 
3,000 ng/ml). Each box plot represents the mean of four 
independent assays for each treatment, and lines represent the 
whiskers. Values are expressed relative to the value in untreated 
cells (control) that was taken as 1. Different letters above bars 
indicate a statistical difference between each treated group and the 
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Expression levels of LHR and FSHR in ovine OSE cells over 
mature corpora lutea (CL) (n = 12), over large antral follicles (n = 
17), and over stroma. Data were standardized to the stroma means, 
and are presented as means ± SEM of three independent assays. 
Different letters above bars indicate a statistical difference 
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Bovine OSE cells in culture. Photomicrograph represents cultured 
bovine OSE cells (confluent) with a compact, cobblestone-like 
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Photomicrographs representing cytokeratin expression in (A) OSE 
cells and (B) inclusion cyst of bovine ovaries (blue arrows). 
Brown staining indicates the cytokerstin expression (cytoplasmic 
localization). Red arrows show the negative staining in ovarian 
stroma (OS) and tunica albuginea (TA) layers. (A) at 40X and (B) 
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Histogram representing in situ localization of apoptotic cells 
within the OSE cells and inclusion cysts at cycling (n = 8), 55-80 
d pregnancy (n = 8) and 90-140 d pregnancy (n = 8) groups. 
Different letters above the bars indicate statistically differences 
between groups among OSE and asterisks represent statistical 
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Photomicrographs representing apoptotic cells in bovine OSE 
layer and inclusion cysts. (A and B) show apoptotic cells in OSE 
and inclusion cyst of cycling group, (black arrows show the 
apoptotic cells with brown stained nuclei and red arrows show the 
negatively stained cells). (C) Shows the TUNEL labelling in the 
inclusion cyst of mid pregnant group (completely stained). D is a 
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Histogram representing apoptosis in bovine cultured OSE cells 




were incubated without treatment (control) or in the present of 
steroids (17- estradiol and progesterone) at different doses (30 
ng/ml and 30 µg/ml) or incubated with 5 mM H2O2 (positive 
control for apoptosis). Values for each treatment are expressed 
relative to the values of the control, which was taken as unity (1). 
Different letters over bars indicate statistical differences between 
each treated group and control (P 0.05). Data expressed as a 
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4.6 
Histogram representing the percentage of p53 immunostaining 
after steroid treatments in cultured bovine OSE cells. Cultured 
OSE cells were incubated without treatment (control) or in the 
present of steroids (progesterone and 17- estradiol) at different 
doses (30 ng/ml and 30 µg/ml) for 24 h. Control cells were 
incubated with serum free medium under the same conditions. 
Different letters over bars indicate statistical differences between 
each treated group and control (P 0.05). Data expressed as a 
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Photomicrographs showing p53 immunostaining within the nucli 
of OSE cells over different areas of the ovary. P53 expression in 
the OSE cells over the (A) CL, (B) large antral follicle and (C) 
ovarian stroma. Blue arrows show the positively stained cells 
(Brown nuclei). Panel D and E show positive control for p53 
immunostaining in cells lining the inclusion cysts (IC) of human 
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Box plots representing P53 immunohistochemistry in the OSE 
cells of cycling heifers (n = 8) through different regions of the 
ovary (overlying corpora lutea (CL), antral follicles (AF) and 
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and asterisks represent the outliers. Data are the number of OSE 
labelled cells over each region for each section (3 
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4.9 
PCR gel showing p53 gene expression of freshly isolated bovine 
OSE cells. OSE cells were collected from different regions of the 
ovaries (n =14) in relation to the underlying compartment. Lane 
A. OSE cells overlying corpora lutea (n = 8), lane B. ovarian 
stroma, lane C.  antral follicles (n = 15) and lane D. negative 
control. Total RNA was reverse transcribed and amplified by PCR 
using p53 specific primers (upper panel). Detection of GAPDH 
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Figure  
5.1  
Photomicrographs showing BrdU labelling within the granulosa 
cells of growing follicles in marmoset ovary. Histological sections 
at (A) follicular phase of the ovulatory cycle (blue arrow indicates 
high level of BrdU labelling in granulosa cells of antral follicle) 
and (B) at pregnancy (red arrow indicates low level of BrdU 
labelling in granulosa cells of preantral follicle), A at 40X and B 










Box plots indicating BrdU incorporation into the marmoset OSE 
cells over the total area of the ovary at early (n = 4), mid (n = 5) 
and late stages (n = 6) of the follicular phase, and early (n = 5), 
mid (n = 5) and late stages (n = 5) of the luteal phase and at week-
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 percentiles and asterisks represent the 
outliers. Data are the number of BrdU labelled cells in OSE cells 
in each section (2 sections /animal). Total number of counted cells 




   
Figure 
5.3 
Box plots indicating the distribution of BrdU labelled cells in 
marmoset OSE through different regions (overlying stroma, antral 
follicles and corpora lutea (CL)) at the follicular phase (n = 15), 
the luteal phase (n = 15) and at week 1 and 2 pregnancy (n = 8).  
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 percentiles and 
asterisks represent the outliers. Data are the number of BrdU 
labelled cells in OSE cells at each region for each section (2 
sections/ animal). Total number of counted cells is presented in 











   
Figure 
5.4 
Photomicrographs showing BrdU labelling within the marmoset 
OSE cells. BrdU labelling within the OSE cells at follicular phase 
of the ovulatory cycle (A) over large antral follicle and (B) over 
stroma. C-D demonstrate the morphology of OSE cells at luteal 
phase (C) over mature CL and (D) over stroma. E-F OSE cells at 
pregnancy (E) over stroma and (F) over CL. Red arrows indicate 










   
Figure 
5.5 
Photomicrographs representing the morphological changes of the 
OSE cells at different regions of the marmoset ovary. (A) OSE 
covering large antral follicle (arrow indicates flattened shaped 
cells), (B) over a mature CL (arrow indicates squamous shaped 









   
Figure 
5.6 
Box plots indicating BrdU incorporation into the marmoset OSE 
cells over the total surface area of the ovary after GnRH-
antagonist treatment from day 5-10 (n = 5; 5 sections/animal) and 
day 0-10 (n = 5; 3 sections/animal) follicular phase, ovaries from 
day 10 follicular phase were used as a control (n = 5; 4 












percentiles and asterisks represent the outliers. Data are the 
number of BrdU labelled cells in OSE cells for each section. Total 
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1.1 General introduction 
 The mammalian ovary is surrounded by a complete layer of epithelial cells 
(Ovarian Surface Epithelium; OSE) which has to adapt to the cyclical changes that occur 
within the ovary before and after ovulation (Gaytan et al. 2005). Abnormal changes in 
the OSE can result in ovarian cancer which is the fifth most common cancer in women 
and affects about 6700 women annually in Britain (Beral et al. 2007). Despite its clinical 
relevance there is still little known about the features of OSE cells and how they respond 
to local ovarian factors and cyclical changes. This thesis is concerned with identifying 
and characterising features of the OSE in relation to stage of the reproductive cycle, 
ovarian development and paracrine and endocrine factors. This Introduction will provide 
background to the origin and characteristics of OSE as well as reviewing current 
knowledge of normal and abnormal OSE regulation within the context of ovarian 
development and reproductive cycle. 
 
1.2 Embryonic origin of OSE cells in mammals 
 The embryonic development of human OSE has been described by Auersperg et 
al. (2001). OSE cells are generated from the mesodermally derived epithelial lining of 
the intraembryonic coelom. In the embryo this covers the presumptive gonadal ridge and 
proliferates and differentiates to form the gonadal blastema. Within 10-20 weeks of 
gestation the flat-to-cuboidal simple epithelium with inconspicuous and fragmentary 
basement membrane changes to multistratified, papillary epithelium with a well defined 
basement membrane. The cells exhibit short microvilli and wide intercellular 
cytoplasmic projections (Katabuchi & Okamura 2003). The OSE has characteristic 
differences from other epithelia, for example expression of cancer antigen 125 (CA125), 
a surface glycoprotein of unknown function, in the adult is localized in oviductal, 
endometrial and endocervical epithelium and some extraovarian epithelia, but not in the 
OSE (Maines-Bandiera & Auersperg 1997; Jacobs & Bast, Jr. 1989). Therefore, either 
OSE has never acquired this differentiation marker or it is lost early in development 
(Kabawat et al. 1983). CA125 is, however, expressed in tumorigenic OSE suggesting 
that the original coelomic characteristic has been retained by OSE but is only expressed 
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under pathological conditions (Jacobs & Bast, Jr 1989). OSE is believed to be the source 
of at least some of the ovarian granulosa cells (Byskov et al. 1977; Hirshfield 1991). The 
epithelium invaginates as ovarian cords and penetrates deep in the ovarian cortex where 
it gives rise to the granulosa cells that will form the primordial follicles, which are 
subsequently detached from the surface epithelium (Figure 1.1). Besides its role as a 
progenitor of granulosa cells, the coelomic epithelium also protrudes inwards in the 
vicinity of the presumptive gonads to give rise to Müllerian (paramesonephric) ducts, 
which constitute the epithelia of the oviduct, endometrium, and endocervix. 
 
Figure 1.1 Embryonic changes in human gonadal coelomic epithelium which 
proliferates and forms cords in cortex and gives rise to granulosa cells in primordial 
follicles that detach from the OSE. The Müllerian duct forms from invaginations of 
coelomic epithelium. Taken from Auersperg et al. (2001). 
 
1.3 Dynamic changes in mammalian OSE structure and function 
 The OSE is separated from the underlying ovarian structures by a basement 
membrane and the tunica albuginea. OSE organization in the adult ovary has been 
described extensively by Auersperg et al. (2001). OSE cells have been shown to be held 
together by zona occludens along their lateral surfaces. Several typical proteins are 
produced by OSE cells which are different from the other extraovarian epithelia. E-
cadherin (epithelial) is a typical calcium-dependent adhesion protein produced in resting 
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porcine species (MacCalman et al. 1994; Ryan et al. 1996) while, it is N-cadherin 
(neural) that is found in human OSE cells and the granulosa cell lining of the growing 
follicles (Makrigiannakis et al. 1999; Peralta et al. 1995). It is believed that when 
surface epithelial cells undergo transformation into a columnar shape due to metaplastic 
or neoplastic differentiation, particularly in inclusion cysts and crypts, the E-cadherin 
starts to co-express along with N-cadherin (Davies et al. 1998; Maines-Bandiera & 
Auersperg 1997). Another form of adhesion protein, P-cadherin (placental) is also 
typical of Müllerian origin epithelia, but is absent in resting OSE, and occasionally 
expresses in adenocarcinoma cell lines derived from cancerous OSE cells. Thus, it 
appears that E-/P-cadherins are induced during OSE neoplasia (Wong et al. 1999; van 
der Linden et al. 1994).  
 The most plausible function of OSE is to transport nutrients, hormones and 
minerals from the outer peritoneal cavity and to take part in tissue remodelling required 
for repair at the sites ruptured due to ovulation. OSE also aids follicle rupture and release 
of the oocyte by secreting lysosomal proteolytic enzymes. It is possible that the OSE 
secreted substance alters the underlying tunica albuginea and prior to ovulation makes it 
thin (Bjersing & Cajander 1975). Synthesis of both epithelium (re-epithelization) and 
connective tissue-like components of extra-cellular matrix may contribute to the 
rejuvenation of the ovarian cortex. Since connective tissue fibroblasts are responsible for 
wound healing in diverse tissues and in cultures OSE cells maintain both epithelial and 
fibroblast mesenchymal characteristics it is reasonable to believe that OSE also 
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1.4 Inter-relationship between OSE layer and underlying stroma  
The epithelial-mesenchymal transition (EMT) is a cellular mechanism that 
allows the conversion between epithelial and mesenchymal structures. EMT plays an 
important role during embryogenesis (Hay 1995), it has a capacity towards wound 
healing in diverse tissue types (Lee et al. 2006), and there exists a signalling mechanism 
for such transition. Normally epithelium to mesenchymal transition requires alterations 
in morphology, cell architecture, adhesion and mobility. It has been shown that EMT of 
OSE cells may be a mechanism to repair the perturbed stromal components and also 
tunica albuginea following every round of ovulation (Ahmed et al. 2006). Besides, OSE 
also helps in weakening the follicular wall through degradation of tunica albuginea and 
the underlying theca. In sheep and frogs, scraping off the OSE layer hinders ovulation. 
Hence, this layer facilitates ovulation and post-ovulatory repair. Murdoch & McDonnel 
(2002) put forth a model based on observations in oestrus ewes, human, mice and pig 
that explains how OSE interacts with the connective tissue and follicular wall. As shown 
in Figure 1.2, the most notable actions are collagen breakdown and cellular death at the 
apex of the preovulatory follicle through apoptosis and inflammatory necrosis. 
Gonadotrophins circulating in blood of capillaries and venules towards the theca interna 
stimulate secretion of urokinase-type plasminogen activators (u-PA) from within the 
OSE cells directed towards the tunica albuginea. Since OSE cell surface luteinizing 
hormone receptors (LHR) are up-regulated at post-oestrus due to oestradiol produced 
from preovulatory follicles, it is obvious that gonadotrophin-effect on u-PA synthesis 
and secretion would be under follicle’s control. Besides, coinciding with this time there 
is also the preovulatory LH surge in higher mammals. Localized accumulation of u-PA 
triggers conversion of zymogenic plasminogen to a serine protease, plasmin. Unlike 
tissue-type plasminogen activator (t-PA), u-PA has no role in blood fibrinolysis. Plasmin 
synthesis occurs in the apical hemisphere of the follicle and conjoined tunica albuginea. 
Plasmin in turn activates local collagenases and releases tumor necrosis factor- (TNF-
). The cytokine TNF- is secreted by thecal endothelial cells of the preovulatory 
follicle. TNF- binds to almost any cell, and its action is mediated through activation of 
TNF- receptor-R1 (TNFR1) which is constitutively present on the cell surface. Upon 
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binding to the target cells it can evoke a cascade of proteolytic response which leads to 
apoptotic DNA fragmentation and cellular disintegration. TNF- can also activate the 
transcription of zinc-containing MMP-1 and MMP-2 collagenases. MMP’s are 
synthesized by fibroblast cells in stroma and the steroidogenic granolosa cells of 
follicles. All these factors collectively degrade the coelomic epithelial layer and 
follicular granulosal wall at the junction to facilitate ovulation. Basement membranes on 
which OSE cells and the follicular granulosa cells rest are composed of type IV collagen 
(Lind et al. 2006). The follicular wall is supported by collagen I. Mammalian 
collagenases belong to group of matrix metalloproteinases (MMP) which degrade 
collagen. Accumulation of plasmin directly correlates with collagenase activity and with 
collagen degradation at follicular wall and basement membranes.  
 After the gondotropin-induced u-PA release from OSE, there is increased activity 
of apoptosis (plasma membrane phosphatidyl-serine translocation, internucleosomal 
DNA fragmentation) in the region of the surface epithelium in proximity to the follicle, 
adjacent tunica albuginea and apical follicle wall. Apoptosis is followed by cellular 













Figure 1.2 Ovulation-related biochemical interaction of OSE and underlying tissues. 
Thecal vascular LH (1) delivered to OSE (2) stimulates secretion of u-PA (3) that 
converts interstitial plasminogen to plasmin (4), activates collagenase MMP’s (5) and 
stimulates TNF- release (6). Collagenases disrupt theca and tunica albugenia (7) and 
promote digestion of the basement membrane (8) and granulosa cells via MMP, which 
eventually ruptures the follicle apex (10). Taken from Murdoch & McDonnel (2002).   
 
1.5 OSE and ovarian cancer 
The cell of origin of epithelial ovarian cancers (EOC) has been the subject of 
much debate (Dubeau 2008) but it is thought to originate from the sequestered and 
detached cells of the epithelial cells lined in the inclusion cysts in the ovarian cortex 
rather than in the surface monolayer. In the reproductive cycle, and post-menstrual phase 
the inclusion cysts are formed in typical regular round to oval shapes following 
ovulation or from mechanical displacement of OSE. These are eventually non-
pathologically destroyed with practically no remains left in the ovary. In patients 
suffering from different stages of ovarian cancer, irregularly shaped inclusion cysts that 
penetrate deeper into the cortex, become prominently visible besides the regular ones. 
The irregular cysts are normally not destroyed and continue to proliferate until 
occasionally they turn malignant. While both types of inclusion cysts have progenitor 
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cells for cancerous growth, the fundamental difference lies at the level of an ability to 
self-destroy the epithelial cells in some but not all inclusion cysts. As shown in Figure 
1.3, the most common OSE cells observed in ovarian surface, clefts and regularly shaped 
inclusion cysts are flat to cuboidal, while within irregularly shaped inclusion cysts and 
tumours the cells that line the tissues exhibit non-ciliated columnar to Müllerian type 
morphology. The nuclear proliferative marker Ki-67 clearly illustrates the extent of 
multiplication of different cell types during ovarian cyst development. The flat to 
cuboidal cells of clefts and regularly shaped cysts do not display any proliferative 
activity, but a sizable population of columnar cells in irregularly shaped cysts displays 
extensive proliferation. Consequently, genomic and epigenetic changes initiate pre-
neoplasia within such cells, and eventually they lead to advanced cancerous growth.  
Unlike in humans, ovarian cyst formation and EOC are extremely rare 
phenomena in rodents even after artificial gonadotrophin induced super-ovulation. One 
of the explanations for this is that an anti-proliferative signalling system in OSE prevents 
detachment of the cells to the underlying stroma after every cycle of normal or 
artificially induced ovulation. In mice OSE, one of the transforming growth factor-beta 
family ( TGF) of proteins; activin, initiates a signalling pathway mediated through 
phosphorylation of the downstream proteins, SMAD2 and SMAD3 that regulate 
transcription of a number of genes preventing cyst formation, OSE proliferation and 
invagination (Burdette et al. 2007). 
 A study was undertaken to ascertain to what extent apoptosis leads to degenerate 
regular and irregular inclusion cysts, an attribute that determines initial stage of 
tumourigenesis (Slot et al. 2006). It was revealed that expression of apoptosis markers - 
Fas, Fas ligand, and inactive form of pro-caspase 3 was missing or was redundant in flat 
to cuboidal cells but started to be seen in the columnar cells of irregularly shaped cysts, 
borderline tumours and carcinomas. Caspase 3 activation is essential for the ultimate 
execution of apoptosis signals manifest by surface Fas/Fas ligand (Krammer 1999). 
There was negligible to low expression of this protein relative to proliferative and other 
apoptotic markers in the irregular cysts, borderline tumours and advanced carcinomas. A 
limited number of apoptotic cells among the highly prevalent proliferating cells may 
lead to a disturbed balance between cell growth and death in irregularly shaped cysts, 
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and this could be a factor behind the onset of tumourigenesis. Inflammatory response in 
the cortex releases cytokines - interleukin-1ß, TNF, IFN etc. that activate the Fas/Fas 
ligand mediated apoptosis signalling in all kinds of inclusion cysts (Quirk et al. 1997). 
While in the regular cysts apoptosis leads to degeneration of proliferating cells, in 
irregular cysts signalling stops beyond pre-caspase 3, thereby initiating the apoptotic 
pathway but never completing it. As a result, a population of the epithelial cells 
profusely proliferates but is not subsequently destroyed, and this attribute triggers 
signals of pre-neoplasia in these cysts (Slot et al. 2006). 
 Mesodermally derived OSE is ubiquitous, expressing both epithelial (keratins) 
and mesenchymal (vimentin, N-cadherin) markers, but little or no E-cadherin. Clefts and 
cortical inclusion cysts also rarely express E-cadherin. On the other hand EOC, 
originating from deep irregular inclusion cysts, clefts, papillary cortical cysts and early 
tumours express E-cadherin at the initial stage of tumourigenesis. Recent findings 
(Hudson et al. 2008) suggest that unlike the other epithelia in which tumour progression 
is mediated through EMT, OSE undergoes mesenchymal to epithelial transition (MET) 
to develop the early tumours.  
 
Figure 1.3 Ki67 immunohistology of human ovarian surface (A), clefts (B), regular (C) 
and irregular (D) shaped inclusion cysts and mucinous carcinoma (E), arrows show 
positive immunostaining for Ki67 within the nuclei of OSE cells and (F) is the negative 
control. Taken from Slot et al. (2006).     
A B C 
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1.6 Histopathological evidence for origin of EOC 
 It is generally believed that EOC arises from the OSE that covers the ovarian 
surface (Salazar et al. 1996; Feeley & Wells 2001; Connolly et al. 2003; Lee et al. 
2007). However, the cell of origin of ovarian epithelial tumours remains a debatable 
issue. Auersperg and colleagues (2001) proposed that surface epithelial carcinoma can 
not be considered in isolation from the other ovarian epithelia derived from Müllerian 
duct during embryonic development. Histologically, the OSE malignancy can be 
considered to be serous (oviduct/fallopian tube-like), endometrioid (endometrium-type) 
and mucinous (endocervical-like) adenocarcinomas, with serous adenocarcinoma 
comprising about 80% of the total epithelial ovarian carcinoma (Levanon et al. 2008). 
According to Auersperg et al. (2008) high grade serous ovarian carcinoma of OSE do 
not arise from the OSE layer, as was previously thought, but it originates from a distal 
fimbriated part of the fallopian tube/oviduct, and are only secondarily manifested in 
metastasis within the ovarian surface. This concept is based on the common embryonic 
origin of OSE and the Müllerian ducts in the foetal coelomic epithelium. Cheng et al. 
(2005) indicated that the epithelial cells of serous, endometrioid, and mucinous ovarian 
carcinoma, as opposed to coelomic epithelium, express a set of HOX genes suggesting 
their common Müllerian origin. Several studies with convincing evidence suggested that 
the majority of EOC (borderline malignancy and low-grade carcinomas) originate from 
cortical inclusion cysts (CIC) within the ovarian stroma (Drapkin & Hecht 2002; 2006; 
Fleming et al. 2006).  These CIC are lined with epithelial cells resembling those cells 
lining the Müllerian epithelium that closely resembles the fallopian tube (Levanon et al. 
2008).  
 Another school of thought put forward the hypothesis of extra-Müllerian origin 
of EOC. Secondary Müllerian system are microscopic structures sometimes extending to 
the ovarian medulla or even in the deeper cortical regions, these structures are lined by 
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1.7 Cancer stem cells constitute a small proportion of OSE stem cells 
 The cyclic and repeated disruption and repair of the OSE with complex 
remodelling has led to a belief that there exists a population of somatic stem/progenitor 
cells within the OSE layer responsible for sustained wound healing (Szotek et al. 2008). 
Somatic stem cells are just the normal tissue cells with an ability to renew themselves by 
asymmetric division, and thereby they produce a set of daughter cells committed to 
rectify the damage by regeneration and repair. Parrot and colleagues (2000) investigated 
the expression of markers specific to somatic stem cells in the human and bovine OSE 
layer. Both human and bovine OSE cells exhibited positive staining for Kit ligand (KL) 
and its tyrosine kinase receptor c-kit which are typical stem cell factors (Parrot et al. 
2000a).  
 Increasing evidence supports the hypothesis that OSE tumour growth capacity 
depends on cancer stem cells (CSC’s) that arise from a small proportion of OSE stem 
cells (Pan & Huang 2008). It has been reported that CSC’s are responsible for 
aggressiveness of the disease, metastasis and resistance to chemotherapy (Bapat et al. 
2005). In EOC cell, a small subset of tumour stem cells, called side population (SP), 
actually proliferates as CSC’s and the rest of the population behaves like stem cells 
destined for damaged tissue repair. SP can be detected by their ability to efflux the 
DNA-binding dye Hoechst 33342 through an ABC membrane transporter (Pan & Huang 
2008). In a mouse model, several proliferative markers were used to distinguish the 
quiescent population of OSE cells from highly proliferative cells surrounding the post-
follicular wounded region in OSE layer (Szotek et al. 2006). A significant result was that 
two nuclear proliferation markers, bromo-dUracil (BrdU) and histone 2B green 
fluorescent protein (2HB-GFP) were retained by a quiescent cell population for up to 
four months, while another population within the same tissue rapidly lost the markers in 
a short period (Szotek et al. 2006). With high resolution confocal microscopy these 
authors demonstrated the possibility of asymmetric division of coelomic epithelial cells, 
which is highly characteristic of stem cells. The conclusion was that those cells which 
lost the markers were highly proliferative somatic stem cells showing asymmetric 
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division, and were distinct from the OSE tissue specific cells that were dividing less and 
as a result maintained the nuclear markers for longer periods (Szotek et al. 2006). 
 
1.8 Epidemiology and heredity of epithelial ovarian cancer (EOC) 
 Ovarian cancer is the fifth leading cause of cancer deaths, and results in the 
highest mortality rate among female cancers (Jackson et al. 2009). Over 90% of ovarian 
cancers arise from surface epithelium (Murdoch & McDonnel 2002). The extent of 
lethality in this cancer is the highest among various malignancies. At the initial stage the 
five year survival chances are only 45% and as the disease advances, the chances in the 
patients reduce further to 30% (Ponnusamy & Batra 2008; Landen, Jr. et al. 2008). Most 
ovarian cancers have no racial or ethnic prevalence, even though the incidences are 
generally higher in the Western countries. Though occurrence of ovarian cancer is 
recognized as sporadic, about 5-10% of incidences have familial history and risk among 
first-degree relatives (mother, sister and daughter) increases by 50% (Murdoch & 
McDonnel 2002). Wong & Auersperg (2003) and Sowter & Ashworth (2005) reviewed 
the nature of inheritable traits responsible for familial lineage of EOC. In many cases 
people carrying germline mutations in one of the alleles of the tumour suppressor genes 
BRCA1 (Breast cancer antigen 1) or BRCA2 are at significantly higher risk of acquiring 
breast or ovarian cancers. The BRCA1 and BRCA2 genes code for proteins that are 
responsible for DNA double stranded breaks by homologous recombination (Tutt & 
Ashworth 2002). Consequently, several chromosomal abnormalities and genetic 
instability lead to onset of cancerous transformation of mammary and ovarian epithelia. 
While BRCA protein is widely expressed in all kinds of cells, the prevalence of BRCA 
mutations in some tissues and not others, relates to the microenvironment of a particular 
tissue which becomes crucial for pathogenesis. Women inheriting mutations of BRCA1 
or BRCA2 genes have a ~40% or ~10% risk, respectively, of developing ovarian cancer 
by the age of 70. To a lesser extent, ovarian cancer risk increases in families with cases 
of heredity non-polyposis colon cancer (HNPCC). Internalization of OSE to form 
inclusion cysts is a highly proliferative act of the epithelial cells, which happens 
cyclically in the ovary at ovulation (Sowter & Ashworth 2005). Despite the 
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genotoxic/mitogenic effect of the local environment and inhibition of apoptosis, 
epithelial cells can maintain healthy progression so long as the BRCA proteins remain 
functional. Figure 1.4 shows the process of follicle ovulation and subsequent events 
leading to EOC. 
 Epidemiological studies revealed that the number of ovulations plays an 
important role in the initiation of ovarian cancer (Fathalla 1971; Meisler 2000), and 
repeated cycles of ovulation increases the risk of ovarian cancer (Tiedemann 2000). 
Contrary to this, factors that suppress ovulation process such as pregnancy, 
administration of oral contraceptives and lactation have been shown to exert a protective 
role against onset of ovarian cancer (Tiedemann 2000). Epidemiologic and cohort 
studies point to possible association between superovulation drugs and increased risk of 
ovarian cancer (Whittemore et al. 1992b; Rossing et al. 1994). However, a subsequent 
study supported by international pooled analysis of large sample showed no overall 
elevated risk of ovarian cancer after use of fertility drugs and gonadotrophins (Ness et 
al. 2002; Jensen et al. 2009).   
 Normally, glucocorticoids, like oestradiol, are believed to act as mitogenic and 
inflammatory agents enhancing the OSE cell proliferation at post-ovulatory damaged 
sites and may induce neoplastic transformations unless these cells are periodically 
removed by apoptosis. However, in a recent study using cultured human OSE cells it 
was found that there exists a local intracrine mechanism operational under inflammatory 
responses like interleukin stimulation, that enable OSE cells to overcome the damage 
during ovulation, A number of cytokines are known to be released and are present in 
high concentrations during the ovulation process (Kenny et al. 2008). Rae et al. (2009; 
2004) have worked on this system and proposed for the first time that cortisol, 
synthesized by the enzymatic activity of type I 11-hydroxysteroid dehydrogenase, 
inhibits the expression of several inflammation-related genes, and thereby act as an anti-
inflammatory agent. This anti-inflammatory cortisol in conjunction with paracrine 
progesterone suppresses the expression of matrix metalloproteinase (gelatinase), which 
is otherwise up-regulated in response to diverse ovulation-associated inflammatory 
agents, like cytokines.    
 




Figure 1.4 Diagrammatic representations of the normal ovulatory cycle and events 
leading to EOC. (A) Progressive role of ovulation in chronology of EOC and (B) OSE 
during repeated ovulation and mitogen exposure and accumulated mutations particularly 
in individuals with BRCA lesions invaginates as inclusion cysts and epithelial cells turn 
malignant and then manifest as serous carcinoma. Adapted from Murdoch & McDonnel 
(2002) and Sowter & Ashworth (2005).  
 
1.9 Ovarian follicle development  
 The ovary is a dynamically changing environment and the OSE cells are likely to 
interact with the underlying stroma and follicles at all stages. In mammals, OSE assists 
in dissolution of the follicle apex and all the underlying connective tissue and helps in 
releasing the matured ovum. Further, the mitogens mostly present in follicular fluid 
influence the OSE proliferation, re-epithelization and tumourigenesis. Given this nature 
(A) (B) 
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of intimate relationship between the two integral tissues of ovary, it is necessary to 
discuss in the following section the key features of mammalian follicle development. 
The oocytes and their surrounding somatic cells constitute the fundamental 
reproductive unit of the ovary, the ovarian follicle. The ovarian cortex of a young 
woman is largely filled with progressively developing follicles, whereas with aging due 
to repeated ovulation and atresia most of the follicles are replaced by fibrous tissue. The 
maximum number of ovarian follicles is found just prior to birth, and this gradually 
declines during childhood and then drops sharply before menopause leaving just ~1000 
aging follicles which are non-ovulatory (Faddy & Gosden 1996). There are two distinct 




 The germ cells originating from embryonic ectoderm migrate during early 
gestation to the genital ridge. In humans, once the gonad has differentiated as an ovary, 
germ cells develop into oogonia (between 7 and 9 weeks gestation). These oogonia 
continue to multiply through mitosis (Faddy et al. 1992) until they start to enter meiosis 
(around 10-11 weeks gestation) and oocytes become arrested at diplotene stage of the 
first meiotic prophase. These oocytes are termed primordial oocytes. By the fifth month 
of human gestation about 7 million oocytes are produced, followed by extensive wave of 
atresia (Baker 1963) of which only 2 million remain at birth. At puberty approximately 
400,000 primary oocytes still remain (Faddy 2000), and this is the quota for the 
reproductive phase of a woman. From this population of oocytes only a maximum of 
400-500 (0.1%) of follicles mature and ovulate, whereas the remainder become atretic.  
 Recent studies have suggested that postnatal oogenesis may also occur in female 
mammals (Johnson et al. 2004). They suggested that germline stem cells can repopulate 
the postnatal ovary and renew the primordial follicle pool. This group subsequently went 
on to suggest that these cells were derived from bone marrow (Johnson et al. 2005). This 
has attracted a great deal of attention as well as criticism (Gosden 2004; Byskov et al. 
2005; Telfer et al. 2005). This is an ongoing debate but the balance of evidence suggests 
that renewal is not a major factor in ovarian development (Eggan et al. 2006).  
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 From the onset of puberty to menopause approximately 15-20 primary oocytes 
are released into the growing pool in each menstrual cycle, completing the meiosis-I and 
continuing through meiosis-II until metaphase. The second meiotic cycle only completes 
upon fertilization.  
 
1.9.2 Folliculogenesis    
 This is a sequential process in which the follicles mature from primordial to the 
preovulatory stage. The pool of primordial follicles develops during fetal life in some 
species (e.g primates, ruminants), but in others it develops during the early neonatal 
period (e.g rodents, rabbits) (Marion et al. 1971). Two major processes accomplish this 
development, a) recruitment of the follicle in to the growing follicle pool, and b) 
proliferation and differentiation of theca and granuolsa cells. The first process is 
controlled by localized autocrine and paracrine factors produced within the ovary, 
whereas the latter is regulated by both localized internal factors as well as the endocrine 
signals from outside the ovary. 
 
1.10 Stages of follicular development 
 The quiescent primordial follicle in bovine (diameter, ~40 µm) is constituted by 
the immature oocyte surrounded by a single layer of squamous (flattened) pre-granulosa 
cells, and covered by a basement membrane which separates the follicles from 
surrounding ovarian cortex (Gosden 2002). Two events transform primordial follicles to 
primary follicles, a) granulosa cells start to proliferate and grow into large cuboidal cells, 
and b) transcription in the oocyte is activated resulting in cell-to-cell paracrine signalling 
between the oocyte and surrounding granulosa. At this stage both the cell types start to 
grow and mutually interact. Primary follicles (diameter, 40-80 µm; bovine) are the first 
level of activation of the recruited primordial follicles. A significant property of 
granulosa cells is that they secrete mucopolysaccharides around the growing oocytes to 
form the zona pellucida (ZP) (Epifano et al. 1995; Wassarman 1988). ZP is a thick layer 
of glycoproteins and proteoglycans between oocyte and the granolosa layer. The exact 
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source of ZP glycoproteins is not clearly established because both granolosa and 
primordial oocyte have been shown to produce these proteins (Gook et al. 2008).  
 Occasionally, a fraction of the pre-granulosa cells transform to cuboidal 
granulosa cells typical of primary follicles. Surrounding the basement membrane are the 
cumulus cells that keeps a gap junction with the oocyte plasma membrane by projecting 
their microvilli through the ZP (Li et al. 1995). This allows bidirectional exchange of 
nutrients, metabolite precursors, and signal molecules, including growth factors (Eppig 
1991). As granulosa cells proliferate further and form multiple layers around larger 
oocytes, the follicles differentiate into secondary or preantral follicles (diameter, 80-250 
µm; bovine). Additional stromal cells from the surrounding region are recruited over the 
basement membrane to produce two distinct layers, called theca interna and theca 
externa. At this stage the follicles start to obtain their blood supply through 
microvascular tissue developed between the two theca layers (Reynolds et al. 1992). 
With the advent of blood supply, circulating follicle stimulating hormone (FSH) 
facilitates formation of a multi-lamellate follicle of many layers of actively dividing 
granulosa cells. FSH receptors begin to appear on the granulosa cell surface, while LH 
receptors are exclusively seen in theca cells.  
 The early antral follicle (diameter, 250-500 µm; bovine) contains a fluid filled 
sac called the antrum, which contains blood exudates and local secretions including 
hormones and metabolites. Upon stimulation with LH the theca cells produce androgen, 
which is then converted to oestrogen within the granulosa cells. A large fluid-filled 
Graafian or antral (tertiary) follicle represents a mature follicle. These follicles contain 
two distinct layers of granulosa cells - the cumulus granulosa cells surrounding the 
oocyte and mural granulosa cells along the follicle wall. Bovine preovulatory follicles 
may reach a size of approximately 20 mm. During the ovulatory cycle many antral 
follicles start to grow but only one will ovulate with the rest becoming atretic. Figure 1.5 
presents an outline of different stages of folliculogenesis. 
 





Figure 1.5 Folliculogenesis and classification of developing follicles in human ovary. 
Taken from Gougeon (1996). 
 
1.11 Follicular growth during the menstrual and oestrus cycle 
 Analysis of development of large follicles (secondary to preantral) in mammalian 
species shows that their development occurs only at particular reproductive states or 
during particular times of the reproductive cycle (Fortune 1994). In humans and other 
primates, a large ovulatory follicle only appears at a particular time rather than randomly 
during the cycle. A cohort of growing follicles emerges at the early follicular phase and 
only one follicle continues to grow through to the late follicular phase whereas the rest 
of the cohort regresses. No ovulatory size follicles develop in the luteal phase. In the 
other species (cattle, horses, sheep) follicular development involves the development of 
ovulatory size follicle throughout the cycle, including the luteal phase. Two-to-three 
times during the cycle a “wave” of 3-6 follicles continues to grow until they reach a size 
close to 5 mm. One of them, slightly larger than the others, continues to grow further 
while the remaining subordinate follicles regress. Follicular waves also occur during the 
luteal phase and even during pregnancy and the pre-pubertal phase. The emergence of 
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each follicular wave in ewes (Toosi et al. 2010) and heifers (Adams et al. 1992) is 
preceded by a sharp increase in circulating FSH concentrations.  
Conventionally, the ovarian cycle in women starts on the first day of 
menstruation, it commences with a follicular phase followed by “mid point” ovulation 
and then a luteal phase. In between the two consecutive cycles there exists an inter-
ovulatory interval (IOI) which starts with luteal phase of the preceding cycle followed 
by the follicular phase of the next cycle. It has been recently demonstrated by Baerwald 
et al. (2003) that selection of a dominant follicle over the subordinate follicles in women 
occurs not just once during the follicular cycle as perceived earlier, but 1-3 times during 
IOI which is in consistent with the observation with the bovine and equine. Distinct 
major and minor waves of follicular growth were observed in ovaries of women and 
mares (Baerwald et al. 2003; Ginther 1993). Major waves were those in which dominant 
follicle was selected for further growth until ovulation, while in minor waves growth and 
dominance of the follicle was not manifest. In bovine species all waves during IOI were 
major and only the last one called “ovulatory wave” led to the development of the 
dominant ovulatory follicle. The dominant follicles in preceding waves did develop but 
then these underwent regression, resulting in “anovulatory waves”. In contrast, women 
exhibited major and minor waves during IOI. The final wave of IOI was a major 
ovulatory wave and the preceding waves were either anovulatory major waves or were 
minor waves. In women too, the circulating FSH surge was associated with anovulatory 
major waves in IOI, but the ovulatory wave was independent of FSH level. Hence, for 
all practical purposes the mammalian species exhibit a similar wave pattern of 
folliculogenesis in the IOI phase. 
 
1.12 Local regulatory growth factors/hormones and signalling molecules  
1.12.1 Transforming growth factor- (TGF-) superfamily in follicle recruitment and 
development 
 About 40 proteins with similar structures including six cysteine residues belong 
to this superfamily that influences the growth and development of the follicle (Erickson 
& Shimasaki 2000). Broadly, three categories of growth factors namely TGF- itself; 
Chapter One                                                                                                                20
 
 
activins and inhibins; and bone morphogenetic proteins (BMP’s) and growth and 
differentiation factors (GDF’s) induce a cascade of signal pathways in growing 
granulosa through two transmembrane serine/threonine kinase receptors, the activin 
receptor like kinase 5 (ALK5; type I) and BMP receptor II (BMPRII; type II). According 
to Hutt & Albertini (2007), GDF-9 is expressed in oocytes throughout folliculogenesis. 
Deletion of the gdf-9 gene in mice resulted in infertility with ovaries in which follicle 
development was hindered due to lower proliferation of granulosa cells and reduced 
ability in assembly of theca cells. Eventually the oocytes degenerated. GDF-9 signals are 
mediated through type I and II receptors and the SMAD2/3 pathway in granulosa cells. 
BMP-15 is a homologue of GDF-9 and is also constantly secreted by oocytes. Mutation 
in the bmp-15 gene arrested follicle development at the primary stage and oocytes were 
lost from granulosa cell clusters. BMP-15 binds to type II receptor and functions in 
conjunction with GDF-9. More recent findings supported a hypothesis that these factors 
contribute to a bidirectional cell-to-cell interaction through gap junctions and paracrine 
signalling between oocytes and surrounding mural granulosa and cumulus cells in 
preantral follicles (Li et al. 2008). This attribute is advantageous for oocyte competence 
and good quality, being regulated by the somatic cells. BMP-15 and BMP-6 protect the 
cumulus cells from undergoing apoptosis, and thereby the oocyte creates a favourable 
microenvironment of surviving cumulus cells (Hussein et al. 2005). GDF-9/BMP-15 
cooperatively regulates cholesterol biosynthesis in cumulus cells (Su et al. 2008).  
During early folliculogenesis, GDF-9/BMP-15 stimulates Kit ligand (KL) 
expression in granulosa cells. Together with its tyrosine kinase receptor c-Kit present in 
oocytes, KL is responsible for survival, growth and differentiation of primordial germ 
cells. KL/c-Kit in a paracrine mode down-regulates the expression of GDF-9/BMP-15 
and thereby creates a negative feedback loop between granulosa cells and the oocyte. 
Hutt et al. (2006) elucidated a role of KL/c-Kit in folliculogenesis. Activation of 
primordial follicles and recruitment is promoted by KL. KL may also be involved in 
survival of primordial and preantral follicles most likely by evading apoptosis. In the 
growing follicle, KL also maintains the arrested status of meiosis-I. The LH surge 
decreases production of KL in cumulus and mural granulosa, a condition that resumes 
oocyte meiotic division. KL has also been shown to facilitate theca cell recruitment 
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(Parrott & Skinner 1998) and interaction between theca and granulosa cells in 
preovulatory follicles, especially the step of oestrogen biosynthesis from androgen 
(Parrott & Skinner 1997). 
According to Nilsson et al. (2007), transition of primordial to primary follicle is 
controlled by inhibitory and stimulatory growth factors. Among the stimulatory factors 
prominent are fibroblast growth factor-2 (FGF2) and KL (Nilsson et al. 2001b; 2006). 
One of the inhibitory factors is Anti-Müllerian hormone (AMH), a member of TGF- 
superfamily which binds to AMH receptor 2 (AMHR2) on the granulosa cell surface and 
suppresses proliferation by way of up-regulation of genes under the control of SMAD 
proteins (Carlsson et al. 2006). AMH is also reported to partially block the binding of 
FSH and LH to their receptors and the gonadotrophin-induced follicle development is 
also consequently suppressed (Durlinger et al. 2001). In microarray analysis, AMH was 
found to negatively interact with different stimulatory growth factors specific to oocyte 
and granulosa/theca cells, and affect the downstream signalling pathway necessary for 
follicle transition and development (Nilsson et al. 2007). 
 
1.12.2 Angiogenic factors 
 The second important component of follicle development is the vasculature for 
blood supply of oxygen, nutrients, hormones and removal of CO2 arising from 
respiration. According to Bruno et al. (2009) a wide range of pro-angiogenic and anti-
angiogenic factors regulate folliculogenesis and any perturbation leads to atretic 
degeneration of the follicle at any stage of development. Quiescent primordial to slow 
growing preantral follicles do not have a blood supply of their own, but as the antrum 
develops the thecal layer acquires vasculature in the form of two capillary networks in 
theca interna and externa (Stouffer et al. 2001). The most crucial granulosa cell-
produced angiogenic factor is the Vascular Endothelial Growth Factor (VEGF) (Fraser 
& Duncan 2009), responsible for establishing and increasing the density of the capillary 
network and assembling the circulating endothelial cells. The assisting pro-angiogenic 
growth factors that function in conjunction with VEGF are FGF-2 and angiotensin 
(ANG II) (Redmer et al. 2001). VEGF also enhances capillary permeability and 
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maintains endothelial cells for microvascularization (Bruno et al. 2009). VEGF is 
produced in oocytes of primordial to primary follicles (Ferrara et al. 2003) but in 
dominant follicles granulosa and theca cells take over this function (Barboni et al. 2000). 
Angiogenic endothelial cells display positive VEGF receptor expression, and they start 
to assemble towards inner theca as initial steps of vascularization.  
 
1.12.3 Systemic hormones in follicle development 
 In different mammalian species the pituitary gonadotrophins (FSH and LH) and 
insulin-like growth factor I and II (IGF-I and IGF–II) have considerable impact on the 
later development of multi-lamellar follicles and on ovulation (Ryan et al. 2008; 
Campbell et al. 2009). In fact, the effect of the gonadotrophins is seen mostly on the 
dominant ovulatory follicle when the other sub-ordinate follicles start to regress. Both 
gonadotrophins, FSH and LH induce steroidogenesis and proliferation via binding to 
specific G protein-coupled receptors, which lead to a rise in cyclic adenosine 
monophosphate (cAMP) and activation of the protein kinase A (PKA) pathway (Seger et 
al. 2001), which is considered as the principle mediator; additionally these hormones 
stimulate other signalling pathways; the extracellular signal-regulated kinase (Erk) 
(Babu et al. 2000) and Akt (Zeleznik et al. 2003) pathways. Beside gonadotrophins other 
growth factors, mainly IGF’s, stimulate theca and granulosa cell proliferation and 
augment gonadotrophin action to stimulate steroidogenesis (Davidson et al. 2002). In 
addition IGF’s display high anti-apoptotic effect primarily on the dominant follicle, 
while its expression diminishes in the atretic subordinate follicles that are prone to 
apoptotic degeneration (Chamoun et al. 2002). These signalling pathways up-regulate 
the production of progesterone and oestradiol in the granulosa cells. In addition, the 
follicles also express high levels of TGF- family growth factors like inhibin-A, activin-
A and AMH, which interact with gonadotrophin-mediated signal transduction. Thus, 
local growth factors not only modulate the gonadotrophin-independent primordial to 
primary follicle development, they also regulate LH and FSH action on granulosa and 
theca cell proliferation at later stages of folliculogenesis. BMP-6 is a factor that 
augments the gonadotrophin action by increasing FSH induced oestradiol and inhibin A 
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production while decreasing FSH induced progesterone production by granulosa cells 
(Campbell et al. 2006; Otsuka et al. 2001). AMH acts as an inhibitor of gonadotrophin-
induced follicle development without affecting steroidogenesis. Further, BMP-15 and 
GDF-9 exert an inhibitory effect on LH-induced thecal steroidogenesis. Increased 
activity of gonadotrophin augmenters (BMP-6) and decreased activity of gonadotrophin 
attenuators (AMH, BMP-15, and GDF-9) may increase FSH sensitivity resulting in 
alteration in the mechanisms of follicle selection (Campbell 2009). 
 
1.13 Rationale of endocrine and developmental factors in ovulation 
 According to Diaz et al. (2007), preovulatory antral follicles are comprised of 
somatic cells that exhibit both endocrine and developmental functions. The cumulus 
cells in proximity to the oocyte obtain the developmental signals responsible for growth 
and competence of the oocyte via the micro-environment created by adjoining cumulus 
cells (Figure 1.6). Prior to the LH surge, oocyte-derived TGF- signaling pathways 
regulate the function of cumulus cells and oppose FSH action. Consequently, cumulus 
specific transcripts, Slc38a3, Amh and Ar, required for oocyte growth and competence 
are produced in cumulus cells. Opposing FSH action maintains the cumulus phenotype 
in these granulosa cells without them being converted to mural granulosa cells. FSH 
interacts with the mural granulosa beneath the follicle wall and induces transcripts for 
steroidogenesis (Cyp11a1), ovulation (Lhcgr) and immune function (Cd34). After the 
LH surge, not much change occurs in mural granulosa, but the mRNA expression profile 
of cumulus cells radically change to cumulus expansion specific transcripts, Has2, 
Ptgs2, Ptx3 and Tnfaip, which enables detachment of the developed oocytes in the antral 
fluid for release upon follicle rupture (Diaz et al. 2007).  





Figure 1.6 (A) Oocyte-cumulus cell regulatory loop showing release of TGF- factors 
which influence cumulus phenotype enabling oocyte developmental competence. (B) 
Shifting of gene expression due to LH surge and expression of cumulus expansion genes 
enabling freedom of oocyte for release. Adapted from Li et al. (2008) and Diaz et al. 
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1.14 Aims of the project 
 Epithelial ovarian cancer is thought to arise from ovarian surface epithelial cells 
that are entrapped within the ovarian cortex during or after ovulation. Epidemiological 
studies reveal that pregnancy and progesterone-based contraceptive drugs play a 
protective role against ovarian cancer though the underlying mechanism is largely 
unknown. Although OSE has attracted the attention of researchers due to its structural 
and functional involvement in progression of over 90% of the ovarian cancers, a 
systematic investigation of such a fragile layer has been difficult for several reasons, 
namely a) OSE comprises a small fraction of the whole ovary, therefore only a small 
number of cells can be obtained for the in vitro study, b) in cultures OSE cells take 
around 3-4 weeks to attain confluence, and c) it is difficult to compare in vivo and in 
vitro conditions. It is therefore essential to study OSE morphology in vivo and to 
determine how underlying ovarian tissue and stage of cycle interacts with OSE cells.  
Much of the earlier research on OSE , particularly its involvement in neoplastic 
development, used the mouse as a model but this is not the best model for human since: 
a) ovarian senescence and malignancy in cycling and breeding mice is quite rare and so 
experimental material would not be normally available unless artificially induced, b) 
although there are some recent contradictions, mouse OSE cells are believed to be held 
together with E-cadherin whereas for human it is N-cadherin, and this difference has 
direct implication in mesenchymal-epithelial transformation, c) human epithelial ovarian 
cancer often forms metastasis in the peritoneal cavity and ascites, which may be 
fundamentally different in the mouse due to the presence of a bursa sac that forms a 
physical barrier around the ovary preventing immediate access to the peritoneal space, 
and d) precancerous surface marker, CA-125 is not produced in mice. Therefore models 
such as sheep and cows that share many similarities to human may be more appropriate  
The work presented in this thesis is the first to carry out an in situ morphological 
and functional analysis of OSE cells at different stages of ovulatory and luteal cycles, 
and during pregnancy using different animal model systems. This allows us to tackle the 
question of whether the effect of pregnancy on OSE cells is a general phenomenon seen 
in other species. 
Chapter One                                                                                                                26
 
 
The specific objectives pertaining to each chapter embodied in this thesis are: 
(1) To examine the proliferative activity of the ovine OSE cells through the regular 
ovarian cycle and during pregnancy in ovine model by monitoring proliferation in vivo 
using immunohistochemistry (IHC) of proliferation markers PCNA and Ki-67, and also 
to investigate whether the underlying growing follicles have any influence on OSE layer. 
This was achieved by monitoring the follicular dynamics and proliferation during 
oestrus and anoestrus stages and during pregnancy (Chapter Two). 
(2) To examine, using cultured ovine OSE cells, a role of local ovarian components, 
namely growing follicles and corpora lutea and their chemical constituents - steroids and 
growth factors, in regulating the proliferative activity of OSE (Chapter Three). 
(3) To test the hypothesis that pregnancy suppresses EOC by inducing apoptosis within 
the OSE layer and inclusion cysts, a process mediated through over-expression of p53 
gene, which is under the control of high progesterone and oestrogen level. For the in situ 
tests bovine histological tissues and for in vitro analysis cultured OSE cells were used. 
This is because the EOC is reported in cows but not in sheep (Chapter Four).  
(4) To examine a role of pregnancy and of inhibition of pituitary gonadotrophin 
production by administration of GnRH antagonist, on OSE cells’ morphology and 
activity in a non-human primate, the marmoset monkey. For this, IHC method was 
selected using BrdU proliferative marker at different stages of the ovulatory cycle and 
during pregnancy (Chapter Five).  







The Influence of the Reproductive Stage on OSE 
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2.1 Introduction 
The ovarian surface epithelium (OSE) forms a lining around the entire ovary and 
actively participates in the ovulatory cycle. Before ovulation occurs OSE cells close to 
the rupture site of the follicle undergo apoptotic cell death (Murdoch 1996). It is 
assumed that the wound caused by ovulation is repaired by proliferating OSE cells 
(Osterholzer et al. 1985). Research in rabbits has shown proteolytic enzymes capable of 
degrading the basement membrane and apical follicular wall are produced by the OSE 
(Bjersing & Cajander 1975). The biology of OSE cells is of interest since the majority of 
human ovarian cancers originate in these cells (follicular granulosa cells, stroma, and 
germ cells account for the remainder) (Vanderhyden et al. 2003). 
Epithelial ovarian cancer (EOC) is the fifth most common female cancer world 
wide and the most lethal gynaecological malignancy (Jackson et al. 2009). Cancerous 
growth in these cells is thought to be associated with high proliferative activity in the 
OSE cells where multiple ovulations have occurred. Murdoch (2005) hypothesized that 
repeated cycles of ovulation-induced trauma and repair of the OSE at the site of 
ovulation contributes to malignancy and may be associated with mitogenic effects of 
hormones. This hypothesis is supported by in vitro experiments where isolated murine 
OSE cells continuously maintained in proliferative conditions acquired malignant 
features, including loss of contact inhibition, substrate-independent growth, and the 
ability to form tumours in nude mice (Roby et al. 2000).  
Epidemiological data has shown that pregnancy and the use of oral 
contraceptives can reduce the risk of EOC development (Clow et al. 2002). 
Additionally, it has been reported that EOC is absent in animal species in which seasonal 
ovulation and multiple pregnancies take place (Fathalla 1971). Although pregnancy is 
proposed as a protective factor against ovarian cancer, the mechanism by which it works 
is unknown. During pregnancy, several factors may alter the ovarian physiology and 
with it the dynamics of follicular growth. Suppression of ovulation and steroid 
production by the pre-ovulatory follicles may alter the physiological status of the OSE 
specifically at the area of direct contact with the growing follicles.  Therefore, the 
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influence of pregnancy on OSE may be an indirect effect via changes in growth of 
ovarian follicles.  
Several studies have focused on follicular dynamics during pregnancy (Rizzo et 
al. 2009; De los et al. 2006; Ohshima et al. 2002; al-Gubory & Martinet 1986), but none 
of them looked at the effect of pregnancy on the OSE cells. Indeed, as most of the OSE 
research has been conducted in vitro, little data exists regarding the in vivo situation.  
This study was designed to investigate the relationship between stage of the 
reproductive cycle, follicle dynamics and OSE activity. The sheep was used as an in vivo 
model since this is a mono-ovular species and a seasonal breeder; therefore it is a 
suitable model to investigate the proliferative activity of the OSE during a quiescence 
stage such as anoestrus. Ovulatory cycles in most sheep breeds in the northern 
hemisphere occur in a regular pattern between autumn and winter with oestrus cycles 
that range in length from 14 to 18 days (Hafez 1952). Ewes exhibit an anoestrus phase 
that starts from the end of spring until the start of summer. Ovaries from ewes at 
different stages of the cycle and during pregnancy can be easily obtained from the local 
abattoir. 
The aims of the work described in this chapter were: 1) to examine the 
relationship between reproductive stage of the cycle (pregnancy, anoestrus, and oestrus), 
and the proliferative activity of the OSE and 2) determine whether a relationship exists 
between OSE activity and its location within the ovary, specifically the influences of 
growing follicles on OSE cells morphology and activity.  
A detailed morphometric analysis to categorise the ovarian follicle population 
during different stages of the reproductive cycle was carried out. To correlate the pattern 
of follicle development dynamics with OSE activity, cell proliferation was monitored 
using immunohistochemistry (IHC) of proliferating cell nuclear antigen (PCNA) and Ki-
67 proteins, which are standard methods for detecting proliferating cells in tissue 
sections (Tomanek & Chronowska 2006; Scholzen & Gerdes 2000). 
 PCNA is a nuclear protein whose expression is markedly increased during the 
proliferative phase of the cell cycle (Travali et al. 1989). It has a critical role in the 
process of DNA damage repair, including nucleotide excision repair and mismatch 
repair (Nichols & Sancar 1992; Umar et al. 1996). Another competitive proliferating 
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marker is Ki-67 whose expression is strictly correlated with the active phase of the cell 
cycle. The Ki-67 antigen is consistently absent in quiescent cells and is not detectable 
during the DNA repair processes (McCormick et al. 1993). 
The hypothesis being tested is that periods of anovulation through either 
pregnancy or seasonal anoestrus results in down regulation of follicular activity and 
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2.2 Materials and methods 
2.2.1 Animals  
Adult ewe ovaries from cycling and pregnant animals were collected from a local 
abattoir. The ovaries were gently handled during collection to avoid cell loss by 
excessive handling as the OSE is a very fragile layer. Ovaries were then transported in a 
sterile thermos containing culture media of M199/MCDB 105 supplemented with 100 
U/ml penicillin and 100 µg/ml streptomycin (Sigma).  The ovaries were classified 
according to the reproductive status of the ewes: 1) ovaries from cycling ewes (n = 6) 
(visible ovarian activity and corpus luteum (CL) present) in the age range of 14–18 
months were collected during February (breeding season), 2) ovaries from anoestrus 
ewes (n = 5) (absence of the follicular activity and no CL) were collected during June 
(non-breeding season), and 3) ovaries from ewes with an identifiable pregnancy 
(presence of the foetus in the uterine horn). This last group was further sub-divided into 
two groups based on the stage of pregnancy using foetal crown-rump length to 
determine the stage of pregnancy (Sivachelvan et al. 1996). The two groups were as 
follows:  ovaries in early-mid gestation (30–75 days) (n = 8) and ovaries in mid-late 
gestation (80–135 days) (n = 9), full term pregnancies range from 144–155 days. 
Material from pregnant animals was collected alongside material from cycling animals, 
and only ovaries from singleton pregnancies were used for this study. 
 
2.2.2 Histological methods 
 Ovaries were processed for histological analysis by fixing them in Bouin’s 
solution. They were then transferred through 70 to 100 percent graded alcohols, cleared in 
cedar wood oil, and embedded in paraffin (McCormack Scientific, St Louis, Mo). Wax 
mounted ovaries were serially sectioned at 6 µm using a microtome (Leica, model Jung 
RM2035, Nussloch, Germany). The sections were mounted on SuperFrost plus 
microscope slides (VWR International Ltd., Leicestershire, UK) and left to dry overnight 
at 37 ºC.  
For the morphology and morphometric study, analysis was done on every tenth 
section with sections in between left aside for IHC. Sections were dewaxed and 
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rehydrated (100 to 70%) using descending concentrations of ethanol. The sections were 
stained with eosin (Sigma Chemicals, Poole, Dorset, UK) and haematoxylin (BDH 
Laboratory Supplies, Poole, UK), dehydrated through ascending series of ethanol. After 
placing the sections in xylene, DPX (BDH Laboratory Supplies, Poole, UK) was applied 
as a mounting medium. Sections were examined microscopically using a light 
microscope (ML2300/T/S Meiji) fitted with an ocular micrometer and digital video 
camera (JVC TK-1381 CCD) for image capture.  
 
2.2.3 Follicle classification 
Ovarian follicular distribution during the different reproductive stages was 
studied by classifying and counting each stage of follicle development in each group. 
Morphological observations were carried out on every tenth section. Follicles were 
classified according to criteria described by McNatty et al. (1999) as primordial, 
transitory, primary, preantral, and antral (Table 2.1). In the classification system for 
ovine follicles used in this study, the follicles are classified as a primordial follicle when 
the oocyte is surrounded by one layer of flattened granulosa cells (GCs); a transitory 
follicle when the oocyte is surrounded by one layer of flattened and cuboidal GCs; a 
primary follicle when the oocyte is surrounded by one or two layers of cuboidal GCs; a 
preantral follicle when the oocyte is surrounded by four to six layers of GCs thereby 
making the follicle variable in size; and an antral follicle when the oocyte is surrounded 
by more than six layers of GCs and has a visible antral cavity (Figure 2.1). 
To avoid counting the same follicle more than once through the sections, only 
follicles with a clearly visible oocyte nucleolus were counted. An ocular micrometer was 
used to measure the diameters of antral follicles. Two measurements for each antral 
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Table 2.1 
Classification and characterisation of ovine follicles 
Follicle type Layers of GCs cells 
Presence of theca 
(%) 
Primordial 1 layer of flattened cells 0 
Transitory 1 layer of flattened and cuboidal cells 0 
Primary 1–2 layers of cuboidal cells 35 
Preantral 4-6 layers  100 


















Figure 2.1 Histological representation of ovine follicles at different stages of 
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2.2.4 Quantification of ovarian follicles 
Due to the large size of the ewe ovary (~1.5 x 1 x 0.8 cm) follicle counts were 
carried out using a sampling method. To determine whether sampling from one region of 
the ovary was representative of others, the whole ovary was divided into three parts, and 
each part was analyzed individually (Figure 2.2). The exact number of follicles cannot 
be assessed reliably using this sampling technique, but will enable a sufficiently accurate 




Figure 2.2 Sampling method to estimate ovarian follicle distribution per ovary. A 
sampling technique was performed to determine whether a part (one-third) of the ovary 
is representative of the distribution of ovarian follicles. One whole ovary from each 
group of the study (cycling, anoestrus, and pregnant) was studied. (A) One ovary was 
chosen randomly from each group, (B) selected ovaries were divided longitudinally into 
three equal parts, (C and D) each part was processed for histology (sectioned at 6µm) 
and (E) microscopic analysis.  
 
The result from Kruskal-Wallis test (P< 0.05) revealed that the distribution of follicular 
stages was representative throughout the three parts of the ovary tested; therefore, only 
one part of the ovary was selected for subsequent analysis of the remaining ovaries. 
Counting was carried out for every tenth section for each of the three parts using a light 







A B C D E 
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Table 2.2  
Ovarian follicle distribution from cycling ewes 















Primordial 1152  39.0 655  25.0 238 35.0 
Transitory 1617 55.0 1758 67.0 419 61.0 
Primary 125 5.0 182 7.0 19 3.0 
Preantral 23 0.8 14 0.5 7 0.9 
Antral 13 0.4 11 0.4 6 0.1 
 
Table 2.3 
Ovarian follicle distribution from anoestrus ewes 















Primordial 2301 57.9 2061 58.0 2019 56.0 
Transitory 1562 39.4 1393 39.0 1478 41.0 
Primary 85 2.1 81 2.2 84 2.3 
Preantral 7 0.2 9 0.3 11 0.2 
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Table 2.4 
Ovarian follicle distribution from pregnant (mid-late gestation; 80–135 days) ewes 















Primordial 2464 27.0 1504 33.0 2633 36.0 
Transitory 6253 69.0 2816 62.0 4558 61.0 
Primary 289 3.0 158 4.0 191 3.0 
Preantral 36 0.4 21 0.5 32 0.4 
Antral 24 0.2 11 0.2 19 0.2 
 
2.2.5 PCNA and Ki-67 immunohistochemistry 
The effect of the reproductive stage (oestrus, anoestrus or pregnancy) on 
proliferative activity of the OSE and GCs was investigated using IHC to PCNA and Ki-
67 in order to quantify proliferating cells. Sections were de-waxed in xylene, and 
hydrated in descending grades of alcohol to distilled water, and followed by double 
washing with phosphate buffer saline (PBS). A heat-induced epitope retrieval method 
was performed (antigen retrieval) by microwaving (high power at 800W) the sections in 
a 0.01M citrate buffer (pH 6.0) for 10 min, and letting them stand in hot buffer for a 
further 20 min. Endogenous peroxidase activity was inactivated through incubation with 
3 percent hydrogen peroxide in methanol. An Invitrogen PCNA staining kit was used for 
PCNA detection (93-1143, Invitrogen Corporation, Camarillo). All the reagents included 
in the kit (blocking solution, biotinylated mouse anti- rat PCNA monoclonal antibody, 
streptavidin-peroxide, and 3,3-Diaminobenzidine tetrahydrochloride (DAB) chromogen 
were ready prepared. Sections were incubated with blocking solution for 10 min 
followed by overnight incubation with the primary antibody (biotinylated mouse anti-
PCNA clone PC10) at 4° C.  After rinsing with PBS, sections were incubated for 10 min 
with streptavidin-peroxide complex at room temperature. Following the PBS wash, DAB 
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solution was added to the sections for between 5 and 10 min. After being washed with 
tap water, sections were counterstained with hematoxylin for 25 sec, dehydrated in 
graded alcohol, cleared, and then mounted with DPX.   
 Ki-67 lyophilized rabbit anti-human polyclonal antibody (NCL-Ki 67p, 
Novocastra Laboratories Ltd., UK) was used for Ki-67 detection. Antigen retrieval and 
endogenous peroxidase activity blocking were performed as described previously 
(PCNA staining). The NovoLink polymer detection system (RE7 150-K, Novocastra 
Laboratories Ltd., UK) was used for visualization. Sections were incubated with protein 
block for 5 min, followed by an overnight incubation with the primary antibody (1:2000 
at 4° C). After being washed with PBS, a post-primary block was performed for 30 min. 
Sections were incubated with the NovoLink polymer solution for 30 min, and then 
washed with PBS. Peroxidase activity was developed using a DAB solution for 5 min. 
Sections were counterstained using hematoxylin stain. Further optimization of Ki-67 
antibody was necessary to enhance the permeability to the tissue. Antibody incubation 
time and temperature were adjusted to overnight at 4° C instead of 60 min at 37° C.  For 
PCNA, we increased the washing step to three times in order to reduce background.  
As a negative control, the blocking solution was left on the sections instead of 
the primary antibody to insure the purity of the staining procedure (Figure 2.3). Sheep 
tonsil was used as a positive control. At each run of IHC, a set of slides including 
sections from all groups of study plus negative and positive control were run together 
under the same experimental condition. Three sections from each ovary were selected 
randomly for the analysis (for each antibody). Immunostaining was examined using a 
light microscope, and images were captured with a digital video camera.  
 
2.2.6 Quantification of PCNA and Ki-67 immunostaining 
PCNA and Ki-67 staining was quantified by counting OSE and GCs (positive or 
negative). All of the OSE cells overlying the ovary in the circumference of the section 
were counted at 400X magnification. The number of
 
positive nuclei of all counted cells 
was used to calculate the percentage of proliferation. The proliferation index for large 
antral follicles (larger than 750 µm) was assessed by counting at least 400 GCs/area 
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from four different areas around the follicle using an eyepiece graticule (cross lines) at 
200X magnification. 
 
2.2.7 Statistical analysis 
  Immuohistochemistry results for Ki-67 and PCNA labelling in OSE and GCs 
were expressed as a mean percentage of labelled cells. The total number of cells 
(labelled and unlabelled) was counted for each ovary. Data for proliferative cells 
distribution at different regions of the OSE was expressed as a total percentage of 
labelled cells at each region. Results of follicle distribution at different stages of 
development (primordial, transitory, primary, preantral and antral) were expressed as a 
mean percentage of each type per ovary. Data for antral follicle sizes were demonstrated 
as total percentages of antral follicle size per group. Data was not normally distributed in 
accordance with the Kolmogorov-Smirnov test and box plot graphs, therefore, Kruskal-
Wallis test was selected as a useful test for comparing more than two groups. The Mann-
Whitney test was applied in order to compare two groups (Ki-67 and PCNA labelling in 
OSE cells). Chi-square test was used to compare the total percentages between groups 
(distribution of OSE proliferative cells and antral follicles size variation). Differences 
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2.3 Results 
2.3.1 PCNA and Ki-67 immunostaining in OSE cells 
PCNA and Ki-67 IHC was performed on serial sections of ewe ovaries. In these 
sections, PCNA and Ki-67 positive cells showed brown nuclear staining. The 
photomicrographs in Figure 2.3 show the positive and negative immunostaining for Ki-
67 and PCNA in antral and preantral follicles. Ki-67 and PCNA both show a high level 
of expression when compared to the OSE cells. 
There was no evidence of labelling for either marker PCNA or Ki-67 in the OSE 
from pregnant and anoestrus groups since no stained nuclei within the OSE cells could 
be detected (Figure 2.4). Positive immunostaining was identified only in the OSE layer 
of cycling ewes, 0.53 ± 0.05% for PCNA and 0.30 ± 0.07% for Ki-67 (Figure 2.5). High 
staining for PCNA was observed in OSE invagination, these cells were cuboidal in 
shape. Although the percentage of both markers was very low, the PCNA expression 













Figure 2.3 Photomicrographs showing the immunohistochemical staining for (A) PCNA 
and (B) Ki-67 in GCs of ovine growing follicles. Panels (C) and (D) demonstrate the 




44 m 24 m 
44 m 24 m 
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Figure 2.4 Photomicrographs showing PCNA and Ki-67 immunostaining in the OSE 
layer. No detectable staining for either marker was observed in OSE cells in (A) 
anoestrus or (B) pregnant groups (TA: tunica albuginea). Panels C through E 
demonstrate PCNA localization in OSE cells in the (C) cycling group, at (D) OSE 
invagination, and (E) over the ovarian stroma in close proximity to large antral follicles 
(arrows). Panel F shows Ki-67 staining in OSE cells over a large antral follicle in the 





















































Figure 2.5 Box plots representing OSE cell proliferation as indicated by PCNA and Ki-





 (median) and 75
th




 percentiles. Data 
are the percentage of labelled cells for each section (18 sections/ marker).  Total number 
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Table 2.5  






























1 15 1891 0.79 2 1214 0.25 
1 9 1771 0.60 1 1009 0.10 
1 10 1710 0.58 5 911 0.55 
2 5 1327 0.38 0 1152 0.26 
2 9 1219 0.73 0 979 0.20 
2 5 1109 0.45 4 1201 0.33 
3 13 1659 0.42 0 992 0.00 
3 8 1210 0.33 7 1216 0.57 
3 7 1398 0.50 0 1165 0.00 
4 9 1425 0.63 4 1076 0.37 
4 7 1502 0.46 4 995 0.40 
4 6 1279 0.47 6 1108 0.63 
5 11 1677 0.90 0 1092 0.00 
5 5 1814 0.38 0 1184 0.00 
5 5 1312 0.23 5 1119 0.44 
6 8 1430 0.56 1 1175 0.09 
6 11 1643 0.67 7 1002 0.68 
6 9 1447 0.48 2 1023 0.59 
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2.3.2 Distribution of OSE proliferating cells in cycling group 
 Analysis of PCNA staining over different regions of the OSE revealed that the 
majority of PCNA and Ki-67-stained OSE cells were localised over the corpora lutea (44 
and 52%) of the total labelled OSE cells, and over large antral follicles (2.5–3.5 mm in 
diameter)  (39 and 40%). A much lower fraction (17 and 8%; P 0.05) was found over 
the stroma (Figure 2.6).  






































PCNA and Ki-67 labelling distribution
 
 
Figure 2.6 Box plots representing the distribution of proliferating cells in OSE of 
cycling ewes (n = 6) at different regions around the ovary.  PCNA and Ki-67 labelling in 
the OSE layer was examined overlying the corpora lutea (CL), antral follicles (AF) and 











 percentiles and 
asterisks represent the outliers. Data are the number of OSE labelled cells at each region 
(3 sections/ animal).  The total number of counted OSE cells over the three different 
regions of the ovary is presented in Table 2.6.  
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Table 2.6  
Distribution of PCNA and Ki-67 labelling within the OSE cells at different regions 

























CL AF Stroma 
1 15 12 0 3 2 1 0 1 
1 9 6 0 3 1 0 0 1 
1 10 10 0 0 5 5 0 0 
2 5 0 3 2 0 0 0 0 
2 9 0 9 0 0 0 0 0 
2 4 0 2 2 4 0 4 0 
3 13 0 8 5 0 0 0 0 
3 8 0 7 1 7 0 7 0 
3 7 5 0 2 0 0 0 0 
4 9 9 0 0 4 0 4 0 
4 7 4 0 3 4 0 4 0 
4 6 0 6 0 6 6 0 0 
5 11 8 3 0 0 0 0 0 
5 5 5 0 0 0 0 0 0 
5 5 0 5 0 5 5 0 0 
6 8 8 0 0 1 1 0 0 
6 11 0 10 1 7 6 0 1 
6 9 0 5 4 2 1 0 1 
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2.3.3 Morphology of the OSE cells at different regions around the ovary 
 There was variation in the cellular morphology of the OSE cells that correlated to 
location. The OSE layer over large antral follicles was composed of flattened squamous 
cells with a loose attachment to the fragmentary basement membrane. As is typically 
found, the OSE over corpora lutea was a monolayer of simple cuboidal epithelial cells 
with dilated intracellular spaces in between an undetectable basement membrane. Away 
from the active site of ovulation, over the stroma, the OSE exhibited an organized order 
of compact stratified cuboidal cells with a distinguishable basement membrane (Figure 
2.7). The OSE layer in the pregnant group showed a stratification structure of 2-3 layers 

























Figure 2.7 Photomicrographs showing the morphology of the OSE layer (stained with 
hematoxylin and eosin). Panels A through C demonstrate the morphology of the OSE 
layer of cycling ewes:  (A) shows a thin incomplete monolayer of flat cells overlying a 
large antral follicle, (B) an incomplete monolayer of cuboidal cells covering the CL and 
(C) a monolayer of organized flat to cuboidal cells over the stroma. Panel D shows 
complete and well-organized cells in the pregnant group. Panels E and F demonstrate the 
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2.3.4 PCNA and Ki-67 immunostaining in the GCs of growing follicles  
Nuclear staining for PCNA in GCs of all types of follicles was higher than Ki-67 
labelling, which was negligible in some of the follicular GCs. Surprisingly, PCNA 
labelling was detected in oocytes of the early stages of follicle development (primordial 
and transitory follicles) (Figure 2.8). No detectable Ki-67 staining was observed in 
primordial or transitory follicles in any of the groups. Neither stained oocytes nor GCs 
within these follicles were observed. However, there was variation between groups, with 
the highest rate of labelling observed in the follicular GCs of cycling ewes (Table 2.7, 
page 46). Ki-67 was observed in GCs of follicles from the primary stage and beyond 
with variation between groups (Figure 2.9 and 2.10) (Table 2.8, page 47). The 
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Figure 2.8 Photomicrographs showing immunohistochemical staining of PCNA and Ki-
67 in GCs of ovarian follicles. Panels A through E demonstrate PCNA labelling in GCs 
and oocytes of primordial follicles in (A) cycling (arrows show oocyte labelling) and (B) 
pregnant groups (arrows show unlabelled oocyte and labelled GCs); (C) transitory; (D) 
primary follicles in cycling group; and (E) primordial follicles in anoestrus group. Panels 
F and G demonstrate Ki-67 labelling in cells of primary follicle (F) in cycling and  
(G) anoestrus groups. (H) Transitory follicles in the pregnant group are also shown (no 
detectable staining).  
D 
F G H E 
24 m 15 m 15 m 15 m 
24 m 24 m 24 m 24 m 
A B C 
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Figure 2.9 Photomicrographs showing immunohistochemical staining of PCNA and Ki-
67 in GCs of preantral follicles. Panels A through C demonstrate PCNA labelling of 
preantral follicles in (A) cycling, (B) anoestrus, and (C) pregnant groups. Panels D 
through F demonstrate Ki-67 labelling in the GCs of preantral follicles in (D) cycling, 
(E) anoestrus and (F) pregnant groups. 
 
 
A B C 
D E F 
24 m 24 m 24 m 
44 m 24 m 24 m 
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Figure 2.10 Photomicrographs showing immunohistochemical staining of PCNA and 
Ki-67 in GCs of antral follicles. Panels A through C demonstrate PCNA labelling in 
GCs of antral follicles in (A) cycling, (B) anoestrus and (C) pregnant groups. Panels D 
through F demonstrate Ki-67 labelling in the GCs of (D) cycling, (E) anoestrus and (F) 
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Table 2.7  
PCNA immunostaining in the GCs of growing follicles 























follicle     
±SEM 
Cycling 
( n = 6) 
69 87.17±0.76 25 85.65±1.61 25 83.41±1.78 
Anoestrus 
(n = 5) 
29 31.21±0.84 26 26.70±1.16 21 26.94±1.32 
Early-mid 
pregnancy 
( n = 8) 
41 28.58±0.80 33 24.97±0.89 29 28.19±1.39 
Mid-late 
pregnancy 
( n = 9) 
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Table 2.8 
Ki-67 immunostaining in the GCs of growing follicles 























follicle     
±SEM 
Cycling 
( n = 6) 
26 1.62±0.32 24 8.05±1.41 22 14.15±1.83 
Anoestrus 
(n = 5) 
37 0.23±0.10 35 8.58±0.79 35 10.18±0.89 
Early-mid 
pregnancy 
( n = 8) 
31 0.18±0.10 45 1.48±0.26 46 2.91±0.94 
Mid-late 
pregnancy 
( n = 9) 
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2.3.5 Pattern of follicle development at different reproductive status 
In order to investigate the pattern of follicle distribution at different reproductive 
stages, follicles at different developmental stages (primordial, transitory, primary, 
preantral, and antral) in cycling, anoestrus, and pregnant ewes were counted. The results 
are outlined in Table 2.9 and 2.10 (Page 50). The Kruskal-Wallis test revealed 
significant differences between the groups (Figure 2.12), as detailed below: 
Primordial and transitory follicles. There was a significant increase in the mean 
percentages of primordial follicles between anoestrus and all other studied groups and a 
consequent decrease in transitory follicles. No difference was determined between 
cycling and early-mid pregnancy groups. In the mid-late pregnancy group, the 
percentage of primordial follicles decreased and transitory follicles increased 
significantly.  
Primary and preantral follicles. The mean percentages of primary and preantral 
follicles in the cycling group were significantly higher than in the other groups. In the 
mid-late pregnancy group, a significant increase was observed when compared to the 
anoestrus and early-mid pregnancy groups.  
Antral follicles. No difference was detected between the cycling and the 
anoestrus groups in the mean percentages of antral follicles. The number of antral 
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Table 2.9  
Distribution of ovarian follicles in cycling and anoestrus groups 
Cycling (n = 6; 366 sections) Anoestrus (n = 5; 234 sections) 








percentages     
±SEM 
Primordial 12321  41.30 ± 2.20 13514  53.90 ± 1.59 
Transitory 15858  51.61 ± 2.42 10797  43.10 ± 1.75 
Primary 1565  5.60 ± 0.68 527  2.00 ± 0.25 
Preantral 245  0.85 ± 0.07 61  0.30 ± 0.06 
Antral 216  0.80 ± 0.13 152  0.70 ± 0.22 
 
Table 2.10 
Distribution of ovarian follicles in pregnant groups 
Early-mid pregnancy (n = 8; 391 
sections) 











percentages     
±SEM 
Primordial 23783  42.00 ± 3.03 17791  36.39 ± 1.72 
Transitory 27733  54.00 ± 2.44 30671  58.97± 1.93 
Primary 1454  3.00 ± 0.52 1770  3.84 ± 0.34 
Preantral 177  0.40 ± 0.11 250  0.52 ± 0.05 
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2.3.6 Classification of antral follicle sizes 
  The total number and percentage of antral follicles at different sizes are described 
in Tables 2.11 and 2.12.  No significant difference was detected in the percentage of 
antral follicles  1 mm and < 3 mm between groups. The number of antral follicles  3 
mm and < 4 mm decreased significantly in early-mid pregnancy and were completely 
absent in mid-late pregnancy. Antral follicles larger than 4 mm in diameter were not 
observed at all stages of pregnancy. In contrast, a significant increase was detected in the 
percentage of 4–5 mm antral follicles in the anoestrus group when compared to the 
cycling group (Figure 2.13).  
 







1-2 mm 2-3 mm 3-4 mm 4-5 mm





























Figure 2.13 Antral follicles size distribution at different reproductive status. Distribution 
of antral follicles with different diameters  1 mm, 2-3mm, 3-4mm and 4-5mm at 
cycling (n = 6), anoestrus (n = 5), early-mid pregnancy (E-M Preg.) (30-75 days) (n = 8), 
and mid-late pregnancy (M-L Preg.) (80–135 days) (n = 9). Values are total percentages 
of each size of antral follicle per group. Different letters indicate statistical differences 
between groups among antral follicles (size 3-4mm) and an asterisk over the bar 
indicates statistical differences between groups among antral follicles (4-5mm) (P 
0.05). The total number of analyzed follicles is outlined in Table 2.11 and 2.12.  
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Table 2.11  
Total number and percentages of antral follicles of different sizes in cycling and 
anoestrus groups 
Cycling  (n = 6; 366 sections) Anoestrus (n = 5; 234 sections) 
Follicle 
diameter 
Total number of follicles 
= 216 
% 
Total number of follicles 
= 152 
% 
< 2 mm 167 77.31 82.89 
82.89 
2–3 mm 41 18.98 10.53 
10.53 
3–4 mm 5 2.31 3.29 
3.29 
4–5 mm 3 1.39 3.29 3.29 
 
Table 2.12  
Total number and percentages of antral follicles of different sizes in pregnant groups 
Early-mid 
pregnancy (n = 8; 391 sections) 
Mid-late 
Pregnancy (n = 9; 457 sections) Follicle 
diameter 
Total number of follicles 
= 123 
% 
Total number of follicles 
= 147 
% 
< 2 mm 109 88.62 130 88.44 
2–3 mm 13 10.57 17 11.56 
3–4 mm 1 0.81 0 0.0 
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2.4 Discussion 
The cells of the OSE layer are the source of more than 90 percent of ovarian 
cancers. Pregnancy plays a crucial role in the prevention of ovarian cancer, but the 
mechanisms behind this role remain unclear. Understanding these mechanisms will 
increase the ability to develop effective prevention methods for those who are at risk of 
this disease. The following research focuses on the relationship between the OSE cells 
and growing follicles, and the changes that occur within the OSE layer during the 
different stages of reproductive status in the ovary. The results suggest that the 
protective role of pregnancy against EOC could be influenced by the reduction in 
regulation of follicular activity caused by pregnancy factors that lead to a reduction in 
the levels of follicular products (hormones and growth factors). Thus the results suggest 
that during pregnancy and anoestrus the proliferative activity of the OSE cells is 
suppressed and the rate of follicular growth is also reduced.  
The immunohistochemical analyses of the OSE layer using PCNA and Ki-67 
clearly revealed proliferative activity mostly in cycling ewes. Proliferating cells were 
detected only in close proximity to steroidogenic antral follicles and CL suggesting that 
ovulation stimulates multiplication of OSE cells. This may be a mechanism that enables 
the post-ovulatory replenishment of existing cells with new ones.  
Histological analysis shows a variation in the morphology of OSE cells that 
correlated to ovulation activity and location in relation to the ovulation site. At the apex 
of the ovulatory follicle, the OSE cells appeared as flattened and dilated in shape. This 
morphological transformation could be a response of the OSE layer to the ovulation 
process.  It is believed that prior to ovulation, many factors, such as gonadotrophins, 
growth factors, and steroids, are released at the ovulation site (Wong & Leung 2007). 
These factors may induce OSE cell proliferation in order to accommodate expansion in 
the surface area that occurs during follicular growth. OSE cells secrete proteolytic 
enzyme (urokinase-type plasminogen activator) that degrades the follicular wall of the 
ovulatory follicles at ovulation (Murdoch & McDonnel 2002); these enzymes also 
disrupt the underlying basement membrane and the connective tissue of the ovarian 
stroma aiding in follicular rupture and the release of the mature oocyte (Bjersing & 
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Cajander 1975). Post-ovulation, the OSE layer is repaired by rapid proliferation over the 
newly formed CL through a re-epithelialization process.  Over the CL, OSE cells 
became cuboidal in shape, which could be a form of active proliferating cells. It has 
been reported in mice that the highest immunostaining for the PCNA antigen was 
detected at the ovulation site and was associated with cuboidal cells (Tan & Fleming 
2004). Another in vivo study showed that cuboidal GCs have a high rate of proliferation 
(five-fold) as demonstrated by Ki-67 immunostaining compared to flattened GCs (Silva-
Buttkus et al. 2008). 
Distinct features in follicular development were observed in anoestrus and pregnant 
ewes when compared to cycling animals. Pregnancy did not affect the early development 
of follicles (primordial and transitory), but did inhibit the later growth stages (primary, 
preantral, and antral). During pregnancy, several factors, notably high steroidal 
hormones produced in the feto-placental unit and CL (al Gubory et al. 1994), may retard 
follicle development and suppress OSE proliferation. Consequently, large antral follicles 
were absent in this group. In agreement with our finding, it has been reported that the 
diameter of the largest antral follicles at the latest stage of pregnancy does not increase 
beyond 1.5 mm and most of these follicles are atretic (al-Gubory & Martinet 1986). 
After week seven of pregnancy, the human placenta produces a massive amount of 
progesterone that results in up to 10 fold increase in the maternal circulating levels of 
this hormone (Yen 1994). In pregnant ewes, the placenta is the main source of 
progesterone after day 50 of gestation (Al-Gubory et al. 1999), it produces 5 times as 
much progesterone as the ovary (Linzell & Heap 1968).  
 In vivo and in vitro studies suggested a suppressive role of progesterone on 
follicle development.  Ovaries from twin pregnant ewes had fewer growing follicles than 
the ovaries of singleton pregnancy (Bartlewski et al. 1999). Exposure to high levels of 
placental progesterone may alter follicular development during pregnancy. It has been 
shown that, exogenous administration of progesterone reduces LH pulse and exerts an 
atretic effect on the bovine dominant follicle (Savio et al. 1993).  
It was reported that the levels of FSH for cycling ewes are similar to the FSH 
concentration of anoestrus ewes (Bister & Paquay 1983). FSH is the most important 
hormone in controlling folliculogenesis; it is crucial for the later stages of follicle growth 
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(Turzillo & Fortune 1993), and it is considered a survival factor for antral follicles. 
Several studies have indicated that FSH activates GCs differentiation and proliferation, 
and has the ability to reduce the number of atretic follicles grown in vitro in rodents 
(Tonetta & diZerega 1989), cows (Hulshof et al. 1995), sheep (Newton et al. 1999), and 
humans (Roy & Treacy 1993).  
By producing inhibitory factors, such as AMH that is present in GCs of all 
growing follicles (Durlinger et al. 2002), high numbers of mature follicles may prevent 
early follicle differentiation (as seen in the case of anoestrus sheep) as AMH is a crucial 
factor for initial follicle recruitment. 
In pregnant and anoestrus ewes, negligible or low Ki-67 staining was observed in 
GCs in late differentiated follicles. PCNA staining was more intense than Ki-67 and the 
staining followed a similar pattern. In terms of the reliability of PCNA and Ki-67 as 
suitable nuclear proliferative markers, PCNA expression was observed even in the 
resting primordial follicles with ameiotic oocyte, whereas Ki-67 was expressed only in 
the proliferating follicles (at late growth stages and up-regulated in cycling ewes). These 
results agree with a previous study that reported the absence of Ki-67 and MCM2 
(Minichromosome maintenance protein-2) antigens; immunostaining was completely 
absent in the cells of primordial and transitory follicles suggesting that these follicles are 
in a quiescent state (Silva-Buttkus et al. 2008). PCNA immunostaining was considered a 
useful method for counting ovarian follicles, because of its ability to mark all oocyte 
nuclei of ovarian follicles at different maturity stages including primordial follicles that 
were strongly labelled (Muskhelishvili et al. 2005). PCNA expression in primordial 
follicle oocytes is not an indicator of cell proliferation as these oocytes are arrested in 
the first meiosis (Hirshfield 1991); however, PCNA expression could be related to the 
role of PCNA in DNA repair mechanisms. Several studies suggested that PCNA can be 
used as a reliable marker for proliferation (Tomanek & Chronowska 2006), but Ki-67 
seems to be a better marker as PCNA expression can be confused with DNA repair or 
other DNA synthetic activities not necessarily associated with cell division. This is in 
agreement with Scholzen & Gerdes (2000) who argue strongly against considering 
PCNA rather than Ki-67 as a reliable marker for proliferation.  
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In the rodent model, OSE cell differentiation was investigated in the presence of 
exogenously supplemented oestrogens and progesterone (Gotfredson & Murdoch 2007). 
The cells varied in types from simple squamous to stratified. Stratification of epithelial 
cells increased with oestradiol treatment, and was completely suppressed with 
progesterone. Stratified cells were also found to be highly proliferative and prone to 
neoplasia. Apparently, progesterone restores the epithelium of postovulatory ovaries to a 
resting or non-proliferative state. In the present study, though such OSE morphological 
differentiation was not discernable, oestradiol production in cycling antral follicles and 
CL might have induced proliferative activity in nearby OSE cells. The same explanation 
also holds true for observed proliferative activity in differentiating follicular GCs.  
 During pregnancy, progesterone seems to have suppressed these events. It has 
been suggested that high levels of progesterone during pregnancy is responsible for 
follicular development inhibition in heifers (Adams et al. 1992; Ginther et al. 1996).  
It is proposed that oestrogen-progesterone antagonistic regulation of OSE 
proliferation near preovulatory follicle and CL may lead to neoplastic transformations, 
which may eventually initiate epithelial ovarian cancer unless such cells are constantly 
eliminated as they are in apoptosis. Ghahremani and colleagues (1999) suggested that 
the disruption of apoptosis and failure of eliminating those OSE cells lining inclusion 
cysts may enhance the formation of ovarian cancer. It has been shown that progestin oral 
contraceptives induce apoptosis in primate OSE cells (Hankinson et al. 1992; Siskind et 
al. 2000). Rodriguez et al. (1998) suggested that apoptosis induction may be a 
mechanism for the protective factor of combined oral contraceptives against epithelial 
ovarian cancer. An in vitro study on normal and malignant human OSE cells revealed 
that treatment with pregnancy equivalent doses of progesterone induces apoptosis 
through activation of Fas/Fas ligand pathway (Syed & Ho 2003).   
The gonadotrophins, LH and FSH are the other hormones regulating OSE 
proliferation. Their place in the possible transformation into cancerous cells was studied 
in mice. Immature CD1 mice were treated with hormones to stimulate superovulation 
(Burdette et al. 2006). The OSE in proximity to antral follicles and CL proliferated 
significantly more in superovulated animals than in controls. Proliferation was thought 
to be an act of healing surface wounds caused by ovarian surface rupture after each cycle 
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of ovulation. Initially, it was believed that free radicals and other mitogenic factors, such 
as oestrogens, generated at the rupture sites induced ovarian neoplasia. However, it was 
later observed that proliferation occurred before ovulation (Gaytan et al. 2005). This 
challenged the rupture and repair theory of proliferation. According to a recent 
gonadotrophin theory, the expression of LH and FSH receptors on the surface of OSE 
cells is a direct response to gonadotrophins (Leung & Choi 2007). Most likely, the 
hormone-stimulated receptors trigger the localized proliferation events.  
In conclusion, the results indicate that sheep pregnancy leads to inhibition of 
proliferative activity in the OSE and suppression of follicular growth. Progesterone 
appears to be a candidate for suppressing OSE proliferation and preventing follicular 
differentiation, and thereby not allowing antral follicles to form. The effect of 
progesterone during pregnancy seems to override the positive effect of oestrogens on 
OSE proliferation and follicle development. Conditions that suppress ovulation, such as 
multiple pregnancies, breastfeeding, and the use of oral contraceptives, suppress 
follicular differentiation and OSE proliferative activities. This seems to be due to high 
serum progesterone and low LH and FSH concentrations. High serum progesterone may 
have a direct negative effect on gonadotrophin production and might inhibit events 
leading to both follicular development and OSE proliferation.  
Our knowledge of the interaction between preovulatory follicles and the OSE 
layer is not yet fully elucidated, and further in vitro study is needed to definitively 
determine the effect of steroids and other factors involved in ovulation on the 






















Figure 2.11 Box plots indicating the percentage of PCNA and Ki-67 
immunoreactivity in GCs of growing follicles. (A) PCNA and (B) Ki-67 
immunoreactivity in GCs of primary, preantral, and antral follicles at cycling (n = 6; 
18 sections), anoestrous (n = 5; 15 sections), early-mid (E-M) pregnant (n = 8; 24 
sections), and mid-late (M-L) pregnant (n = 9; 27 sections) groups. The lines of the 




 (median) and 75
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 percentiles and asterisks represent the outliers. Values are percentages of 
labelled GCs per follicle, and different letters above the bars indicate statistical 
differences between groups (P 0.05). The total number of analyzed follicles is 












Figure 2.12 Box plots representing the distribution of ovarian follicles at different 
reproductive status. The distribution of (A) primordial, transitory, and primary 
follicles and (B) preantral and antral follicles at cycling (n = 6), anoestrous (n = 5), 
early-mid (E-M) pregnancy (30–75 days) (n = 8), and mid-late (M-L) pregnancy (80–




 (median) and 75
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 percentiles and asterisks represent the 
outliers. Values are percentages of each stage of development per animal, and 
different letters above the bars indicate statistical differences between groups 
(P0.05). The total number of analyzed follicles is outlined in Table 2.7 and 2.8.   
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The previous chapter looked at OSE proliferation in vivo and showed how it was 
related to proximity to other ovarian structures and how this effect is generally due to 
specific endocrine/ paracrine factors. However, to investigate how specific growth 
factors and hormones affect proliferation it is necessary to use an in vitro model. 
Obtaining OSE cells for culture has been problematic because of its fragile and tenuous 
attachment to the underlying layers, and the limited ability of OSE cells to grow in 
cultures. 
The first culture systems for OSE were achieved in the 1980s for rats (Adams & 
Auersperg 1981), humans (Auersperg et al. 1984) and rabbits (Nicosia et al. 1989). The 
principal method for OSE isolation is a gentle scraping of the ovarian surface, as the 
OSE cells adhere only loosely to the underling stroma layer. Extracellular calcium is a 
controller for OSE proliferation, which is mediated by calcium-sensing receptors 
(McNeil et al. 1998). Therefore, every culture medium depends on a certain level of 
calcium. Usually OSE cells in cultures do not proliferate more than four passages before 
they transform into large, senescent flat cells. There are differences in the physiology 
and morphology of the OSE between species, which is likely to be related to changes in 
the reproductive status of the species (Auersperg et al. 2001).  
Normal OSE cells express receptors for several growth factors such as 
keratinocyte growth factor (KGF), EGF, HGF, TGF-ß (Berchuck et al. 1991; 1992; 
Parrott et al. 2000b). Additionally, oestrogen, androgen, and progesterone receptors are 
expressed in normal OSE cells in humans (Karlan et al. 1995) and rats (Adams & 
Auersperg 1981). Several studies have shown that steroids increase OSE proliferation in 
vitro, in a dose-dependent manner (Wright et al. 2005). LH and FSH receptors are 
present in bovine (Parrott et al. 2001) and human OSE cells (Syed et al. 2001). There are 
indications that LH and FSH have the ability to stimulate OSE cell proliferation in 
human and ovine OSE cells (Gubbay et al. 2004). Intra-ovarian factors play an 
important role in modulating OSE function, and they might be involved in the malignant 
transformation of these cells (Parrott et al. 2001).  
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Follicular fluid (FF) is a major constituent of the mature ovarian follicle; it plays 
an important role in most of the ovarian physiological processes. Steroidogenesis, oocyte 
maturation and ovulation depend on the endocrinological alterations in the FF. The 
ovarian fluid is made up of a different novel secretion e.g. steroids hormones, peptides 
and glycosaminoglycans (GAGs), and a plasma exudate, especially its proteins. The 
concentration of hormones within the FF changes in correlation to the stage of follicular 
development.  The concentration of steroid hormones in human FF was extensively 
reviewed by Lenton & colleagues (1988). There are several studies determining steroid 
contents in FF in different species, specifically after the LH surge (Chaffin et al. 1999; 
Dieleman et al. 1983). According to Baird & Fraser (1975), the level of steroid 
hormones in FF differs markedly approaching ovulation. A noticeable shift from 
oestrogen to progesterone production is a major event in the preovulatory phase (Hillier 
1985). In the human, after the LH surge, progesterone concentration reaches 
approximately 17500ng/ml follicular fluid, whereas oestrogen concentration declines 
from 3700 ng/ml before the LH surge to 800ng/ml after 30 hours of the LH surge 
(Lenton et al. 1988). Microarray for gene analysis revealed that the expression of StAR, 
CYP17A1 and P450 Oxidoreductase were increased in preovulatory follicles (Agca et 
al. 2006).  Gonadotrophins, FSH and LH are present in FF and their concentrations 
increase in preovulatory follicles, although remaining below levels in systemic blood.  
Rodents have been used in several studies investigating the function and 
physiological roles of normal OSE (Burdette et al. 2006; Gaytan et al. 2005); however, 
ruminant models with reproductive cycles relatively similar to the human cycle are 
preferable. Sheep OSE have been shown to be an adequate model for in vitro studies on 
human OSE (Gubbay et al. 2004) which is why this study uses them as a model.   
Cytokeratins (CKs) belong to the intermediate filaments, which create a 
cytoskeleton in almost all eukaryotic cells. The CK family is a highly complex multi-
gene family of polypeptides, the molecular weight of which ranges from 40 to 68 kDa. 
CKs are generally held to belong to the most fundamental markers of epithelial 
differentiation, and until now, 20 distinct CK polypeptides have been found in various 
human epithelia (Moll 1998). OSE is characterized by keratin types 7, 8, 18 and 19, 
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which represent the keratin complement typical for simple epithelia (Auersperg et al. 
2001). 
In the study in Chapter 2, a sheep model was used to determine the role of local 
ovarian structures (growing follicles and corpora lutea) in the regulation of OSE 
proliferative activity. The aims of the following study are to examine the effects of 
follicular and luteal products on the proliferation of OSE cells in culture, and to analyse 
the influences of large antral follicles and corpora lutea on the expression of 
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3.2 Materials and methods 
3.2.1 OSE isolation and cell culture 
Sheep ovaries were collected from adult cycling sheep immediately after 
slaughter at a local abattoir. Ovaries were transported to the laboratory in a sterile 
thermos containing culture media of M199/MCDB 105 supplemented with 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma).  
OSE cells were obtained by gently scraping the surface of the ovaries (n = 20) 
using the blunt edge of a sterile scalpel. OSE cells were transferred into sterile flasks (n 
= 4), which were pre-coated with foetal calf serum (FCS), and contained culture media 
of M199/MCDB 105 (1:1) supplemented with 1mM L-glutamine, 10% foetal bovine 
serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin. OSE cells were 
examined with a phase-contrast microscope to ensure sufficient flakes of OSE had been 
obtained. OSE cells were incubated at 37 ºC in a humidified incubator with an 
atmosphere of 5% CO2 in air for up to 28 days with media changed every 7 days 
according to Hillier et al. (1998). Confluent cells were normally obtained after three to 
four weeks.  
 
3.2.2 Cytokeratin immunocytochemistry (ICC) 
To confirm the purity of the cultured cells (epithelial origin), a fraction of the 
cells were seeded in chamber slides (Sigma-Aldrich Ltd) for ICC to detect cytokeratin (a 
marker of epithelial cells). Cells were fixed in ice-cold 80% methanol, air-dried then 
washed in PBS, followed by incubation for 20 min with 10% normal horse serum and 
further 30 min with cytokeratin antibody (1:50 mouse monoclonal cytokeratin Clone 
MNF116 Dako Cytomation, Denmark A/S) at room temperature. Following the washing 
stages, cells were incubated for 30 min with anti-mouse IgG Biotinylated antibody. 
Finally, cells were incubated with Vectastain Elite ABC kit (Vector Laboratories, Inc. 
California, USA) for 30 min then washed in PBS. For visualization, slides were 
incubated with DAB for 10 min, then counterstained with haematoxylin. 
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3.2.3 Proliferation assay 
In order to investigate the effect of steroids and growth factors on OSE cell 
proliferation, confluent cells were recovered using trypsin EDTA (0.05% trypsin and 
0.02% EDTA) for 5 min at 37 ºC. Fresh media was added to the trypsinised cell pellet 
and a fraction was taken to be counted using a haemocytometer. 
OSE cells were seeded into 96 well plates at a density of 5,000 cells per well and 
cultured for 24 h in media containing serum to ensure cell attachment. Cells were 
incubated for a further 24 h in serum-free media containing 0.01% bovine serum 
albumin (BSA). The treatments (each treatment was applied to three different wells) 
were administrated to the cells and incubated for 72 h.   
Follicular fluid was aspirated from medium (6–8 mm, n = 20) and large (10–12 
mm, n = 15) bovine antral follicles from the ovaries (n = 18) obtained from a local 
abattoir. A fraction of the fluid was charcoal-extracted to achieve a steroid-free fluid 
(van Tol & Bevers 2001). Extracts from mature bovine corpora lutea (n = 7), 
progesterone (3 ng/ml, 30 ng/ml and 3,000 ng/ml; Sigma-Aldrich), 17-oestradiol (3 
ng/ml, 30 ng/ml, 3,000 ng/ml; Sigma-Aldrich), recombinant human IGF-1 (100 ng/ml; 
NHPP, Torrance, California), and FCS (final concentration in culture media, 10%) were 
used as a positive control for the assay. Luteal extracts were obtained by grinding freshly 
collected bovine corpora lutea. Ground tissue was filtered, centrifuged and sterilized 
using sterilization filter, and then stored at –20 ºC. Doses of steroids were representative 
of preovulatory follicular fluid levels (reaches levels of 1 µg/ml E2 and 17 µg/ml P4) and 
circulating levels (range 1 ng/ml E2 and 30 ng/ml P4) (Lenton et al. 1988). 
OSE cell proliferation was measured using the Cell Titer 96® AqueousOne 
Solution Proliferation Assay (Promega, Southampton, UK) which is based on the 
conversion of MTS tetrazolium to a coloured formazan product by viable active cells.  
Following the instructions of the manufacturer, 20 µl of the MTS/PES solution was 
added to each well, followed by three hours incubation in a humidified atmosphere. The 
amount of formazan converted during this period was measured as absorbance at 490 nm 
in a spectrophotometer. Cell growth in untreated control cells was assigned a value of 1, 
and relative cell growth in a treated culture was expressed as fold change over the 
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untreated control cells. Data points are group mean values ± SEM from four independent 
experiments. For each treatment, mean values were calculated from triplicate wells. 
 
3.2.4 Real-time PCR for expression of LH-R and FSH-R 
To perform real time reverse transcriptase polymerase chain reaction, OSE cells 
were obtained by scraping the surface of ovaries from cycling sheep (n = 20). Cells were 
collected from different areas of the ovary: areas overlying large antral follicles ( 5 
mm; n = 17), areas covering mature corpora lutea (n = 12), and areas over the ovarian 
stroma (i.e., no visible underlying follicles or CL). Six different pools of cells 
corresponding to each of the three areas (2 different pools for each area) were obtained 
from 20 animals, and RNA was immediately extracted.  
The Tri Reagent (Sigma-Aldrich) method was used to extract the total RNA from 
suspended ovarian surface epithelial cells. Following the manufacturer’s instructions, 
RNA samples were purified by a phenol-chloroform extraction followed by precipitation 
with ethanol. The amount of RNA was estimated by spectrophotometer at 260/280 nm. 
One microgram of each total RNA was reverse-transcribed using Super Script III 
Reverse Transcriptase (Invitrogen Corp., Carlsbad), and using random primers 
(Promega, Madison, WI, USA) and a dNTP mix to generate single-strand cDNA for 
each sample using the thermocycler (Biomefra TGradient). Selection of primers (Table 
1) for LHR, FSHR, and 18S was performed using LightCycler Probe Design software 
(Roche Applied Science, Mannheim, Germany). Quantification of mRNA levels for 
LHR and FSHR was analysed using a RT-PCR cycler (Stratagene Mx3000P). A portion 
(1/4) of each cDNA was used for quantitative PCR using a master mix (2X SensiMix 
DNA kit, Quantace Ltd., London, UK) that included SYBR green solution, SensiMix, 
and MgCl2. PCR settings were in all cases set at 95 °C for 10 min followed by 40 cycles 
of 95 °C for 15 sec, 60 °C for 30 sec, and 72 °C for 30 sec. All real-time experiments
 
were run in triplicate, and mean values were used for the determination
 
of mRNA levels. 
The negative controls consisted of RT-negative (RNA template with no reverse 
transcriptase enzyme) and RT-H2O (water in place of RNA template). The abundance of 
each target mRNA was determined relative to the housekeeping gene 18S. Changes in 
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the average fold was calculated with Mx3000P real-time PCR system analysis software 
(Stratagene) using the cycle threshold for each sample relative to a standard curve 
constructed from RNA extracted from granulosa cells.   
 
Table 3.1 
Primers for real-time PCR  




























AJ311673 209 bp 
 
3.2.5 Statistical analysis 
  The Kolmogorov-Smirnov test and Box plot graphs were used in order to decide if 
the data was normally distributed. Data for proliferative response of OSE cells to 
different treatments was presented as mean values from four independent experiments. 
Results were normally distributed, therefore one-way analysis of
 
variance (ANOVA) 
was used as a robust test for analysing normally distributed data. After a significant 
ANOVA, a Tukey post-hoc test was performed in order to locate the significant 
differences between the groups. Analysis was done using Minitab version 15. Data for 
gene expression was presented as mean values from three different assays, data was not 
normally distributed in accordance to the Kolmogorov-Smirnov test; therefore, the 
Kruskal-Wallis test was selected because it is the non-parametric analogue of ANOVA 
that compares more than two groups. The Dunn's test was used as a post-hoc test to 
locate the significant differences between the groups. Analysis was conducted using 
GraphPad Prism statistical software. Differences were considered to be significant at P 
0.05. 




3.3.1 Cytokeratin expression in OSE cells 
To confirm the purity of the epithelial cells in the ovine isolated cells, 
immunohistochemistry against cytokeratin was performed. Cultured OSE cells stained 
positively for keratin.  Also, the complete intact layer of the OSE was completely stained 
with the antibody. No negative cells for cytokeratin immunostaining demonstrating the 
purity of the culture (Figure 3.1). 
 
 
Figure 3.1 Cytokeratin expression in ovine OSE. Immunohistochemistry for (A) intact 




























































3.3.2 Proliferative response of cultured OSE cells to follicular fluid and CL extracts 
The effects of the main ovarian compartments of follicular fluid and CL on the 
proliferative activity of the ovine OSE cells were investigated. Cells were grown in the 
presence of the treatments or medium alone (control). Administration of FCS was used 
as a positive control for the proliferation assay. Incubation with follicular fluid and CL 
extracts stimulated the proliferation of cultured OSE an average of about 2.5 fold 
relative to the control (untreated cells) (P= 0.001). There were no effects of follicle size 
or previous charcoal extraction in the proliferative response to follicular fluid (P= 0.1) 














Figure 3.2 Box plots are of the proliferative responses of cultured sheep OSE cells to 
FCS, corpora lutea extracts (CL-E, n = 7), follicular fluid from medium follicles (6–8 
mm) (FF-MF, n = 20) and large follicles (10–12 mm) (FF-LF, n = 15). Follicular fluid 
was separately pooled from medium or large follicles, and a fraction from each pool was 
charcoal-stripped (CS). Each box plot represents the means of four independent assays 
for each treatment, and lines represent the whiskers. Values are expressed relative to the 
value in untreated cells (control) that was taken as 1. Different letters above bars indicate 
a statistical difference between each treated group and the control, P 0.05. 
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3.3.3 Effect of steroid hormones and growth factors on the proliferation activity of 
cultured ovine OSE 
Cultured OSE cells were treated with progesterone or oestrogen in a number of 
concentrations. Steroids administration at different doses (low and high) had no 
significant effect on cell proliferation (P= 0.1).  Only IGF-1 administration induced OSE 
















Figure 3.3 Box plots are of the proliferative responses of cultured sheep OSE cells to 
FCS, recombinant human IGF-1 (100 ng/ml), progesterone (P) (3,300 and 3,000 ng/ml) 
and 17-estradiol (E) (3,300 and 3,000 ng/ml). Each box plot represents the mean of 
four independent assays for each treatment, and lines represent the whiskers. Values are 
expressed relative to the value in untreated cells (control) that was taken as 1. Different 
letters above bars indicate a statistical difference between each treated group and the 
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3.3.4 FSHR and LHR  expression 
To investigate whether gene expression of FSHR and LHR were regulated by the 
underlying ovarian compartments, the levels of FSHR and LHR mRNA in the OSE cells 
(isolated from different areas around the ovary) were determined. Both receptors LHR 
and FSHR showed a variation in the level of their expression. Distribution of FSHR was 
statistically varied between the three areas. The highest expression was detected in the 
OSE cells collected from the area over the large antral follicles (P 0.01). In OSE cells 
overlying the ovarian stroma, mRNA of FSHR significantly decreased (P 0.01). OSE 
cells over the CL expressed very low levels of FSHR (Figure 3.4). Although the level of 
LHR expression was not significantly different among the three areas, the distribution of 
the receptor was following the same trend of the FSHR with the highest level of LHR 





























Figure 3.4 Expression levels of LHR and FSHR in ovine OSE cells over mature corpora 
lutea (CL) (n = 12), over large antral follicles (n = 17), and over stroma. Data were 
standardized to the stroma means, and are presented as means ± SEM of three 
independent assays. Different letters above bars indicate a statistical difference between 









During every cycle, the OSE over the preovulatory follicles is exposed to high 
concentrations of steroids, growth factors, and inflammatory reagents. There is evidence 
that OSE cells proliferate after ovulation in order to repair the ruptured area.  
Preovulatory follicles are the main source of several hormones and growth factors, and 
these factors are implicated in the tumourgenesis of the OSE cells through mitogenic 
effects. The current study investigates the effects of steroid hormones produced in a high 
concentration by the antral follicles on the proliferative activity of the OSE cells. The 
results show that factors in follicular fluid can induce OSE proliferative activity, and this 
stimulation effect could be not attributed to steroids in follicular fluid since oestrogen 
and progesterone treatments failed to stimulate OSE cells. Other factors within the 
follicular fluid are responsible for the mitogenic effect of this fluid.  
The addition of FCS in the serum-free medium enhanced OSE cell proliferation 
when compared to controls. FCS seems to contain some undefined compound(s) that 
stimulates proliferation. Serum supplementation provided essential nutrients (amino 
acids, vitamins, lipids) and adherence material for growing cells (Masters 2000). Reports 
suggest that some undefined serum factors may influence epithelial-mesenchymal cell 
transformation (Auersperg et al. 2001). Fetuin, a glycoprotein component of FCS that 
contributes to attachment of the cultured cells, may cause adherence of the epithelial 
cells in a way that happens in re-epithelialisation of the OSE layer. It has been found that 
Fetuin-A, a Ca
2+
-dependent adhesion factor in FCS induces cell-to-cell adhesion leading 
to tumorigenesis (Kundranda et al. 2005). Initial adherence may influence synthesis of 
cellular Ca
2+
-dependent adhesion factors, such as N- and E-cadherins, and these in turn 
may influence proliferative activity.  
In this study, follicular fluids from medium and large follicles and extracts of CL 
stimulated the growth of OSE cells. Follicular fluid is partially an exudate of serum, and 
therefore it is expected to contain at least some of the mitogenic factors found in serum. 
These extracts or fluids contained a number of anterior pituitary glycopeptide 
hormones, FSH and LH/hGC, steroidal hormones, oestrogen and progesterone, and 
several localized growth factors, such as IGF and HGF. In addition, receptors of these 
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follicular modulating hormones are present on the surface of OSE cells. While most of 
the steroidal hormones regulate follicular cycle and maintain luteal cycle, their role in 
the OSE is not clearly understood. Oestrogens are implicated in OSE neoplastic 
transformation. In order to examine whether steroidal hormones affect OSE 
proliferation, the follicular fluids and CL extracts were processed by passing them 
through charcoal to remove steroidal components. However, even these steroid-free 
fluids accelerated OSE proliferation over the serum-free controls. Apparently, steroids 
have no direct effect on in vitro OSE cell multiplication. Steroids may regulate the 
growth of OSE cells via indirect effects. It has been demonstrated that oestrogen 
administration induces ovarian cancer cell proliferation by increasing the expression of 
TGF- (Simpson et al. 1998). Previous investigation has indicated mitogenic effects of 
TGF- and EGF on bovine OSE cells (Doraiswamy et al. 2000). In order to further 
verify the ineffectiveness of steroidal hormones, pure oestrogen (oestradiol) and 
progesterone at graded concentrations were added to the cultured OSE cells. Neither 
hormone made any significant difference in proliferative activity of OSE cells over the 
controls, which is consistent with observations of the human and rhesus OSE cells 
(Ivarsson et al. 2001; Wright et al. 2003). The results of the current study suggest that 
factors other than steroids may be responsible for in vitro proliferation of OSE. The 
likely candidates could be gonadotrophins and the local growth factors produced in 
follicles, which trigger a sequence of reactions leading to proliferative response.  
FSH in particular has been implicated in increasing in vivo OSE proliferation 
(Choi et al. 2007). However, in vitro results were conflicting, and in various species 
stimulatory, inhibitory, and non-responsive influences of these hormones were noticed. 
One explanation for such variation is that the differential expression of surface 
gonadotrophin receptors and follow-up downstream signalling molecules affect 
proliferation. It has been reported that hCG and oestradiol may regulate OSE 
proliferation indirectly through an IGF-I pathway (Wimalasena et al. 1993). In addition, 
a study in bovine OSE revealed that hCG and FSH could increase the levels of mRNA of 
KGF and HGF (Shoham 1994). These growth factors utilize multiple signal pathways to 
suppress OSE apoptosis, and thus may lead to a mitogenic effect resulting in OSE 
malignancy. It was a matter of interest to examine whether such localized growth factors 
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have a direct influence in the multiplication of ewe OSE cells. It was observed that 
relative to controls IGF-1 stimulated the proliferative response over two times. It can be 
presumed that in cycling ewes the oestrogen response to OSE proliferation could be 
mediated in part by an increase in the transcription of IGF-1 and HGF. Charcoal 
stripping is a useful method to eliminate steroids, but also may remove cytokines and 
growth factors from serum (Mckeehan et al. 1984). However, in this study we suggest 
that charcoal stripping did not remove all growth factors from FF and IGF-I may be the 
factor responsible for the stimulatory effect of FF on OSE cell proliferation.  
FSH and LH may also mediate through their receptor expression (an independent 
transcriptional activation of such growth factors), and thus the ultimate manifestation of 
oestradiol and gonadotrophins is the same. One of the underlying signal transduction 
operating transcriptional controls is the cAMP-dependent protein kinase A (PKA)-
mediated phosphorylation (Gubbay et al. 2006). One factor is the cAMP response 
element binding protein (CREB) and the activating transcriptional factor-1 (ATF-1). In 
sheep, CREB/ATF-1 accounted for the survival of OSE through the stimulation of 
proliferative activity, and the prevention of apoptosis. OSE cells are exposed to the 
gonadotrophin inflammatory response during ovulation, and cytokines e.g. interleukins-
1, -6 may induce oncogenic response. Elimination of such cells by apoptosis at the 
rupture site during post-ovulatory epithelialisation is presumably an oncoprotective 
mechanism. In the surrounding regions, gonadotrophins stimulate an opposite response 
by evading apoptosis and up-regulating CREB/ATF-1 expression. Thus collateral OSE 
cells take over the rupture site and contribute to the healing process. In humans, the 
gonadotrophin cAMP-PKA signalling pathway was found to down-regulate N-cadherin 
protein (Pon et al. 2005). N-cadherin, a Ca
2+
-dependent cell-to-cell adhesion protein, 
was found to be controlling the survival capabilities of OSE. In the absence of adhesion 
due to N-cadherin down-regulation, the cells were non-aggregated and had a tendency to 
undergo apoptosis. This feature is observed at the postovulatory rupture site. Thus 
follicular hormones appear to have both antagonistic effects on OSE cells at the rupture 
site and in the surrounding region.  
Although the expression of gonadotrophin receptors in the OSE has been 
reported in several species (Parrott et al. 2001; Syed et al. 2001), the distribution of 
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receptor expression across the ovarian surface has not previously been considered. The 
expression of LH and FSH receptors over large follicles (5 mm or larger) were two and 
four times higher than those over stroma and CL respectively, suggesting that OSE 
proliferation over growing follicles results at least in part from a local increase in the 
sensitivity of OSE cells to circulating gonadotrophins. It has been reported that treatment 
of anoestrous sheep with oestradiol increased LH receptor expression in the OSE 
(Murdoch et al. 1999), and in granulosa cells both oestradiol and IGF-1 up-regulate the 
expression of gonadotrophin receptors (Knecht et al. 1984; Hirakawa et al. 1999). 
Therefore, an increase in gonadotrophin receptor expression in the OSE overlying large 
follicles may be mediated by paracrine follicular influences.  
In conclusion, OSE proliferation in cycling sheep is associated with underlying 
developing follicles and CL, mediated by, at least in part, the up-regulation of 
gonadotrophin receptors, and facilitated by the action of mitogenic glycopeptides and 
growth factors, but not steroids.  
The last two chapters focused on the effect of the mitogenic factors within the 
ovary and their roles in OSE regulation. The study would be more inclusive if the role of 
apoptosis in the physiology of the OSE layer was investigated. It might be that apoptosis 
in pregnancy is a protective factor for ovarian cancer. Further, changing the model 
system to an animal with more similarities to humans (no seasonality) would improve 























In Vivo and in Vitro Studies on Apoptosis in OSE Cells 




























 The OSE shows a high degree of metaplasia transformation to a differentiated 
state, and this can lead to the development of EOC. The first step in tumourigenesis of 
the surface epithelium is the formation of epithelial inclusion cysts derived from crypts 
or invaginations of the OSE (Cramer & Welch 1983). During post-ovulatory repair, OSE 
cells tend to modulate to fibroblast-like mesenchymal cells with an appearance similar to 
the underlying stroma. The epithelio-mesenchymal conversion of the OSE layer is 
considered to be a homeostatic mechanism that helps to accommodate trapped OSE cells 
after ovulation, and then to incorporate them into the stroma as part of stromal fibroblast 
(Auersperg et al. 2001). Some displaced segments of damaged OSE fragments retain the 
epithelial features and produce surface invaginations (cleft) and inclusion cysts in the 
ovarian cortex (Murdoch 1994). The healing process also results in the formation of 
crypts in the ovarian surface, which penetrates the ovarian stroma, where they form 
inclusion cysts lined with OSE cells (Godwin et al. 1993).  
Why these otherwise non-proliferating resting OSE cells become tumourigenic 
has been explained through the “incessant ovulation theory” (Fathalla 1971), which 
speculates that repeated ovulation leads to malignancy due to frequent rupture and repair 
of the damaged OSE layer. Under the influence of mitogens and other stress factors, 
some of the mutagenized cells undergo neoplasia transformation (Wong et al. 2004). 
Women with multiple pregnancies or those who are on oral contraceptives have shown 
reduced risks of EOC (Risch 1998; Ness et al. 2000). The validity of Fathalla (1971) 
hypothesis has been challenged because progestin-only contraceptives, which do not 
restrict ovulation, have been found to be as effective in suppressing malignancy as the 
oral ovulation-inhibitory contraceptives. Moreover, women with polycystic ovarian 
syndrome who have decreased ovulatory cycles have a high vulnerability towards 
ovarian cancer (Spritzer et al. 2005). Risch (1998) suggests that the protection gained 
from pregnancy is through the 8-9 months of continuously high progesterone levels. In 
vitro and in vivo analyses have shown that progesterone inhibits regular cell cycle by 
inducing apoptosis in normal and malignant human OSE cells (Bu et al. 1997; Hu & 
Deng 2000). The domestic chicken (hen) is a persistent ovulating animal, and like 
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humans it also develops ovarian cancer which reacts with a panel of antibodies specific 
for human ovarian cancers (Giles et al. 2006)Rodriguez-Burford et al. 2001). Hens 
treated with progesterone have shown decreased incidences of EOC, supporting the 
hypothesis that progesterone induces apoptosis of damaged OSE cells (Fredrickson 
1987; Rodriguez et al. 1998). Progesterone has also been shown to reduce the risk of 
developing ovarian carcinoma in postmenopausal women who have undergone 
oestrogen and progesterone replacement therapy (Schneider & Birkhauser 1995). Such 
therapies have also clinically helped treatment of selected ovarian tumours (Key 1995). 
Administration of progesterone at a high concentration similar to levels during 
pregnancy inhibited cultured human OSE cell proliferation (Syed et al. 2001). There is 
also growing evidence indicating an etiological role of localized inflammation, which 
accompanies each ovulation, with an associated release of cytokines, mitogens and 
intrusion of inflammatory cells, leading to genetic damage in the OSE cells (Landen, Jr. 
et al. 2008). It has been proposed that progesterone most likely has a role in apoptotic 
elimination of such genetically damaged OSE cells derived from inflammatory and 
mitogenic responses, although the underlying mechanism is not fully understood.  
Apoptosis in a tissue is manifest as distinct morphological characteristics and 
energy dependent biochemical changes (Elmore 2007), that helps in normal cell 
turnover, development and functioning of the immune system, hormone dependent 
atrophy, embryonic development, chemical induced cell death etc. Aberrations in 
apoptosis lead to neurodegenerative diseases, ischemic conditions, autoimmune diseases 
and several forms of cancers, including EOC (Baldwin et al. 1999). Microscopically, 
cell shrinkage and pyknosis, condensation of cell organelles and chromatin, cell 
clustering and excessive plasma membrane blebbing are observable. The fragmented 
cells are eventually phagocytosed by macrophages. Three interlinked biochemical 
processes (the extrinsic, intrinsic and granzyme B pathways) execute a common terminal 
pathway in which caspase 3 (cysteinyl aspartic acid protease 3) is activated and that in 
turn triggers DNA breakdown, protein cleavage and cross-linking, and surface 
phagocytic recognition. Caspases are widely expressed in all kind of cells as inactive 
pro-enzymes, and once activated start to proteolytically activate the other pro-caspases 
in a cascade of reactions. To date ten different caspases have been recognized and 
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categorized as the initiators (caspase 2, 8, 9, 10), effectors or executioners (caspase 3, 6, 
7) and inflammatory caspases (caspase 1, 4, 5). Caspase-3 expression and activation has 
been detected in the ovary of rats (Boone & Tsang 1998), mice and human (Matikainen 
et al. 2001) and hens (Johnson & Bridgham 2000). In mice, deletion of the caspase -3 
gene results in apoptosis failure in granulosa cell (Matikainen et al. 2001) and aberrant 
luteal regression (Carambula et al. 2002). Moreover, inactivation of caspase-2 gene 
significantly decreases germ cell death and consequently leads to an elevation in the 
number of primordial follicles in mice ovaries (Bergeron et al. 1998).  
Mechanistically, the mitochondrial transmembrane permeability and electrical 
gradient is altered causing release of cytochrome c, the Second Mitochondria derived 
Activator of Caspase (Smac)/DIABLO and other proteins, that complex with 
procaspase-9 to form “apoptosome” for final activation of capsase 3. Members of B-cell 
leukaemia/lymphoma 2 (Bcl-2) family of proteins activated by tumour suppressor 
protein p53 is responsible for maintaining mitochondrial permeability and consequently 
promoting apoptosis. Depleted growth factors, hormones, cytokines, and radiation, 
reactive oxygen species (ROS), toxins, hypoxia etc. can initiate intrinsic apoptosis.  
A key component in investigating apoptosis is P53, a tumour suppressor protein, 
also referred to as “guardian of the genome”, is an important regulator of cell cycle by 
blocking progression through G1 phase (Livneh & Fishman 1997). Either it triggers 
apoptotic response or halts the cell cycle, including cyclin-dependent kinase inhibitor 
p21. Both p53 and p21 were also suggested to regulate G2/M checkpoint that is the 
transition from G2 to M phase. Mutations in p53 or inactivation through interaction with 
viral or cellular proteins are the most frequent alterations observed in cancer cells 
(Levine 1997). P53 gene was found to be over-expressed as a result of repetition of 
ovulation trauma each cycle (Aunoble et al. 2000). 
It is unclear whether steroidal hormones, specifically progesterone, suppress 
OSE malignancy by activating tumour suppressor genes, in particular p53, and direct the 
cells towards apoptotic destruction from the ovulation site. A connection between 
progesterone and p53 was evident from the work on epithelial layer of salivary glands. 
Adenoid cystic carcinoma in these cells was accompanied with increase in surface 
progesterone and oestrogen receptors and concomitant higher expression of p53 (Barrera 
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et al. 2008). Since OSE cells also express p53 besides oestrogen and progesterone 
receptors, and are exposed to changing levels of steroid hormones, this study 
hypothesized that during pregnancy an accumulation of progesterone may be a factor 
responsible for p53-mediated apoptotic progression of mitogenic and mutationally 
damaged OSE cells.  
In this section of the study we used the cow as an animal model since this is a 
mono-ovular animal that ovulates in a regular pattern, has the same size of follicles (~ 20 
mm) and luteal phase similar in length to that of the human (~ 15 days), although the 
follicular phase is shorter in heifers (2-3 days). Even though these animals spend their 
short life span either gestating or lactating, bovine ovarian cancer has also been reported 
(Marchant 1980), suggesting that the tumourigenic potential of bovine OSE is similar to 
human OSE. Therefore, bovine ovaries present a useful model for studying oncology of 
OSE and inclusion cysts. Normal gestation period in cattle also averages 278-284 days. 
Like the human, during pregnancy gonadotrophin levels remain low but serum 
progesterone concentration continues to build up and stays high until the last month 
before parturition. After the first trimester of pregnancy, oestrogen levels also begin to 
increase again and climb consistently until the eighth month, when they level off for 
about two weeks and then increase rapidly until parturition (Henricks et al. 1970). The 
most noticeable similarity for which bovine OSE can be modelled for human has been 
the expression profiles of localized hepatocyte growth factor (HGF) (Parrott & Skinner 
2000)(Parrott & Skinner 2000), and kit legend stem cell growth factor (KL) and its 
receptor c-kit (Parrott et al. 2000) in OSE layer. Moreover, the extent of expression of 
these proteins in cultured human and bovine OSE cells were also alike. One can expect 
that the underlying signal transduction mechanism leading to HGF/KL-associated up-
regulation of tumour-associated genes would also be similar.  
This study was designed to test the hypothesis that pregnancy induces apoptosis 
within the OSE layer and inclusion cysts, a process mediated through over-expression of 
p53, which is under the control of high progesterone and oestrogen level. This was 
achieved by 1) measuring apoptotic cell death in inclusion cysts and OSE, 2) 
determining how progesterone and oestradiol affect cell death in vitro and 3) localization 
of p53 and its expression profile under progesterone influence.  
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4.2 Materials and methods 
4.2.1 Animals  
Ovaries for histological analysis and for isolation of OSE cells were obtained 
from pregnant and non pregnant heifers from a local abattoir. Ovaries were sorted and 
collected from the pregnant heifers at different stages of gestation (55-80 d, n = 8) and 
(90-140 d, n = 8), stage of pregnancy was determined using foetal crown-rump length. 
For the control groups, ovaries were collected from cycling heifers (n = 8). Gestation 
period in heifers lasts from 278-284 days. 
 
4.2.2 In vivo detection of apoptosis  
In situ terminal transferase-mediated dUTP nick end labelling (TUNEL) method 
was used in order to examine the effect of pregnancy on the apoptotic activity in the 
epithelial cells of the ovarian surface and inclusion cysts. Bovine ovaries were fixed in 
4% paraformaldehyde and processed for histology by standard procedures (Chapter 2). 
According to the instructions of the commercial kit (FragEL™, DNA Fragmentation 
Detection Kit, Colorimetric - TdT Enzyme- calbiochem, EMD Chemicals Inc), 
histological sections at 5 m were pre-treated with proteinase K (2 mg/ml proteinase K 
in 10 mM Tris-HCl buffer, pH8) at 37ºC for 20 min. Endogenous peroxidase activity 
was inactivated by incubating the slides with 30% H2O2  for 5 min at room temperature. 
The slides were then covered with an equilibration buffer (1 M Sodium Cacodylate, 0.15 
M Tris, 1.5 mg/ml BSA, 3.75 mM CoCl2, pH 6.6) for 30 min before incubation with 
TdT enzyme (Terminal Deoxynucleotidyl Transferase) for 90 min at 37ºC (labelling 
reaction). The reaction was stopped with the 1X stop buffer (0.5 M EDTA, pH 8) for 10 
min. After washing with TBS, sections were incubated with blocking buffer (4% BSA in 
TBS) for 10 min. In a humidified chamber, slides were incubated with peroxidase 
streptavidin conjugate for 30 min. The reaction was detected with DAB in TBS 
containing freshly prepared 1% H2O2 for 10 min. Background counterstaining was done 
by using haematoxylin. Apoptotic nuclei stained dark brown. Negative controls were the 
sections incubated in the absence of TdT-enzyme. Every time the experiment was run, a 
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batch of sections from all the groups plus negative and positive control were included at 
the same time.  
 
4.2.3 Immunolocalization of p53 and cytokeratin 
 In order to investigate whether the pattern of p53 distribution is related to 
ovulation events, sections from ovaries of non pregnant heifers (n = 8) were processed 
for IHC according to the procedure described in chapter 2. The monoclonal antibody 
(mouse anti-p53 primary antibody; Novocastra) at 1:100 dilution in PBS was used. 
Avidin-biotin peroxidase complex (ABC) method with DAB as chromogen was used. 
Negative control for each experiment was run by replacing the primary antibody with 
normal serum. A tissue from human ovarian tumour was used as a positive control for 
P53 expression. Slides were counterstained with haematoxylin. To verify the epithelial 
origin of the OSE cells and cells in the inner lining of inclusion cysts, sections were 
processed for IHC staining of cytokeratin (discussed in details in chapter 3). 
 
4.2.4 Microscopy and data quantification 
Staining density for apoptosis and p53 antigen was evaluated. Cells were 
analyzed under magnification of 400X. A total of 8 fields from each tissue section (4 
sections per ovary) were randomly selected, and approximately 100 epithelial cells from 
each field were counted. All inclusion cysts observed within each section were analyzed. 
Data was expressed as a percentage of stained cells within the OSE layer and completely 
stained inclusion cysts.   
 
4.2.5 OSE isolation and culture for in vitro studies 
OSE cells were isolated from ovaries of non pregnant heifers (n = 14) by gently 
scraping off the cells from the ovarian surface using sterile plastic scraper. The cells 
were incubated in M199/MCDB 105 medium (1:1), containing 1 mM L-glutamine, 100 
IU/ml penicillin, 100 µg/ml streptomycin and 10% FBS. The presence of OSE flakes in 
the scrapings was confirmed using a phase-contrast microscope. The cells were grown in 
above culture medium poured in 4 culture flasks and were incubated at 37ºC under 5% 
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CO2 atmosphere. Medium was changed every 3-4 days until cultures reached confluence 
stage (normally after 3 to 4 weeks). Once the cells had grown to confluence (Figure 4.1), 
the cells were harvested in trypsin /EDTA (0.05% trypsin and 0.02% EDTA) and 









Figure 4.1 Bovine OSE cells in culture. Photomicrograph represents cultured bovine 
OSE cells (confluent) with a compact, cobblestone-like growth pattern, at 400X 
magnification.  
 
4.2.6 Induction of apoptosis by steroid treatment  
To investigate whether apoptosis in the OSE cells and inclusion cysts is 
controlled by steroids, an in vitro quantification method was used. Apoptosis was 
quantitatively determined using APOPercentage™ apoptosis assay kit (Biocolor Ltd., 
Belfast, Ireland). The assay uses a dye that is selectively incorporated into apoptotic but 
not necrotic cells. The incorporation of dye is considered to be due to the membrane 
“flip-flop” event when phosphatidyl serine is translocated from the inner membranes to 
the outer site. 
 Trypsinized OSE cells (5x10
4 
cells/well) were seeded in 96-well tissue culture 
plates in 200 µl fresh culture medium supplemented with 10% serum. This was 
incubated for 24 h before any treatment was given. The cells were incubated at 37ºC in a 
humidified incubator under an atmosphere of 5% CO2 in air for 24 h followed by 24 h 
incubation with serum free medium under the same conditions. After 24 h, the culture 
medium was removed and replaced with 100 µl/well of each treatment in the medium. 
Chapter Four                                                                                                                   88 
 
 
 For steroid treatments, progesterone and 17-oestradiol (Sigma-Aldrich) were 
administrated in two doses (30 ng/ml for the low does and 30 µg/ml for the high does). 
Levels of steroids in preovulatory follicular fluid reach levels of 1 µg/ml E2 and 17 
µg/ml P4 (Lenton et al. 1988), it is expected that during pregnancy progesterone levels 
increase 100 times comparing to the normal cycle. We used the low does which 
represent the systemic levels (range 1 ng/ml E2 and 30 ng/ml P4) (Lenton et al. 1988) and 
high does that might represent the luteal progesterone during pregnancy. Progesterone 
and oestrogen were dissolved in absolute ethanol and supplemented to a final 
concentration in serum-free culture medium. For positive control, OSE cells were treated 
with 5 mM freshly prepared H2O2 (APOPercentage™ apoptosis assay kit 
recommendation). Control was the OSE cells incubated with medium and ethanol only. 
The OSE cells were then incubated for 24 h at 37ºC in 5% CO2 incubator.  
 After incubation of the OSE cells in the presence of the two concentrations of 
progesterone
 
and 17-oestradiol or equivalent alcohol, the medium was discarded 30 
min before the completion of the incubation. Then the cells were incubated with 200 µl 
of serum-free medium containing 10 l of APOPercentage dye and these were incubated 
at 37 °C in humidified air supplemented with 5% CO2 for another 1 h. After washing 
twice with PBS, cell surface-bound dye was extracted by lysis solution. The absorbance 
was measured at 590 nm wavelength using a microplate reader. All treatments were 
given in four replicates. 
  
4.2.7 P53 expression at different areas of the OSE 
An in vitro study was required in order to investigate the role of ovarian 
compartments in the regulation of p53 expression. OSE cells were isolated from ovaries 
of non pregnant heifers (n = 14) from three different locations, 1) over large antral 
follicles (size range 10-15 mm; n = 15), over mature corpora lutea (17 mm; n = 7) and 
over stroma in positions away from ovulatory activity. Sheets of OSE layer were 
removed by gentle scraping of the ovaries surface using sterilized plastic scraper. OSE 
cells were quickly removed from the scraper by placing the scraper into fresh media 
followed with centrifugation at 300 rpm.  
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4.2.8 Reverse transcription-PCR (RT-PCR) for determining p53 gene expression 
The Tri Reagent method was applied to extract total RNA from suspended OSE 
cells. Following the manufacturer instructions, RNA samples were purified by phenol-
chloroform extraction and precipitated with absolute ethanol. The amount of RNA was 
determined spectrophotometrically at 260/280 nm. The PCR was carried out in 50 µl 
reaction mixture prepared in ice bath. The reaction mixture contained 25 µl AccessQuick 
Master Mix, 0.5 µM upstream primer, 0.5 µM downstream primers, 1 µl AMV Reverse 
Transcriptase and 1 µg RNA template. The customized PCR primers used for 
amplification were synthesized by (Sigma-Genosys) on the basis of the available bovine 
sequences (Table 4.1). The PCR conditions were as follows: 45ºC for 45 min as a 
starting point for first strand cDNA synthesis, followed by 40 cycles at 95ºC for 2 min, 
52.8ºC for 1 min, and 72ºC for 1 min, respectively, and then final extension step of 5 
min at 72ºC. After amplification, 10 µl of the PCR products were separated by 
electrophoresis on 1.5% agarose gels containing 0.002% ethidium bromide, and 
visualized under a transilluminator and then photographed. The equal loading of the 
RNA samples was ensured by RT-PCR analysis of a housekeeping gene, GAPDH. 
Negative controls (reactions without template) were run in parallel to verify the absence 
of DNA contamination in RNA preparations. 
 
Table 4.1 
PCR primers for p53 and GAPDH genes, annealing temperature (Ta), number of cycles 
and cDNA size used for gene expression analysis.  
















54ºC 30 255bp 
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4.2.9 Role of steroids in p53 regulation 
To test if p53 expression in the OSE cells is regulated by steroids, an ICC assay 
was performed. OSE cells were obtained from culture flasks (Section 4.2.5); cells were 
transferred onto chamber slides (5x10
4 
cells/well) and incubated in M199/MCDB 105 
medium for 24 h at 37ºC under atmosphere of 5% CO2 in air. This was followed by 
further 24 h incubation in serum free medium. Cells were treated with either 
progesterone (30 ng/ml and 30 µg/ml) or 17-oestradiol (30 ng/ml and 30 µg/ml) for 24 
h. For control, cells were incubated in serum free culture medium for the same period 
and under same conditions. After incubation, the cells were fixed with ice-cold methanol 
for 10 min and washed with PBS. The cells were then permeabilized by rinsing with 
Triton-X 100 solution in PBS, incubated for 30 min with 10% normal goat serum and for 
1 h with anti-p53 antibody. After primary antibody treatment, cells were washed twice 
with PBS, and incubated for 30 min with secondary goat anti-mouse antibody. Slides 
were again washed in PBS prior to 30 min incubation with the preformed Vectastain 
ABC reagent. After post incubation washings with PBS, the slides were rinsed with few 
drops of DAB stain, and left to develop for 3-6 min. A positive reaction produces a 
brown endpoint, which was stopped by rinsing the slides with water. Sections were 
counterstained with haematoxylin, for 10-15 sec and dehydrated through graded alcohols 
(70% to absolute alcohol). Sections were cleared by xylene then mounted with DPX. 
Treatments were replicated in triplicates. 
 
4.2.10 Statistical Analysis 
  The Kolmogorov-Smirnov test was used in order to test whether the data was 
normally distributed or not. According to the normality test that was used, the data set 
for in vivo apoptosis detection in OSE cells and inclusion cysts was not normally 
distributed therefore the Kruskal-Wallis test was selected as a powerful test for 
comparing more than two groups. Values of in vitro studies (induction of apoptosis and 
p53 expression) were presented as means of three independent assays, data was normally 
distributed and therefore ANOVA was selected as a robust test for analysing this type of 
data. After a significant ANOVA, a Tukey post-hoc test was performed in order to locate 
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the significant differences between the groups. Chi-square test was used to compare the 
total percentages of p53 expression between three different areas. Differences were 































4.3.1 Cytokeratin expression in OSE layer and inclusion cysts  
 The epithelial cell origin of the cells lining the inclusion cysts was confirmed by 
their positive anti-cytokeratin
 
immunostaining, characteristic of most types of epithelial 
cells
 
(Figure 4.2). The area of the OSE around the ovary in cycling animals was 
completely stained with cytokeratin. Additionally, all the inclusion cysts which were 
distinctly detected under microscope were also expressing the epithelial marker 
cytokeratin. Most cysts were typically lined with a single layer of epithelial cells, flat to 




Figure 4.2 Photomicrographs representing cytokeratin expression in (A) OSE cells and 
(B) inclusion cyst of bovine ovaries (blue arrows). Brown staining indicates the 
cytokerstin expression (cytoplasmic localization). Red arrows show the negative staining 
in ovarian stroma (OS) and tunica albuginea (TA) layers. A at 40X and B at 200X 
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4.3.2 Immunohistolocal staining of apoptotic cells in OSE and inclusion cysts in 
pregnant and cycling heifers 
After having confirmed the epithelial nature of the OSE and inclusion cyst 
layers, the extent of apoptosis was enumerated in these layers at different reproductive 
stages. Apoptosis positive cells by TUNEL assays were recognized according to their 
staining patterns and morphological features such as chromatin condensation on the 
periphery of the nucleus, and grossly stained nucleus. Microscopic observations showed 
that very few apoptotic epithelial cells were discernable within the total OSE cells 
examined in all groups of the animals; both non-pregnant and pregnant. Tissues with 
relatively high apoptotic index of 6% were found in OSE cells during 55-80 d 
pregnancy, whereas tissues collected from 90-140 d pregnant group of animals showed 
significant reduction in the number of apoptotic OSE cells in proportion to total cells 
(2%) (P0.05). The least apoptotic index was found in the OSE cells of non-pregnant 
group (0.8%) (P 0.05) (Figure 4.3). 
 When inclusion cysts were considered for such analysis, a similar trend of 
apoptotic index was observed within epithelial cells of different group of animals as was 
found in case of the OSE cells. Data analyses showed that 37% of the inclusion cysts in 
the ovarian tissues from 55-80 d pregnancy animals were completely apoptotic. In fact 
under the microscope all the lining cells seemed to be apoptotic (Figure 4.4). 
Conversely, the apoptosis analysis through the ovarian tissues from 90-140 d pregnant 
animals indicated that the number of completely apoptotic inclusion cysts was reduced 
to 10% (P0.05). Interestingly, the microscopic observations showed that the vast 
majority of inclusion cysts in the ovarian tissues of non-pregnant animals were 


















































Figure 4.3 Histogram representing in situ localization of apoptotic cells within the OSE 
cells and inclusion cysts at cycling (n = 8), 55-80 d pregnancy (n = 8) and 90-140 d 
pregnancy (n = 8) groups. Different letters above the bars indicate statistically 
differences between groups among OSE and asterisks represent statistical difference 



















Figure 4.4 Photomicrographs representing apoptotic cells in bovine OSE layer and 
inclusion cysts. (A and B) show apoptotic cells in OSE and inclusion cyst of cycling 
group, (black arrows show the apoptotic cells with brown stained nuclei and red arrows 
show the negatively stained cells). (C) Shows the TUNEL labelling in the inclusion cyst 
of mid pregnant group (completely stained). D is a high-power view of B and E is a 
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4.3.3 Induction of apoptosis by progesterone in cultured OSE cells 
APOPercentage™ assay, a colorimetric apoptosis detection system was used to 
detect apoptotic cell death in the cultured OSE cells upon treatment of two 
concentrations of progesterone and 17-oestradiol. After 24 h of 30 µg/ml progesterone 
treatment, as shown in (Figure 4.5), the level of apoptotic cells in population of total 
OSE cells reached 2-fold relative to the control (untreated cells). Under the same 
conditions, level of cell apoptosis was approximately 1.1-fold in OSE cells treated with 
low dose of progesterone (30 ng/ml). Treatment of OSE cells with low dose of 17-
oestradiol (30 ng/ml) did not induce apoptosis when compared with controls OSE cells 
incubated with equivalent ethanol. On the other hand, treatment with high dose of 
oestrogen (30 µg/ml) resulted in 1.6-fold increase in apoptosis, which was similar to the 
result of low dose of progesterone.  















































Figure 4.5 Histogram representing apoptosis in bovine cultured OSE cells after 
incubation with different treatments for 48 hours. OSE cells were incubated without 
treatment (control) or in the present of steroids (17- oestradiol or progesterone) at 
different doses (30 ng/ml and 30 µg/ml) or incubated with 5 mM H2O2 (positive control 
for apoptosis). Values for each treatment are expressed relative to the values of the 
control, which was taken as unity (1). Different letters over bars indicate statistical 
differences between each treated group and control (P 0.05). Data expressed as a mean 
± SEM; (three independent assays).  
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4.3.4 Effect of steroids on p53 expression in cultured OSE cells 
Since the results of cellular apoptosis revealed a direct influence of progesterone 
and to some extent oestrogen, we wanted to determine whether this process was 
associated with increased expression of p53 in the same cells. To study the effect of 
progesterone and oestrogen on p53 expression, cultured OSE cells were treated with 
oestrogen and progesterone at the doses 30 ng/ml and 30 µg/ml. Results from ICC 
revealed that low dose (30 ng/ml) of both the steroid treatments did not induce p53 
expression. However, a high dose of progesterone (30 µg/ml) increased p53 expression 
significantly over controls (P  0.01). Oestrogen treatment at high dose 30 µg/ml also 
increased the level of p53 expression significantly (P  0.05) but to a lesser degree than 
the high dose of progesterone (Figure 4.6).  
 

































Figure 4.6 Histogram representing the percentage of p53 immunostaining after steroid 
treatments in cultured bovine OSE cells. Cultured OSE cells were incubated without 
treatment (control) or in the present of steroids (progesterone and 17- oestradiol) at 
different doses (30 ng/ml and 30 µg/ml) for 24 h. Control cells were incubated with 
serum free medium under the same conditions. Different letters over bars indicate 
statistical differences between each treated group and control (P 0.05). Data expressed 
as a mean ± SEM; (three independent assays). 
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4.3.5 P53 Immunohistolocalization in cycling animals 
Since both apoptosis induction and p53 expression were regulated by direct 
hormone treatments, we aimed to detect p53 expression in different regions of OSE layer 
in cycling animal. Microscopic observations showed that p53 expression within the 
nuclei of the OSE cells was very low in most of the areas around the ovary. Analyzing 
the labelling index in each area of the OSE layer; over the large antral follicles, over the 
CL and over the stroma away from ovulation events showed, that more immunoreactive 
cells were detected over CL than in the other areas. The labelling index of p53 antigen 
was 4% over the CL, which was significantly higher than the number of labelled cells, 
which detected over the large antral follicles (1%) (P0.05). No positive stained cell for 
p53 was detected in the OSE cells over the stroma (Figure 4.7 and 4.8). 
 
Figure 4.7 Photomicrographs showing p53 immunostaining within the nuclei of OSE 
cells over different areas of the ovary. P53 expression in the OSE cells over the (A) CL, 
(B) large antral follicle and (C) ovarian stroma. Blue arrows show the positively stained 
cells (Brown nuclei). Panel D and E show positive control for p53 immunostaining in 
cells lining the inclusion cysts (IC) of human ovarian tissues, A and E at 400X, B and C 
at 600X and D at 200X magnifications.  
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P53 immunostaining in the OSE cells
 
 
Figure 4.8 Box plots representing P53 immunohistochemistry in the OSE cells of 
cycling heifers (n = 8) through different regions of the ovary (overlying corpora lutea 











 percentiles and 
asterisks represent the outliers. Data are the number of OSE labelled cells over each 
region for each section (3 sections/animal).  Total number of counted OSE cells over 












P53 labelling in OSE cells of cycling heifers 
 














1 5 795 0 800 
1 7 793 0 800 
1 2 798 0 800 
2 0 0 2 792 
2 2 798 0 800 
2 0 800 1 799 
3 3 797 1 799 
3 3 797 2 798 
3 5 795 1 799 
4 8 792 0 800 
4 4 796 0 800 
4 6 794 0 800 
5 6 794 0 800 
5 9 791 1 799 
5 2 798 1 799 
6 0 800 2 798 
6 0 800 0 800 
6 0 800 0 800 
7 3 797 0 800 
7 2 798 1 799 
7 4 796 1 799 
8 5 795 0 800 
8 1 799 1 799 
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4.3.6 P53 gene expression in different region of the OSE layer in cycling animals  
To understand whether differential p53 expression at different OSE regions were 
due to higher turnover of the pre-formed p53 protein or de novo synthesis, the p53 gene 
expression was monitored at mRNA level by RT-PCR analysis. Results indicated that 
the level of p53 gene expression of the OSE cells collected over the CL was higher than 
the equivalent cells from other areas. The p53 gene expression of the OSE cells collected 
from over the large follicles was lower than corresponding values found over the CL. 
There was no apparent p53 gene expression observed in the OSE cells collected from 











Figure 4.9 PCR gel showing p53 gene expression of freshly isolated bovine OSE cells. 
OSE cells were collected from different regions of the ovaries (n = 14) in relation to the 
underlying compartment. Lane A. OSE cells overlying corpora lutea (n = 8), lane B. 
ovarian stroma, lane C. antral follicles (n = 15) and lane D. negative control. Total RNA 
was reverse transcribed and amplified by PCR using p53 specific primers (upper panel). 
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GAPDH 255 bp 
  
p53 233 bp 
 




 Elevated progesterone concentration during pregnancy and use of progesterone-
like contraceptives are known to reduce ovarian cancers (Risch 1998). This study was 
undertaken to investigate whether or not there is a relationship between progesterone 
(also oestrogen)-mediated OSE apoptosis and expression of p53. The results of the 
current study concluded that progesterone during cycling and pregnancy plays a role in 
suppressing ovarian cancer by ceasing cell cycle and diverting damaged and 
mutagenized OSE cells for apoptosis, and the process may be mediated through elevated 
p53 synthesis. However, it is also possible that progesterone and p53-induced apoptosis 
may be entirely different cancer suppressive actions but coincidently happening 
together.   
 The immunohistochemical analysis of the tissues revealed that cytokeratin 
staining was present only in the surface epithelia. Anti-cytokeratin antibody used in this 
test recognizes only the epithelial cells’ cytoplasmic microfilaments and not the 
mesenchyma, which might arise due to epithelial-mesenchymal conversion after 
ovulation. Due to the fact that the inclusion cysts were also stained, we rule out any 
possibility of invasion by fibroblast-like mesenchymal cells in the cysts. The inclusion 
cyst epithelium is the preferred site for metaplasia transformation and tumourigenesis, 
and epithelial-mesenchymal transformation is a mechanism to prevent this 
manifestation. Since the objective was to demonstrate that apoptosis could be a 
mechanism to avert malignancy in these tissues, it was necessary to verify that the cells 
were of epithelial origin and not mesenchymal. Using standard TUNEL assay which 
recognizes apoptotic nuclei, very high percentage of epithelial cells from inclusion cysts 
during the pregnancy period (55-80 days) acquired the staining. Although the percentage 
of apoptosis-positive cells was much lower in the OSE layer than in the inner lining of 
inclusion cyst, the highest frequency in this tissue was also seen during 55-80 days 
pregnancy period. There were negligible cells with nuclear stain in the cycling animals, 
suggesting that practically no apoptosis took place in the oestrus period. The frequency 
of apoptotic cells started to decrease as the animals approached 90-140 days pregnancy. 
This observation was rather unexpected because the serum progesterone level reaches its 
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maximum during late pregnancy period (Smith et al. 1973). This indicates that serum 
hormone level may not reflect the actual concentration of progesterone in the vicinity of 
the ovarian surface. Until mid pregnancy, the CL produces progesterone, and when it 
starts to regress, the placenta takes over. Because of the proximity, the effective 
hormonal concentration around the OSE is expected to be high under the influence of the 
CL rather than placenta, even though both of them might contribute some progesterone 
level in the blood stream. Once the CL starts to regress, that is during mid-pregnancy, 
the effective concentration starts to decline. 
To ascertain a direct effect of steroidal hormone on apoptotic response on OSE, 
the cells were cultured in M199/MCDB 105 medium with standard additives. For bovine 
cells there seems to be some flexibility in choice of medium, because for culture 
purposes Dulbecco’s modified Eagle’s medium has also been used by some workers 
(Parrott & Skinner 2000). One concern with OSE cell culture is that through growth 
passages, epithelial cobblestone compact cells tend to convert to spindle shaped 
mesenchymal phenotype (fibroblast-like shape) (Auersperg et al. 2001). The cultivated 
bovine OSE cells maintained usual cobblestone morphology of original source cells of 
OSE layer, and probably the genetic makeup also remained unchanged. There were two 
noteworthy findings with the cultured cells. Oestrogen at high and progesterone at both 
high and low concentrations significantly increased the in vitro apoptotic activity. In 
fact, high progesterone stimulated apoptosis to nearly the same extent as positive control 
(H2O2-treatment). Besides, both hormones also induced expression of cell-cycle arrester 
and apoptosis-inducer protein, p53. We propose that progesterone, and to some extent 
oestrogen, through their receptors may up-regulate a cascade of downstream pathways 
leading to cell-cycle arrest and programmed cell death, and further that p53 protein 
seems to be responsible as a mediator molecule. Progesterone and oestrogen receptors 
have been localized within the bovine OSE cells (D'Haeseleer et al. 2007; D'Haeseleer et 
al. 2006; van den et al. 2002).  
The results of in vitro hormonal effects paved the way to test the actual in vivo 
influence. For this, p53 expression at mRNA and protein level was examined in those 
regions of OSE layer that are directly in contact with stroma, large antrum follicle or CL. 
The CL is the source of progesterone in cycling animals, and one can expect that OSE in 
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its proximity would be under the progesterone influence. Antral follicle and CL are also 
the source of oestrogen and they might also affect the neighbouring OSE layer. In this 
situation p53 expression should be high in only those regions of OSE which are in 
contact with the CL or antrum. Accordingly, we found a very high extent of p53 
immunoreactivity and PCR product of p53 gene mRNA in OSE layer overlying CL. The 
control, GAPDH expression was nearly identical in all the cells. There was some 
marginal expression of p53 protein in OSE overlying antral follicles, which is most 
likely due to oestrogen release. Although not tested, we hypothesize that in the cow, 
induced apoptosis during mid pregnancy phase is due to elevated progesterone, and is 
perhaps mediated through p53. The relationship between progesterone induced anti-
cancerous effects in OSE layer and p53-mediated apoptosis and thereby evading 
tumourigenesis may be purely coincidental. This is because the signals inducing p53 
expression are mitogenic and/or DNA damaging activities (Corney et al. 2007) rather 
than steroids.  
Wilcox et al. (2007) for the first time elucidated a direct contact effect of 
progesterone on anti-cancerous properties of cultured human OSE cells. The approach 
was microarray-based transcriptional profiling of over 22,000 transcripts (cDNA’s 
generated from total RNA’s) of progesterone treated and un-treated control cells. The 
most significant up-regulation in treated cells was of the enzymes and transporter 
proteins of cholesterol biosynthetic pathway, besides the progesterone receptors, PR-A 
and PR-B. Among the cholesterol biosynthesis genes, TMEM97 gene encoding a trans-
membrane protein of unknown function was found to be most expressed. It was 
concluded that progesterone through its receptors mediate an up-regulation of 
cholesterol and lipid biosynthesis in OSE cells. This in turn decreases the cell membrane 
fluidity, and such cells are less vulnerable to inflammatory and physical damage due to 
ovulation.  
Another microarray analysis was carried out to elucidate p53 gene targets in 
cultured mouse OSE cells (Corney et al. 2007). For this, microRNA (miRNA) 
expression of OSE cells in p53 knock-out mutant and wild type mice was compared. It 
was found that two genes for miRNA’s, termed miR34-b and miR34-c were over-
expressed in wild type cells. Upon induction of p53 gene these two miRNA’s also over-
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expressed. These miRNA’s were shown to “silence” several cancer-related genes like 
Delta-like 1, Notch-1, Met, Myc, Cdk-6, Cyclin D1 etc. Mi-RNA-mediated repression of 
these downstream target genes was considered to be a mechanism whereby p53 
suppresses the tumour progression. Comparative genome hybridization and microarray 
profiling of normal and neoplastic OSE cells was carried out to elucidate signature genes 
for tumour suppression and many of them were found to be involved with the p53 
pathway (Landen et al. 2008). Mutation of p53 gene and some other ovarian and breast 
tumour suppressor genes like BRCA1 and BRCA2 are linked to “high-grade pathway” of 
malignancy due to unchecked proliferation, inhibition of apoptosis, angiogenesis, 
stromal invasion, separation and survival away from the primary tumour, and 
implantation and growth within new tissues.  
In conclusion, progesterone and p53 seem to be associated with suppression of 
bovine EOC in both cycling and pregnant animals. At least two distinct mechanisms 
may be attributed to this phenomenon; 1) anti-inflammatory activity due to 
progesterone-mediated increase in cholesterol and lipid biosynthesis, and 2) p53- 
mediated cell cycle-arrest and apoptosis. Whether these attributes are connected to each 
other or whether they are two distinct events independently contributing to tumour 
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5.1 Introduction  
 Gonadotrophin releasing hormones (GnRHs) are decapeptides produced from 
specialized neurosecretary cells in the hypothalamus, targeting the pituitary-gonadal 
axis. Over 20 different forms of GnRH in vertebrate species have highly conserved 
structure (Millar 2005). In mammals, three forms are known, GnRH-I (mammalian 
GnRH), GnRH-II (chicken GnRH-II) and the salmon GnRH (RnRH-III) (Metallinou et 
al. 2007). GnRH-I is a typical pituitary controlling hormone, with affinity to the 
pituitary seven transmembrane domain G protein (Gq/11)-coupled receptors (Stanislaus et 
al. 1997). After binding, GnRH-I modulate membrane phospholipase C (inositol 
phosphate) and calcium channel, and consequently stimulate LH synthesis and secretion. 
A direct control over FSH secretion has not been unequivocally proven. Plasma 
gonadotrophin levels regulate the overall reproductive process, especially the gonadal 
steroidogenic and gametogenic functions (Millar 2005). The GnRH-I and II receptors 
are also found in almost all types of normal and cancerous epithelial cells, including 
those present in gonads (Millar et al. 2001). The extra-pituitary function of these 
receptors in these tissues is not fully understood, but evidence suggests that the GnRH-I 
and II signal transduction pathways in epithelial tissues are different from pituitary cells 
(Emons et al. 2003). Interestingly, GnRH-II receptors in these epithelia have conserved 
regions of GnRH-I and binding of the two GnRHs to their receptors can be mutually 
exclusive (Mamputha et al. 2007). Studies suggest that GnRH-II has a role in 
suppression of cell proliferation and apoptosis by triggering a G-protein (Gi) mediated 
signal pathway in the target cells (Wu et al. 2009).   
 During the last four decades, several thousand peptide and non-peptide GnRH 
agonists and antagonists have been synthesized and tested for clinical efficacy (Fister et 
al. 2007; Agorastos et al. 2004). These compounds, which are generally GnRH analogs, 
competitively bind to pituitary GnRH receptors and by two distinct mechanisms down-
regulate gonadotrophin synthesis and secretion. Within 7-14 days of a GnRH agonist 
administration, a “surge” of gonadotrophins and steroidal hormones, known as “flare”, is 
followed by a rapid fall in their serum concentrations. In contrast, the antagonists lower 
the hormone concentrations from the beginning. Both groups of synthetic analogs also 
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down-regulate expression of GnRH receptors and initiate internalization of the cell 
surface receptors to the nuclear membrane (Herbst 2003). This further hinders the 
binding of GnRH to pituitary cells. Clinically, the agonists/antagonists are used for the 
treatments of prostatic, breast and endometriotic cancers, uterine fibroids, precocious 
puberty, premenstrual and polycystic syndromes, and infertility (Emons et al. 2003; 
Millar 2005; Hayden 2008). Among several GnRH antagonists developed, Antarelix was 
formulated in the 1990’s and extensively used as a polypeptide GnRH-I antagonist 
(Deghenghi et al. 1993). The advantage of this compound is its high water solubility, 
modest allergy and histamine stimulation and high potency. 
 Because they have similar patterns of serum -oestradiol, progesterone, 
testosterone, LH/CG during the ovulatory cycle and pregnancy to that of the human 
being, nonhuman primates are used as experimental models to study hormone-related 
reproductive problems like anovulatory infertility (Steinetz et al. 1995; Abbott et al. 
2004). Among primates, the reproductive physiology of Old World (e.g. rhesus; Macaca 
mulatta) and New World (marmosets; Callithrix jacchus) monkeys differs. Some 
ubiquitous features of marmosets distinct from higher primates are: 1) multi-ovular 
species with ovulatory cycles of ~28 days, comprising short follicular (8-9 days) and 
long luteal (19 days) phases, 2) ovulation rates ranging from one to four follicles per 
cycle (Gilchrist et al. 2001), 3) pituitary gonadotropes secret chorionic gonadotrophin 
(CG) and not LH, 4) LH receptors bind to CG and course of action of two hormones is 
similar (Tannenbaum et al. 2007), and 5) ovarian senescence is more subtle and does not 
resemble the menopause in women. Like humans, the follicular phase is characterized 
by low level of progesterone, rising oestradiol and typical pre-ovulatory “surge” of LH 
(Harlow et al. 1984). Marmoset ovaries contain a multitude of small antral follicles and 
towards the end of the follicular phase; two or three antral follicles enlarge and go on to 
ovulate. There exists clear morphological and size distinction between large ovulating 
and small non-ovulating antra (Gilchrist et al. 2001). Ovarian epithelial proliferation is 
believed to be primarily regulated at the level of gonadotrophins, which stimulate 
follicular oestradiol production. As a mitogen, -oestradiol and other localized factors 
such as insulin-like and hepatocyte-growth factors (IGF, HGF) trigger proliferative 
response in post-ovulatory OSE layer at the sites of rupture. Poly-ovulatory mammals 
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like marmosets have repeated ovulations and therefore repeated rupture and healing of 
the OSE layer. These features accelerate OSE cell multiplication and transformation to 
neoplasia at the rupture sites. Notwithstanding, gonadotrophin-associated incidences of 
ovarian cancers are rarely reported in marmosets, even though EOC affects only 
primates and very rare other mammals. It is likely that the 10-fold higher progesterone 
concentration in pregnant marmosets compared to other primates (Steinetz et al. 1995) 
may help suppress the OSE tumourigenesis in these animals.   
 Antarelix GnRH antagonist has been used in marmosets to suppress LH/CG 
secretion from the pituitary gland, and the follicular and luteal development was 
examined in such treated animals (Taylor et al. 2004). It was found that upon such 
treatment the level of serum -oestradiol rapidly falls and as a result proliferation of 
granulosa cells in antral follicle and CL diminishes. Follicular vasculature remained 
underdeveloped and the resultant follicle’s growth and differentiation was restricted and 
ovulation was unsuccessful (Taylor et al. 2004). The GnRH antagonist may also 
suppress the mammalian OSE proliferation and tumourigenesis in a dualistic manner. 
First, it may do so by inhibiting LH/CG secretion so that follicular development is 
inhibited and ovulation is prevented. Hence the number of re-epithelization events is 
reduced and OSE stays non- proliferative. Second, the antagonists may bind directly to 
OSE cell’s GnRH receptors and impart anti-proliferative response through some 
unknown downstream signaling pathway. Another action could be that reduced LH-
controlled steroidogenesis reduces the production of localized pro-proliferative mitogens 
(-oestrogen) in granulosa cells and other inflammatory agents which cause genetic 
damage to the epithelial cells.  
 According to the gonadotrophin theory of ovarian cancer, a high level of 
gonadotrophins at menopause has a role in the development of epithelial ovarian cancer. 
In this study, we test the hypothesis that GnRH antagonist administration would 
suppress endogenous gonadotrophin, resulting in inhibition of OSE proliferation in 
marmoset. We also hypothesize that changes in the ovarian environment during the 
ovarian cycle (follicular and luteal phase) and at early pregnancy might have an 
influence on the activity and morphology of the OSE cells. To our knowledge this is the 
first report of a GnRH antagonist treatment on OSE proliferation in a primate. 
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5.2 Materials and methods 
5.2.1  Animals and tissue samples 
 Adult female common marmoset monkeys (Callithrix jacchus) (age 2-3 yr) with 
body weight ~350 g, and having a regular 28 d ovulatory cycles or gestation periods 
between 141 d and 145 d, were housed in cages under standard conditions. The ovaries 
used for this study had been collected for analysis on day 0 (n = 4),  day 5 (n = 5) and 
day 10 (n = 6) of the follicular phase (Taylor et al. 2004), and at early (n = 5), mid (n = 
5) and late (n = 5) luteal phase (14-22 d) of the ovarian cycle (Wulff et al. 2001; Rowe 
et al. 2002). Additionally, ovaries from the pregnant animals were collected from second 
(n = 5), third (n = 3) and fourth (n = 6) week of pregnancy (Rowe et al. 2002).  
 
5.2.2 Treatments 
 In order to synchronize the timing of ovulation, marmosets were treated 
intramuscularly with a single i.m. injection of 1 µg of a prostaglandin (PG) F2 analogue 
(cloprostenol, Planate; Cheshire, UK), between days 12-15 of 20 d luteal phase to induce 
luteolysis. The day of the PG injection was designated as follicular day zero. A GnRH 
antagonist Antarelix (Europeptides, Argenteuil, France) was dissolved in water to reach 
a concentration of 10 mg/ml. To provide a slow-release depot, Antarelix was 
administrated at a dose of 12 mg/kg body weight by subcutaneously injecting on 
follicular day 0 (day of PG injection) (n = 5) or day 5 (n = 5) (Taylor et al. 2004). 
Ovaries were collected on day 10 following PG administration, corresponding to the 
periovulatory period in the control animals. Control marmosets were studied in parallel 
on day 0 (n = 5) and day 10 (n = 5) corresponding to PG administration. All animals 
were injected i.v. with 20 mg BrdU (Roche Molecular Biochemicals, Essex, UK) 
prepared in saline. After 1 h they were killed with an i.v. injection of 400 µl of Euthetal 
(sodium pentobarbitone; Rhone Merieux, Harlow, Essex, UK). Ovaries were removed, 
weighed and immediately fixed in 4% neutral buffered formalin. After 24 h, the ovaries 
were transferred to 70% ethanol, dehydrated and embedded in paraffin. The ovary 
sections were prepared and processed for immunohistochemical analysis as described 
(Wulff et al. 2001; Rowe et al. 2002). 




 The changes in the proliferative activity of the OSE throughout the follicular 
phase, luteal phase and early pregnancy and after GnRH antagonist treatment were 
studied by quantifying the number of proliferating cells within the OSE area whose 
nuclei were stained with BrdU. For this, sections were prepared on glass slides and 
stained for BrdU as described previously (Taylor et al. 2004; Wulff et al. 2001; Rowe et 
al. 2002). For BrdU immunostaining, antigen retrieval was performed by pressure 
cooking using a Tefal Clypso pressure cooker (Tefal, Langley, Berks, UK). Sections in 
0.01 M citrate buffer, pH 6, were kept for 6 min at high pressure setting (2). Slides were 
then left for 20 min in hot buffer and washed in Tris-buffered saline (TBS; 0.05 M Tris-
HCl and 1.5 M NaCl). To reduce non-specific binding, sections were blocked in normal 
rabbit serum (NRS; 1:5 diluted with TBS containing freshly added 5% bovine serum 
albumin) for 30 min. Primary antibody, BrdU (mouse anti-BrdU; Roche Molecular 
Biochemicals, Essex, UK) was diluted 1:30 in TBS. Incubation was carried out 
overnight at 4ºC. Slides were washed three times in TBS. Incubation with the secondary 
antibody rabbit anti-mouse IgG (1:60 diluted in NRS: TBS; DAKO Corp.) was carried 
out for 40 min at room temperature, followed by two washings in TBS. and incubation 
with alkaline phosphatase-anti-alkaline phosphatase complex (1:100 dilution in TBS; 
DAKO Crop.) for 40 min at room temperature. Slides were visualized using 500 µl nitro 
blue tetrazolium (NBT) solution containing 45 µl NBT substrate (Roche Molecular 
Biochemicals), 10 ml NBT buffer, 35 µl 5-bromo-3-chloro-3-indolyl-phosphate and 10 
µl levamisole. Sections were counterstained with haematoxylin. The positive 
immunostaining of BrdU within the granulosa cells of growing follicles was used a s a 
positive control, figure 5.1 shows photomicrographs of antral and preantral follicles with 
high levels of BrdU labelling comparing to the OSE cells (Page 114). 
 
5.2.4 Quantification of immunohistochemistry 
 BrdU incorporation of the OSE showing proliferating cells was quantified. 
Proliferation of the OSE was detected all around the circumference and in all sections. 
At least 20 sections for each group of study were examined. The labelling index was 
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determined by counting the number of OSE cells (labelled and unlabelled) in each 
section under 600X magnification, and expressed as the percentage of labelled OSE 
cells. The labelling index is expressed as a mean value for the number of OSE cells in 
each section.  
 
5.2.5 Statistical analysis 
  The Kolmogorov-Smirnov test was used in order to test whether the data is 
normally distributed or not. Data for studies of GnRH antagonist treatment and the 
ovarian cycle influences on OSE cell proliferation was not normally distributed 
therefore; The Kruskal-Wallis test was selected in order to compare different groups.   
Data for BrdU labelling distribution over different areas of the ovary was not normally 
distributed, therefore Chi-square test was used to compare the total percentages between 
groups. Differences were considered to be significant at P 0.05. Analysis was carried 





















5.3.1 OSE proliferation at different stages of the ovarian cycle and during early 
pregnancy 
 Results from this analysis revealed that the highest proliferation was obtained 
during the late follicular and early luteal phase. There was a gradual increase in the 
proliferation activity as the follicular phase advanced, reaching the maximum value 
towards the end of this phase (P 0.05) (Figure 5.2). After ovulation, proliferation in 
early luteal phase ovaries was also high before declining markedly by the mid luteal 
phase (P 0.05). This low level was maintained in late luteal phase ovaries.  
 To ascertain which underlying tissue is contributing to the OSE proliferation, the 
BrdU staining was examined at different regions of the OSE layer. During the follicular 
phase the majority of the proliferating cells were detected over the large antral follicles 
which were very close to the surface (60-75 m), and a lower number of proliferating 
cells were found distributed randomly over the stroma. During the luteal phase, most of 
the proliferating cells were located over the CL and little activity was observed over the 
stroma (Figures 5.3 and 5.4). 
 During all stages of pregnancy (2, 3 and 4 weeks), the OSE cells showed 
diminished or extremely low BrdU labelling, and correspondingly very low labelling 
index as compared to the non-pregnant cycling animals (P 0.05). The OSE proliferation 
was discernable mostly at week 2 of pregnancy (Figure 5.2). During early pregnancy a 
variation in the distribution of the proliferating cells within the OSE was also detected. 
The highest number of proliferating cells was found over the CL, whereas slightly lower 
number of evenly distributed cells was observed over stroma. At this pregnancy stage, 











Figure 5.1 Photomicrographs showing BrdU labelling within the granulosa cells of 
growing follicles in marmoset ovary. Histological sections at (A) follicular phase of the 
ovulatory cycle (blue arrow indicates high level of BrdU labelling in granulosa cells of 
antral follicle) and (B) at pregnancy (red arrow indicates low level of BrdU labelling in 
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Figure 5.2 Box plots indicating BrdU incorporation into the marmoset OSE cells over 
the total area of the ovary at early (n = 4), mid (n = 5) and late stages (n = 6) of the 
follicular phase, and early (n = 5), mid (n = 5) and late stages (n = 5) of the luteal phase 
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and asterisks represent the outliers. Data are the number of BrdU labelled cells in OSE 
cells in each section (2 sections /animal). Total number of counted cells is presented in 





Week-2 Week-1 Early Mid Late 




BrdU labelling in the marmoset OSE cells at early, mid and late stages of the follicular 
phase 









1 3 1979 5 1847 9 1861 
1 6 2094 2 1795 7 1814 
2 2 1235 8 1864 6 1389 
2 3 1634 9 1811 11 1347 
3 0 1928 5 1310 4 1789 
3 2 875 1 1877 5 1157 
4 4 1522 6 1461 17 1831 
4 2 1394 2 1219 4 926 
5   8 1878 10 1841 
5   5 1413 6 931 
6     5 1297 
6     11 1101 
 
Table 5.2 
BrdU labelling in the marmoset OSE cells at early, mid and late stages of the luteal 
phase 









1 7 1391 7 1461 2 1507 
1 4 1678 4 1349 3 1747 
2 19 1126 19 1024 2 993 
2 2 1812 2 1329 2 996 
3 5 886 5 1216 1 1357 
3 12 1326 12 951 3 914 
4 9 1450 9 852 0 1192 
4 2 847 2 913 1 1711 
5 10 1327 10 1285 0 865 











BrdU labelling in the marmoset OSE cells at week-1, 2 and3 pregnancy 
 









1 0 967 1 901 0 947 
1 5 893 0 897 0 1002 
2 0 900 0 996 0 989 
2 4 875 0 781 0 1103 
3 1 1341 0 964 0 997 
3 9 1433 1 835 0 978 
4 1 911   0 1322 
4 1 1215   0 1014 
5 0 1769   0 812 
5 2 992   0 974 
6     0 1016 




























































 Figure 5.3 Box plots indicating the distribution of BrdU labelled cells in marmoset OSE 
through different regions (overlying stroma, antral follicles and corpora lutea (CL)) at 
the follicular phase (n = 15), the luteal phase (n = 15) and at week 1 and 2 pregnancy (n 
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 percentiles and asterisks represent the outliers. Data are 
the number of BrdU labelled cells in OSE cells at each region for each section (2 












The distribution of BrdU labelled cells in the marmoset OSE cells over different regions 
of the ovary at the follicular phase 
 
Group Animal CL GF Stroma Total 
Early follicular 1 0 0 3 3 
1 0 2 4 6 
2 0 2 0 2 
2 0 2 1 3 
3 0 0 0 0 
3 0 2 0 2 
4 0 3 1 4 
 4 0 2 0 2 
Mid follicular 1 0 1 4 5 
1 0 2 0 2 
2 0 2 6 8 
2 0 4 5 9 
3 0 4 1 5 
3 0 0 1 1 
4 0 1 6 6 
4 0 0 2 2 
5 0 2 6 8 
 5 0 2 3 5 
Late follicular 1 0 9 0 9 
1 0 7 0 7 
2 0 5 1 6 
2 0 9 2 11 
3 0 2 2 4 
3 0 5 0 5 
4 0 14 3 17 
4 0 4 0 4 
5 0 9 1 10 
5 0 6 0 6 
6 0 5 0 5 
 6 0 9 2 11 











The distribution of BrdU labelled cells in the marmoset OSE cells over different regions 
of the ovary at the luteal phase 
 
Group Animal CL GF Stroma Total 
Early luteal 1 5 0 2 7 
1 4 0 0 4 
2 14 0 5 19 
2 1 0 1 2 
3 3 0 2 5 
3 8 0 4 12 
4 5 0 4 9 
4 2 0 0 2 
5 7 0 3 10 
 5 7 0 1 8 
Mid luteal 1 0 0 1 1 
1 0 0 2 2 
2 0 0 1 1 
2 0 0 0 0 
3 0 2 0 2 
3 0 0 1 1 
4 1 0 0 1 
4 0 0 0 0 
5 0 0 0 0 
 5 0 2 0 2 
Late luteal 1 0 2 0 2 
1 0 3 0 3 
2 0 2 0 2 
2 0 2 0 2 
3 0 1 0 1 
3 0 3 0 3 
4 0 0 0 0 
4 0 1 0 1 
5 0 0 0 0 
 5 0 2 0 2 











The distribution of BrdU labelled cells in the marmoset OSE cells over different regions 
of the ovary at week-1 and week-2 pregnancy 
 
Group Animal CL GF Stroma Total 
Pregnant Week-1 1 0 0 0 0 
1 4 0 1 5 
2 0 0 0 0 
2 4 0 0 4 
3 1 0 0 1 
3 7 0 2 9 
4 1 0 0 1 
4 0 0 1 1 
5 0 0 0 0 
 5 1 0 1 2 
Pregnant Week-2 1 1 0 0 1 
1 0 0 0 0 
2 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
 3 1 0 0 1 



































Figure 5.4 Photomicrographs showing BrdU labelling within the marmoset OSE cells. 
BrdU labelling within the OSE cells at follicular phase of the ovulatory cycle (A) over 
large antral follicle and (B) over stroma. C-D demonstrate the morphology of OSE cells 
at luteal phase (C) over mature CL and (D) over stroma. E-F OSE cells at pregnancy (E) 
over stroma and (F) over CL. Red arrows indicate labelled cells within the tunica 
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5.3.2 Morphological changes in the OSE cells 
 The distribution of proliferation markers in OSE cells varied considerably during 
different reproductive stages (follicular, luteal and pregnancy). The OSE morphology 
and its adhesiveness to underlying tissues are also expected to alter considering the 
extent of multiplication capabilities within a limited surface area in which the cells can 
expand. The microscopic observation revealed considerable variation in the shape of the 
OSE cells ranging from squamous to cuboidal. Moreover, the association between the 
OSE cells was affected by the ovarian cycle and the ovarian compartments. OSE cells 
over the large antral follicles which were located very close to surface were flattened in 
shape and disarrangement between these cells was noticed. There was no evidence of 
firm attachment with the underlying basement membrane (Figure 5.5-A).Over the CL, 
OSE cells appeared as squamous with very weak association between the cells, and it 
was seen that attachment of these cells with the basement membrane was also loose 
(Figure 5.5-B). The OSE cells observed in a region away from the follicular 
development and the ovarian event over the stroma, displayed highly organised 
arrangement of cuboidal shape, and attachment in between the cells and of the cells with 































Figure 5.5 Photomicrographs representing the morphological changes of the OSE cells 
at different regions of the marmoset ovary. (A) OSE covering large antral follicle (arrow 
indicates flattened shaped cells), (B) over a mature CL (arrow indicates squamous 
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5.3.3 Effect of Antarelix treatment on OSE proliferation 
 Prior studies on Antarelix treatment in marmoset monkeys revealed significant 
reduction in BrdU labelling in ovarian endothelial cells and steroidogenesis in granulosa 
and theca cells of growing follicles (Taylor et al. 2004). It was a matter of interest to 
study how these changes would affect the overlaying OSE cells. A comparison of 
sections prepared from the ovaries of late follicular controls and the treatment groups 
revealed that the OSE cells of GnRH antagonist-treated ovaries from day 0-10 and from 
day 5-10 exhibited a decrease in the proliferation after both treatment schedules. 
Quantitative analysis confirmed significant decrease in cell proliferation in the OSE cells 
in both treated groups, and the effect was more pronounced in the longer treatment 
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Effect of GnRH antagonist treatment on OSE cells proliferation
 
 
Figure 5.6 Box plots indicating BrdU incorporation into the marmoset OSE cells over 
the total surface area of the ovary after GnRH-antagonist treatment from day 5-10 (n = 
5; 5 sections/animal) and day 0-10 (n = 5; 3 sections/animal) follicular phase, ovaries 
from day 10 follicular phase were used as a control (n = 5; 4 sections/animal).  The lines 
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 percentiles and asterisks represent the outliers. Data are the number of BrdU 
labelled cells in OSE cells for each section. Total number of counted cells is presented in 
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Table 5.7  
BrdU labelling in the marmoset OSE cells over the total surface area of the ovary after 
GnRH antagonist treatment 
 






















1 5 1847 1 1 1865 1 1 1425 
1 2 1795 1 0 1998 1 0 1491 
1 8 1864 1 0 1975 1 0 1502 
1 9 1811 1 0 1774 2 0 1479 
2 5 1310 1 1 1876 2 0 1568 
2 1 1877 2 0 1943 2 0 1801 
2 8 1862 2 0 1612 3 0 1799 
2 7 1814 2 0 1787 3 0 1788 
3 6 1389 2 1 1914 3 0 1695 
3 11 1347 2 0 1783 4 0 1702 
3 4 1789 3 0 1881 4 0 1429 
3 5 1157 3 0 1679 4 0 1473 
4 17 1831 3 0 1862 5 0 1398 
4 4 926 3 0 1993 5 0 1412 
4 10 1841 3 0 1765 5 0 1463 
4 3 934 4 0 1871    
5 5 1297 4 0 1840    
5 6 1106 4 0 1895    
5 3 1979 4 0 1882    
5 3 2094 4 0 1612    
   5 3 1792    
   5 0 1747    
   5 0 1913    
   5 0 1862    














 Considering the fundamental role of OSE cells in ovarian tumourigenesis, the 
growth regulation of normal and neoplastic OSE cells by intraovarian regulators may 
play an important role in ovarian cancer development. In this regard, GnRH has been 
implicated as an autocrine regulator of normal OSE (Kang et al. 2000) as well as a 
growth inhibitor of ovarian cancer cells. GnRH antagonists are widely used in the clinic 
during ovarian hyperstimulation programmes to block endogenous gonadotrophin 
secretion (Huirne et al. 2004). GnRH regulates the biosynthesis and secretion of 
gonadotrophins. In this study we have demonstrated two significant findings regarding 
the OSE cell proliferation, under the effects of pregnancy (Page 104) and in response of 
GnRH antagonist treatment (Page 111). We provide evidence that GnRH antagonist 
treatment and pregnancy both significantly reduce the proliferative activity of the OSE.  
 The present results show that during the ovulatory cycle, BrdU staining of OSE 
layer increases towards end of the follicular phase, when it is in contact with large antral 
follicles, and decreases by the mid luteal phase. In fact the highest staining was seen in 
CL at early luteal phase. Low staining of OSE, overlying the stroma shows that the 
resting OSE cells at early follicle development or those which are not in the vicinity of 
the CL or antrum are not rapidly dividing. Since OSE proliferation was associated with 
large antral follicles and CL at all reproductive phases it can be predicted that events 
leading to luteogenesis contribute towards OSE proliferation whereas the reverse 
process, luteolysis, suppresses the proliferative response. Before luteogenesis 
remarkable changes take place in the granulosa and theca cells of growing follicles in 
late follicular phase, notably vascularization, angiogenesis and steroidogenesis. 
Interestingly, these changes are regulated by LH (Dickson & Fraser 2000). Vascular 
endothelial growth factor (VEGF) is a pro-angiogenic factor that plays an important role 
in angiogenesis (Redmer et al. 2001). In granulosa cells of growing follicles, VEGF 
expression is up-regulated most likely due to LH, and high cellular level of this factor is 
maintained up to luteal phase controlled by LH/CG (Stouffer et al. 2001). In the CL the 
same granulosa cells transform to granulosa-lutein cells responsible for steroidogenesis. 
It was therefore a matter of interest to examine whether or not the angiogenic and 
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steroidogenic granulosa cells proliferate at late follicular and early luteal phase. The 
granulosa cells of growing follicles were heavily stained suggesting that these are highly 
proliferative cells, and these rapidly multiplying granulosa cells may secrete some 
mitogenic substances, notably -oestradiol, to influence the surrounding OSE layer to 
proliferate.   
OSE cell morphology is believed to be another marker of proliferative activity (Auersperg 
et al. 2001). It has been suggested that squamous and cuboidal forms of cells represent the 
groups that have not or have undergone post-ovulatory proliferation respectively (Gillett et 
al. 1991). OSE cells tend to assume columnar shapes when they form clefts and inclusion 
cysts (Auersperg et al. 2001). These cells are the primary targets for mitogenic and 
inflammatory action leading to tumourigenic growth (Deligdisch et al. 1995). The OSE 
cells attach to the basement membrane that participate in a number of fundamental 
biological processes such as cell growth, differentiation tissue development and repair 
(Couchman & Woods 1993; Aumailley & Krieg 1996; Aumailley & Gayraud 1998). It has 
been proposed that loss of ovarian surface basement membrane after preovulatory 
stimulation by gonadotrophins is a critical step in early tumourigenicity of the OSE (Yang 
et al. 2002; Roland et al. 2003). We found that non-proliferative cuboidal and tightly 
attached OSE cells were present away from the ovulation sites. The proliferative squamous 
cells with very loose attachment were discernable over CL and disarranged flattened cells 
were present in the OSE layer just before ovulation. Some of these cells might transform to 
columnar cells if inclusion cysts or clefts are formed after ovulation. Interestingly, the 
stratification feature which was common in the OSE layer of pregnant ewes but did not 
occur in marmoset, an explanation of this event would be seasonality in sheep. During 
anoestrous and due to anovulation cycle, the OSE cells enter into a quiescence state (no 
excessive injury and repair) (less chance of cells slough off) this may lead to accumulation 
of cells in multiple layers.   
        Although it was not expected to detect OSE proliferation during pregnancy, 
OSE cells during 2
nd
 week of gestation displayed positive BrdU staining specifically in 
proximity to CL. These observations suggest that the OSE cells at this stage are still 
under the influences of the CL mitogenic factors or probably because the progesterone 
concentration has not been high enough to suppress any proliferative action. Earlier we 
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demonstrated an anti-proliferative role of progesterone, whether produced during 
pregnancy or given as contraceptive pills. It is reasonable to assume that despite 
progesterone presence, CL influences the OSE proliferation and this attribute could be 
due to some factor which supersedes the hormone action. Kisliouk and colleagues 
(2005) indicated the role of prokineticins-1 (PK-1), a member of secreted proteins 
family protineticins in bovine corpora lutea. It has been shown that PK-1 acts as a 
mitogenic and antiapoptotic factor in luteal function (Kisliouk et al. 2005). The data also 
suggests that as pregnancy advances the proliferation becomes diminished because of 
the increasing levels of progesterone. 
 So far the results indicate that, in marmosets, luteogenesis rather than 
folliculogenesis seems to influence OSE proliferation and luteolysis and pregnancy 
reverses this process. In primates LH/CG is necessary for CL development, which 
induces numerous paracrine regulators of luteal development including VEGF that 
controls angiogenesis and vascularization (Duncan & Kalluri 2009; Fraser & Duncan 
2009). As LH concentration starts to recede, the natural luteolysis advances starting 
from mid luteal phase. During luteolysis the LH level falls and all its stimulatory actions 
like angiogenesis and steroidogenesis decline. Additionally, luteal cells produce 
interleukins, prostaglandins and factors like capsase-3 to induce apoptosis and other 
mechanisms to degenerate CL (Fraser et al. 2006). If CL is rescued due to pregnancy, 
CG produced from conceptus takes over the LH functions. It remains to be seen whether 
in primates local ovarian environment influences OSE proliferation or it is simply the 
mechanical ablation of OSE layer to accommodate large antrum or CL that triggers the 
renewed multiplication and neoplastic transformation. In this context it is noteworthy 
that in rhesus monkeys brushing the OSE layer at any reproductive phase is sufficient to 
induce proliferative repair (Wright et al. 2008).     
 In this investigation, the potential anti-proliferative response to treatment with a 
GnRH antagonist was examined on OSE cells in marmoset monkeys. Prior to this 
experiment luteolysis of the CL was artificially induced and the luteal phase was 
prematurely stopped by treatment with prostaglandin F2 analogue towards the end of 
the ovulatory cycle, which is a common practice to synchronize follicular phase in 
cycling marmosets (Steinetz et al. 1995). Luteolysis was verified as a sharp reduction in 
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serum progesterone concentration (Taylor et al. 2004). Towards the end of luteolysis the 
steroidal hormones reach their minimum concentrations and under FSH and LH/CG 
influence the steroidogenesis begins in pre-antral granulosa and antral granulosa and 
theca cells. Blocking FSH and LH/CG release at zero time by Antarelix (0-10 days) in 
this study would have arrested the development of tertiory follicles with consequent 
prevention of ovulation (Taylor et al. 2004). Further, -oestradiol synthesis was 
decreased as Antarelix treatment inhibits steroidogenesis (Taylor et al. 2004). At 5
th
 day 
blockage (5-10 days) some gonadotrophin concentration would have build up in within 
first 5 days which apparently is sufficient to grow follicles up to pre-antral stage. 
Thereafter, LH “surge” which takes place at late follicular phase necessary for ovulation 
and CL formation must have been prevented. Since in marmosets large antral follicles 
are differentiated only after 6 days (Gilchrist et al. 2001), in this situation only the small 
antral follicles are expected to develop and then start to regress into atresia (Taylor et al. 
2004). The depressive effect of Antarelix on OSE proliferative activity was clearly 
discernable regardless of the time of administration. It is proposed that pre-ovulatory 
large antral follicle and its derived CL may be responsible for OSE proliferation in the 
contact regions. This conclusion is derived from the observation that OSE proliferation 
was suppressed when drug was administered on 5
th
 day of follicular cycle when pre-
ovulatory follicles were not able to be differentiated. There could be several 
explanations of Antarelix’s OSE anti-proliferative effect which may function in isolation 
or in combination: 1) reversal of LH/CG up-regulation of localized growth factors like 
IGF and HGF which are responsible for mitogenic action through their anti-apoptotic 
effect on OSE, 2) inhibition of gonadotrophin-induced steroidogenesis in antral follicles 
and CL would minimize production of mitogenic -oestradiol in granulosa cells, and 
consequently OSE proliferation would be inhibited, 3) GnRH antagonists result in skew 
in frequency of antral follicles (Taylor et al. 2004), and apparently this would reduce 
ovulation frequencies and resultant epithelial rupture, and thereby prevent the neoplastic 
growth of OSE, and 4) this compound may bind to GnRH-I/ GnRH-II receptors in OSE 
cells itself and inhibit all downstream pathways which involve mitogen activating 
protein (MAP), P38 and the extracellular signal regulate kinase (ERK-1/2) responsible 
for mitogenic proliferation (Millar et al. 2001; Mamputha et al. 2007).   
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In conclusion, BrdU uptake and immuoreactivity equating to proliferating cells 
was detected at the ovulation site before and after ovulation and lower number of BrdU–
stained cells were found to be distributed randomly in OSE at other sites around the 
ovary, suggesting that the OSE proliferative activity takes place in a cyclic manner 
depending on the ovarian events that occur underlying the OSE during the ovarian cycle. 
GnRH antagonist treatment resulted in complete inhibition of OSE cells proliferation. 
Further study is needed to investigate the mechanisms in which the GnRH antagonist 
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6.1 General discussion 
The work presented in this thesis demonstrates how OSE cells are influenced by 
many factors intrinsic and extrinsic to the ovary. The ovary is a dynamic organ with 
constantly changing structures and micro-environments. The entire ovary is covered by 
the OSE layer which is believed to be the progenitor of most EOC (Auersperg et al. 
1998); the most lethal type of cancer in women. Most established risk factors for this 
disease relate to reproductive events (Tung et al. 2005; Murdoch 2005; Murdoch et al. 
2005). Malignant transformation of normal ovarian epithelial cells is caused by genetic 
alterations that disrupt regulation of proliferation, programmed cell death and 
senescence. The rate of proliferation is a major determinant of the number of cells in the 
population and to prevent excessive proliferation, DNA synthesis and cell division are 
normally controlled within the cell cycle. There is general agreement that the risk of 
ovarian cancer decreases with increasing parity and longer duration of oral contraceptive 
use (Whittemore et al. 1992a; Negri et al. 1991). The main aims of this thesis were 1) to 
examine the proliferative activity of the ovine OSE cells through the regular ovarian 
cycle and during pregnancy by monitoring proliferation in vivo using IHC for PCNA and 
Ki-67, and to investigate whether the underlying ovarian structure specifically growing 
follicles have any influences on the OSE layer; 2) to examine the role of growing 
follicles and corpora lutea and their contents of steroids and growth factors in the 
regulation of OSE proliferative activity by using cultured OSE cells; 3) to test the 
hypothesis that pregnancy may reduce EOC risk by inducing apoptosis within the OSE 
layer and inclusion cysts, a process mediated through over-expression of p53, which is 
under the control of high progesterone and oestrogen level; and 4) to examine the role of 
pregnancy and gonadotrophins inhibition (administration of GnRH antagonist) on OSE 
cells morphology and proliferation in a non-human primate, the marmoset monkey, by 
using the IHC method for BrdU at different stages of the cycle and during pregnancy. 
The investigations carried out in this thesis have revealed that pregnancy inhibits 
epithelial proliferation and this may be responsible for a reduction in the incidence of 
EOC, either by inhibiting the production of gonadotrophins and concomitant localized 
General Discussion                                                                                                   135 
 
  
growth factors and/or by enhancing the p53-mediated apoptosis of damaged and 
mitogenic cells arising from repeated ovulations.   
During the reproductive cycle (cycling, anoestrus and pregnancy) major tissue 
modulation and reorganization of ovarian epithelium takes place and this is under tight 
regulation of gondotropins, localized growth factors and steroidal hormones. All of these 
factors will influence OSE, but the OSE is not homogeneous, as different areas will be 
subjected to different factors depending on the underlying tissue. The in vivo interaction 
between the OSE cells and the underlying compartments, specifically the growing 
follicles, is poorly understood.  
In chapter 2 the relationship between the stage of the reproductive cycle, follicle 
dynamics and OSE activity was investigated, and consistent with a general notion, 
pregnancy did not affect activation of the earliest stages of follicle development 
(primordial), though it suppressed the later stages of development and differentiation. 
The proliferative activity of granulosa cells within growing follicles decreased during 
pregnancy relative to the non-pregnant animals, and this may represent altered growth 
rates at later stages of development, i.e. follicles grow more slowly during pregnancy. 
Differences in circulating gonadotrophins and steroidal hormones are the likely causes 
of follicle suppression and steroidogenesis in granulosa cells. Pituitary gonadotrophins, 
FSH and LH levels are low during pregnancy (Taya & Greenwald 1981b; Taya & 
Greenwald 1981a). FSH has been reported to accelerate granulosa cell proliferation and 
differentiation in cows (Hulshof et al. 1994), sheep (Newton et al. 1999) and humans 
(Roy & Treacy 1993). In agreement with our results, in golden hamsters (Greenwald et 
al. 1967) and cows (Guilbault et al. 1986) during late pregnancy, a pool of transitory 
follicles was observed, whereas the large follicles were missing as they had degenerated. 
High levels of progesterone might be involved in attenuation of follicular development. 
Progesterone inhibits gonadotrophin induced follicular growth in hypophysectomised 
rats (Fukuda et al. 1980), and also inhibits the induction of aromatase activity in rat 
granulosa cells responsible for steroid production (Fortune & Vincent 1983). Loss of 
follicular oestrogenic activity could be responsible for suppression of follicular 
development. Besides, it has been suggested that the conceptus exerts follicle 
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suppressive effects in pregnant ewes (al Gubory & Abdennebi 1996), especially the 
development of the antral follicle. Moreover, residual local inhibitory effects of CL on 
folliculogenesis in pregnant cows may reduce the number of antral follicles (Bellin et al. 
1984).  
Using IHC and cell proliferation markers (PCNA, Ki-67 and BrdU), we have 
demonstrated that pregnancy not only affected the proliferation of granulosa cells but 
also reduced the proliferative activity of OSE cells during early and late stages of 
pregnancy (sheep and marmoset monkeys). We propose that suppression of OSE cells’ 
proliferative activity due to pregnancy is a consequence of prolonged exposure to high 
levels of progesterone, accompanied by low levels of gonadotrophin. Over the first 
month of pregnancy, maternal LH and FSH decline and trophoblast hCG increases, 
which stimulates the CL to continue producing progesterone and not to regress (Jaffe 
1991; Yen 1994). A direct apoptotic effect of progesterone on the OSE cells was 
demonstrated in cell cultures of OSE from bovine ovaries (Chapter 4). Consistent with 
our findings, it was indicated that progesterone treatment in vitro inhibits the growth of 
immortalized normal and malignant human OSE cells through apoptosis induction ( 
Syed & Ho 2003).  
A popular explanation for the onco-protective effect of pregnancy is temporary 
cessation of ovulation (Fathalla 1971). This would reduce constant ovarian epithelial 
disruption and repair that may induce ovarian neoplasia, possibly through the 
accumulation of mutations in tumour suppressor genes such as p53 (Schildkraut et al. 
1997). The results with heifers in chapter 4 demonstrate that progesterone induces 
apoptosis in cultured bovine OSE. Moreover, the in vivo observations revealed that 
pregnancy led to high apoptotic index in OSE cells and in cells lining inclusion cysts. In 
contrast, non-pregnant animals did not produce any evidence of apoptosis in either OSE 
or inclusion cysts. Apparently, elevated progesterone during pregnancy may play a role 
in regulating programmed cell death in OSE. Consistent with our finding, Rodriguez et 
al. (1998) demonstrated that in vivo administration of progesterone to the OSE cells of 
monkeys induced apoptosis. The protective role of progesterone during pregnancy could 
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be the result of a clearing process or exfoliation from the ovary (particularly the OSE 
layer and inclusion cysts) of any DNA damaged OSE that might lead to malignancy.  
Apoptosis may be a key factor to avert such malignant transformation, by way of 
elimination of the cells that have undergone mutations. Progesterone may also up-
regulate the tumour suppressor gene p53, which is a critical regulator of cell cycle arrest 
and apoptosis in response to DNA damage. Mutation of the p53 tumour suppressor gene 
is the most frequent genetic lesion described in human cancers (Berchuck et al. 1994), 
and it is known to play a pivotal role in regulation of both proliferation and apoptosis 
(Braithwaite et al. 1987; Rotter et al. 1983). In normal cells, p53 protein exerts its 
tumour suppressor activity by binding to transcriptional regulatory elements of the genes 
that act to arrest cells at G1 phase. Additionally, p53 is thought to play a role in 
preventing cancer by stimulating apoptosis of cells that have undergone excessive 
genetic damage (Kuerbitz et al. 1992). In this regard, p53 has been described as the 
“guardian of the genome” since it delays entry of cells into S phase until the genome has 
been cleansed of mutations (Lane 1992). If DNA repair is inadequate, p53 may initiate 
apoptosis, thereby eliminating the cells with altered or damaged genotype. In this study, 
it was shown that p53 was more highly expressed within OSE cells overlying the CL, 
with less expression in those overlying the large antral follicles, which might be the 
preovulatory follicle (Chapter 4). In contrast, p53 protein was completely absent within 
the OSE cells in those areas furthest from ovulation events. Moreover, the in vitro results 
demonstrate that progesterone administration significantly increased p53 expression in 
bovine OSE cells. Expression of p53 within OSE cells over the CL may contribute to the 
re-epithelization process. P53 might arrest the cell cycle, enabling DNA repair before 
replication, or it might induce apoptosis if DNA damage is irreparable. Therefore, 
besides cessation of ovulation, pregnancy is also associated with elevated progesterone 
and this may have a protective role by inducing p53 expression.  
High risk of ovarian cancer is almost invariably associated with elevated 
gonadotrophin secretion such as at the postmenopausal stage and after receiving 
ovulation induction drugs ( Rao & Slotman 1991; Whittemore et al. 1992b; Shoham 
1994). In marmoset monkeys treated with GnRH antagonist, OSE proliferation was 
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found to be markedly suppressed (Chapter 5). This finding is consistent with the theory 
that pregnancy protection role is a combination of low gonadotrophin as well as high 
progesterone. Histological studies indicate that the growth and function of OSE cells is 
regulated by paracrine and/or endocrine pathways (Parrott et al. 2000b; Nilsson et al. 
2001a). OSE is an avascular tissue (Clement 1987), therefore a predominant influence of 
paracrine rather than endocrine factors is expected. Both epidemiological and 
experimental investigations have implicated sex steroids in the pathogenesis and growth 
regulation of ovarian cancer (Lukanova et al. 2003). Most of the ovarian steroidogenesis 
occurs in the granulosa and theca cells of developing and mature follicles under the 
control of the gonadotrophins, FSH and LH (Howles 2000; Hillier 2001). Oestrogen 
biosynthesis peaks sharply in the granulosa cells prior to ovulation (Agca et al. 2006; 
Murdoch & Van Kirk 2001). As follicular growth distends the surface of the ovary, the 
epithelial cells multiply and become flattened in shape (Gillett et al. 1991) until 
ovulation, when the epithelial cell’s proteases dissolve the follicle apex and rupture it 
(Kruk et al. 1994). It has been suggested that the epithelium during this stage is exposed 
to more paracrine influences from the granulosa and theca cells (Hafez et al. 1980), or 
this is mediated through diffusion of follicular fluid (Carcangiu & Chambers 1992), as 
before ovulation this fluid may contain high concentration of oestradiol (Murdoch & 
Van Kirk 2001). Results from chapter 3 show that in vitro administration of oestrogen 
and progesterone did not stimulate OSE proliferation, suggesting neither of the steroids 
affect cultured ovine OSE cells, whereas, IGF-1 significantly induced proliferation. 
Moreover, observed stimulatory effect of the follicular fluid treatment may be related to 
ovarian factors other than steroids, such as EGF and IGF-1.  
In the present study, immunohistochemistry data (PCNA, Ki-67 and BrdU) 
indicate that the proliferative activity of OSE cells is related to the ovulation and post-
ovulation repair process. Although immunohistochemistry results in chapters 2 and 5 
showed a variation in the percentage of immunureactivity within OSE cells, the overall 
proliferative indexes were very low compared to the other ovarian compartments such as 
granulosa cells. It seems that during ovarian cycles, the epithelium proliferates at times 
when mitogenic influences are relatively greater, and increased mitotic activity is likely 
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to enhance the risk of mutations. This genetic aberration could then accumulate with 
additional epithelial cell division in further cycles during re-epithelization.  
In this study, some results were different from expected, and further study is 
required to elucidate these issues. Firstly, there was marker-based difference in 
recognition of the proliferative activity among different cell types, i.e. epithelial cells, 
granulosa cells and oocytes (Chapters 2 and 5). In cycling ewes, a baseline PCNA 
staining in granulosa cells of all follicular stages was consistently observed. In contrast, 
the Ki-67 marker was restricted to only the late follicles. One explanation may be that 
DNA damage and repair activity takes place even in non-dividing primordial follicles, 
possibly due to pre-granulosa cell formation and accommodation of oocytes. 
Correspondingly, PCNA staining was discernable in oocytes, suggesting that high 
turnover of DNA in these cells might create an environment for the surrounding cells to 
undergo DNA modulation. Thus, despite Ki-67 negativity we cannot entirely rule out 
that the primordial-transitory follicles are non-proliferative. In marmoset monkeys, low 
but significant BrdU staining of “resting” OSE over stroma was seen, which indicates 
that these cells are also dividing, albeit slowly. This study hypothesizes that this discrete 
proliferation accounts for the formation of the stem cells.  
Secondly, the OSE proliferation during early-pregnancy was not expected in 
marmosets, especially over CL (Chapter 5), whereas progesterone concentration must 
have been high enough to suppress this proliferation. It appears that pro-proliferative 
factors originating from CL might supersede the progesterone’s action, and this effect 
may extend to early pregnancy. The nature of this factor is not known.  
Thirdly, in heifers during mid-pregnancy the number of inclusion cysts increased 
and epithelial cells of these cysts and OSE exhibited substantial apoptotic index 
revealing extensive cell death (Chapter 4). Elevated P53 expression in these cells 
corroborated the fact that apoptotic activity was indeed high. In the normal course of 
events, formation of inclusion cysts and epithelial apoptosis is confined to the ovulation 
process. It is reasonable to assume that at mid-pregnancy, due to some unknown factors, 
there is a tendency of neoplastic transformation of OSE cells and high apoptosis 
stimulated by progesterone is a mechanism to avert this. 
General Discussion                                                                                                   140 
 
  
6.2 Concluding remarks 
 The work presented here has used different model systems to examine and 
characterise OSE under different conditions. This comparative approach using three 
animal models, different timings through the ovarian cycle and different cell 
proliferation markers has attempted to elucidate the possible mechanisms by which 
pregnancy affects the OSE. It is concluded that the possible protective role of pregnancy 
on progression of ovarian cancer is at least in part related to an inhibition of OSE cell 
proliferation and accelerated cell death. Ovarian follicles continue to grow throughout 
pregnancy but they do not reach the ovulatory stage, therefore, cyclic proliferative 
activity of the surface epithelium (OSE injury and repair) is suppressed and a quiescent 
state is maintained. We provide evidence to support an involvement of progesterone in 
apoptosis induction and cell growth inhibition in OSE cells. Additionally, data from 
study of the p53 tumour suppressor gene indicates that this gene, whose expression is 
governed by progesterone and/or some other hitherto unknown factors, might play an 
important role in onco-protection. This feature saves the genome from progressive 
accumulation of mutations. We suggest that any defect in the p53 pathway may lead to 
malignancy either by mutation in the p53 gene, and/or by down-regulation of a cascade 
of reactions responsible for cell cycle attenuation and apoptosis. Expression of p53 has 
to be dealt with care as this protein has a short-half life, and this may give false negative 
labelling and erroneous results.    
The choice of different animal models in this study reflects differences in 
ovulation rate and seasonality i.e. cyclical activity, all of which may affect proliferation 
rate i.e. ewes (mono-ovular seasonal breeder), cows (low ovulation rate) and marmoset 
monkeys (poly-ovular). Ovine ovaries provided information on OSE during the 
anoestrus or resting period from ovulation. Our results indicate that OSE cells were in a 
quiescent state and this could explain why ovarian cancer does not occur in these 
animals. Cows turned out to be good models but there were experimental limitations: the 
animals brought from local slaughterhouse were young and it was too early to detect any 
defect or malformation within OSE or inclusion cysts. Moreover, the age or parity of 
General Discussion                                                                                                   141 
 
  
these animals was not known. If older animals were studied it would have been possible 
to analyze the etiology of ovarian cancer in the quiescence state.  
Overall, the picture from the in vitro supplementation of hormones/growth 
factors on induction of apoptosis or stimulation of proliferation did not entirely match 
with the corresponding analysis on OSE layer in the in vivo models. For example, 
progesterone had practically no influence over the cultured sheep OSE cell proliferation, 
but high progesterone level during pregnancy remarkably suppressed the OSE cell 
proliferation within the ovary. Apoptosis induction by progesterone was clearly 
discernable in heifer OSE cultured cells but was not observed in late pregnancy, at 
which stage progesterone level should have been high. It is likely that absence of the TA 
layer in the in vitro study may have altered the physiological response of OSE cells to 
different treatments. Cultured OSE are grown in a different environment and are 
exposure directly to the effectors in the medium, whereas inside the ovary TA may 
selectively hinder exposure of OSE cells to the effectors produced within stroma or 
follicles, or coming from the circulation. The exact influence of such effectors can be 
better judged in the epithelium of inclusion cysts which are situated within the ovarian 
stroma, and are more exposed to the compounds. Hence, besides searching for a suitable 
animal model for studying OSE physiology, we need to develop a unique OSE culture 
system that mimics the conditions prevailing in vivo. For these kinds of basic 
investigations human subjects cannot be used, therefore it is important to identify 
suitable animal and in vitro models. Given that the work presented in this thesis shows 
the effect of underlying follicular structures on OSE characteristics it can be concluded 
that the isolated OSE monolayer culture model may not be the most appropriate. To 
study human OSE in more detail it would be beneficial to have a culture model that 
supports OSE and underlying follicular tissue in vitro. A culture model recently 
developed in our laboratory supports the growth of follicles and overlying OSE cells 
(Telfer & McLaughlin, 2007, Telfer et al. 2008). The main aim of this system is to 
support follicle development but with adaptation it could be utilised to study the OSE 
interactions with defined follicular components. Such artificial systems would facilitate 
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mimicking the effect of follicular cycle and holds promise for future research on human 
OSE cells.  
 
6.3 Future perspective 
The work presented in this thesis has highlighted many gaps in our understanding 
of OSE cells. An understanding of their basic characteristics is fundamental to 
advancing our knowledge of the causes of aberrant development. Efforts have been 
made over the years to understand the biology of the surface epithelium in an attempt to 
explain the tendency of these relatively inconspicuous ovarian cells to undergo 
malignant transformation. Despite advancements in treatment, ovarian cancer related 
mortality has been relatively constant for over 30 years. Detection of ovarian cancer at 
later (metastasis) stages (III and IV) reduces the 5-year survival chance to 35%. Ovarian 
cancer often presents with non-specific symptoms, which makes it difficult to detect at 
early stage of disease. Therefore it is essential to obtain predictive biomarkers to help in 
diagnosing pre-cancerous cells. The most popular diagnostic mechanism is trans-vaginal 
or pelvic ultrasound followed by serum detection of cancer antigen 125 (CA125) 
(Scholler et al. 2006). CA125 is a reliable marker for monitoring the response of 
treatment and disease recurrence, rather than for early diagnosis. During the past decade, 
numerous biomarkers, independently or in conjunction with CA125, have been clinically 
evaluated for their cancer-associated over-expression, and their expression in normal and 
cancerous OSE cell lines was verified using immunohistochemical procedures. All of 
these biomarkers are normal cell proteins whose serum concentration can be affected by 
the hormonal regime that changes during different stages of the reproductive cycle. 
Hence, the efficacy of the biomarkers in cancer detection depends on a greater 
understanding of the physiological alterations in such proteins prevailing in the OSE 
layer, in follicular fluid and in serum depending on the paracrine and endocrine 
conditions regulating their expression. The work presented in this thesis has 
demonstrated some basic model systems that could be utilised and extended to 
investigate the potential of putative biomarkers. In this study, combined in vivo / in vitro 
methods were performed to monitor the expression of specific proliferative and cell 
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death makers at gene and protein level. The same line of investigation can be extended 
by using the above cancer-determinant biomarkers. If pregnancy and oral contraceptive 
drugs including the progesterone-based pill suppress tumour formation, one can judge 
this fact by using animal OSE cells and the cells grown in cell cultures, just by replacing 
the existing markers with the human cancer biomarkers. In this way one can shortlist a 
few valid markers that are minimally affected by the paracrine or endocrine factors, 
while they only respond to the conditions that lead to tumourigenesis. Among the 
described human biomarkers we have applied p53 marker in the animal model and in 
cultured cells, and our study revealed that progesterone up-regulated the p53 protein 
synthesis and apoptotic destruction of those mitogenic cells that tend to undergo 
neoplastic growth. The same attribute in EOC patients may suppress recurrence of the 
disease. Thus animal models help to understand the possible hormonal therapeutic 
mechanism and to monitor the response of the drug using p53 biomarker. By pursuing 
all of these model systems, we may eventually be able to improve diagnosis and 
treatment. 
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